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ABSTRACT 
Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by 
progressive autoimmune destruction of insulin-producing pancreatic β-cells. Genetic, 
immunological and environmental factors contribute to T1D development. The focus of 
this dissertation is to track the humoral immune response in T1D by profiling 
autoantibodies (AAbs) and anti-viral antibodies using an innovative protein array 
platform called Nucleic Acid Programmable Protein Array (NAPPA).  
AAbs provide value in identifying individuals at risk, stratifying patients with 
different clinical courses, improving our understanding of autoimmune destructions, 
identifying antigens for cellular immune response and providing candidates for 
prevention trials in T1D. A two-stage serological AAb screening against 6,000 human 
proteins was performed. A dual specificity tyrosine-phosphorylation-regulated kinase 2 
(DYRK2) was validated with 36% sensitivity at 98% specificity by an orthogonal 
immunoassay. This is the first systematic screening for novel AAbs against large number 
of human proteins by protein arrays in T1D. A more comprehensive search for novel 
AAbs was performed using a knowledge-based approach by ELISA and a screening-
based approach against 10,000 human proteins by NAPPA. Six AAbs were identified and 
validated with sensitivities ranged from 16% to 27% at 95% specificity. These two 
studies enriched the T1D “autoantigenome” and provided insights into T1D 
pathophysiology in an unprecedented breadth and width. 
The rapid rise of T1D incidence suggests the potential involvement of 
environmental factors including viral infections. Sero-reactivity to 646 viral antigens was 
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assessed in new-onset T1D patients. Antibody positive rate of EBV was significantly 
higher in cases than controls that suggested a potential role of EBV in T1D development. 
A high density-NAPPA platform was demonstrated with high reproducibility and 
sensitivity in profiling anti-viral antibodies.  
This dissertation shows the power of a protein-array based immunoproteomics 
approach to characterize humoral immunoprofile against human and viral proteomes. The 
identification of novel T1D-specific AAbs and T1D-associated viruses will help to 
connect the nodes in T1D etiology and provide better understanding of T1D 
pathophysiology. 
 
 iii 
ACKNOWLEDGEMENTS 
This dissertation would not have been possible without the help of so many 
people. I would like to express my immeasurable appreciation and deepest gratitude to 
the following people who contributed to this work in different ways. 
I would like to acknowledge my advisor, Dr. Joshua LaBaer, for the opportunity 
of working in his laboratory, the Center for Personalized Diagnostics in the Biodesign 
Institute at Arizona State University. I am grateful for his immense knowledge and 
guidance in my projects. He influenced me with an optimistic attitude which will help me 
face more challenges in the future.  
Many sincere thanks to Dr. Ji Qiu, who coached me throughout all the stages of 
my PhD study. He was always available and generously provided invaluable suggestions 
to help me overcome all kinds of obstacles and move this work forward. 
I appreciate my wonderful collaborators Dr. Desmond Schatz, Dr. Mark Atkinson, 
and Mr. Clive H. Wasserfall at the University of Florida for their expertise in type 1 
diabetes and their dedications of providing precious samples and constructive suggestions 
that greatly improved this work. 
I would like to thank my committee members, Dr. Lawrence J. Mandarino and Dr. 
Yung Chang, for their kindness, encouragement and insightful comments. 
I would like to acknowledge all of the current and past members in the Center for 
Personalized Diagnostics, specially, Dr. Shane Miersch, who started this project and 
trained me during lab rotation, Dr. Garrick Wallstrom, who did statistical analysis of the 
protein array data, Dr. Xiaobo Yu and Dr. Gokhan Demirkan, who provided thoughtful 
insights into these projects, Kristi Barker, who critically reviewed this work and gave 
 iv 
valuable feedbacks. Other people that directly contributed to this work include Dr. Mitch 
Magee, Peter Wiktor, Peter Kahn and Al Brunner. I am pleased to work alongside with 
Jie Wang, Brianne Petritis, Carols Morales Betanzos, Justin Saul, Haoyu Wang, Yanyang 
Tang and Kailash Karthikeyan. I would like to acknowledge the NAPPA core (Jennifer 
Viloria and Lisa Miller), sequencing core (Jason Steel, Kristina Buss and Andrea Price), 
production team (Andrea Throop, Kevin Peasley and Hannah Johnson) and 
bioinformatics team (Jin Park, Preston Hunter and Michael Fiacco) for their technical 
support in many ways. Many thanks to Kathleen Stinchfield, Mike Gaskin, Karie Tepper, 
Vanessa Baack and Melissa Gutierrez for their administrative support.  
I am grateful to have been accepted to the Biological Design Graduate Program at 
Arizona State University that provided me the chance to receive a higher education. 
Thanks to the program coordinators Dr. JoAnn C. Williams, Maria Hanlin, Laura Hawes 
and my classmates in the program. 
I could not have anything done without the support of my family. Thanks for their 
patience and unconditional love. 
Last but not least, I would like to thank the Juvenile Diabetes Research 
Foundation (5-2005-1170, 17-2007-1045, 6-2012-513 and 5-2012-537) and National 
Institute of Health (R42GM106704) for funding this work. 
 
 v 
TABLE OF CONTENTS 
Page 
LIST OF TABLES ............................................................................................................. xi 
LIST OF FIGURES .......................................................................................................... xii 
CHAPTER 
1 OBJECTIVES AND CONTRIBUTION ................................................................. 1 
1.1 Significance and Objectives ............................................................................. 1 
1.2 Scientific Contributions .................................................................................... 3 
2 INTRODUCTION ................................................................................................... 6 
2.1 Type 1 Diabetes ................................................................................................ 6 
2.1.1 Overview ................................................................................................... 6 
2.1.2 Natural History of T1D ............................................................................. 7 
2.1.3 Genetic Factors .......................................................................................... 9 
2.1.4 Immunological Contributors ................................................................... 10 
2.1.5 Environmental Triggers........................................................................... 11 
2.2 T1D-associated Autoantigens ......................................................................... 11 
2.2.1 Known T1D AAbs .................................................................................. 11 
2.2.2 Methods for Identifying Novel AAbs ..................................................... 19 
2.2.3 Methods for Measuring Known AAbs .................................................... 21 
2.2.4 Autoantigens Recognized by T-cells....................................................... 24 
2.2.5 Methods for Identifying Autoantigens Recognized by T-cells ............... 27 
2.3 Role of Viral Infection in T1D ....................................................................... 29 
2.3.1 Mechanisms of Virus Induced Diabetes.................................................. 30 
 vi 
CHAPTER                                                                                                                      Page 
2.3.2 Viruses Reported to Be Associated with T1D ........................................ 31 
2.3.3 Methods for Studying Viral and T1D Association.................................. 35 
2.4 Protein Microarray .......................................................................................... 37 
2.4.1 Overview ................................................................................................. 37 
2.4.2 Nucleic Acid Programmable Protein Array ............................................ 39 
2.4.3 High Density-NAPPA ............................................................................. 41 
2.5 Rationale of This Dissertation Study .............................................................. 42 
2.5.1 AAb Biomarker Discovery...................................................................... 42 
2.5.2 Viral and T1D Association Study ........................................................... 46 
2.5.3 Advantages of NAPPA............................................................................ 47 
3 SEROLOGICAL ANTIBODY PROFILING OF TYPE 1 DIABETES BY 
PROTEIN ARRAYS ..................................................................................................... 49 
3.1 Abstract ........................................................................................................... 49 
3.2 Introduction .................................................................................................... 50 
3.3 Experiments .................................................................................................... 54 
3.3.1 Serum Samples ........................................................................................ 54 
3.3.2 Array Production and Quality Assessment ............................................. 55 
3.3.3 Profiling of Serum AAbs......................................................................... 56 
3.3.4 Study Design and Data Analysis ............................................................. 56 
3.3.5 Validation of Candidates by LIPS Assay ................................................ 58 
3.4 Results ............................................................................................................ 61 
3.4.1 Array Production and Quality Assessment ............................................. 61 
 vii 
CHAPTER                                                                                                                      Page 
3.4.2  Screening Strategy.................................................................................. 61 
3.4.3 AAb Candidates Identified from the Second-stage Screening ................ 66 
3.4.4 Validation of Candidate AAbs ................................................................ 68 
3.5 Discussion ....................................................................................................... 71 
3.6 Conclusions .................................................................................................... 77 
3.7 Acknowledgements ........................................................................................ 77 
4 IDENTIFICATION OF NOVEL AUTOANTIBODIES IN TYPE 1 DIABETES 
BY PROTEIN ARRAYS .............................................................................................. 78 
4.1 Abstract ........................................................................................................... 78 
4.2 Introduction .................................................................................................... 79 
4.3 Experiments .................................................................................................... 82 
4.3.1 Study Samples ......................................................................................... 82 
4.3.2 Study Design ........................................................................................... 83 
4.3.3 NAPPA Production and Quality Assessment.......................................... 85 
4.3.4 Profiling of AAbs on NAPPA ................................................................. 85 
4.3.5 Rapid Antigenic Protein in situ Display (RAPID) ELISA ...................... 86 
4.3.6 Statistical Analysis .................................................................................. 87 
4.4 Results ............................................................................................................ 88 
4.4.1 Quality of Protein Array and Serum Profiling ........................................ 88 
4.4.2 Screening-based Approach by NAPPA................................................... 89 
4.4.3 Network Analysis of Sero-positive Proteins on NAPPA ........................ 90 
4.4.4 Knowledge-based Approach by RAPID ELISA ..................................... 91 
 viii 
CHAPTER                                                                                                                      Page 
4.4.5 RAPID ELISA as an Individual Immunoassay to Profile AAbs ............ 92 
4.4.6 Novel AAbs from Two Approaches........................................................ 95 
4.4.7 Characteristics of Identified AAbs .......................................................... 97 
4.5 Discussion ....................................................................................................... 99 
4.6 Conclusions .................................................................................................. 103 
4.7 Acknowledgements ...................................................................................... 103 
5 IMMUNOPROTEOMIC PROFILING OF ANTI-VIRAL ANTIBODIES IN 
NEW-ONSET TYPE 1 DIABETES USING PROTEIN ARRAYS ........................... 104 
5.1 Abstract ......................................................................................................... 104 
5.2 Introduction .................................................................................................. 105 
5.3 Experiments .................................................................................................. 109 
5.3.1 Serum Samples ...................................................................................... 109 
5.3.2 Selection of Viral Strains ...................................................................... 109 
5.3.3 Viral Genes Cloning .............................................................................. 111 
5.3.4 Nucleic Acid Programmable Protein Array (NAPPA) Production ....... 113 
5.3.5 Array Quality Assessment ..................................................................... 113 
5.3.6 Anti-viral Antibody Profiling ................................................................ 114 
5.3.7 RAPID (Rapid Antigenic Protein In situ Display) ELISA ................... 115 
5.3.8 Statistical Analysis ................................................................................ 116 
5.4 Results .......................................................................................................... 118 
5.4.1 Viral Protein Array Production and Quality Assessment ..................... 118 
5.4.2 Profiling of Anti-viral Antibodies ......................................................... 119 
 ix 
CHAPTER                                                                                                                      Page 
5.4.3 Differential Anti-viral Antibody Response on Arrays .......................... 123 
5.4.4 Higher Frequency of Antibody Response to EBV in T1D Patients ...... 125 
5.5 Discussion ..................................................................................................... 128 
5.6 Conclusions .................................................................................................. 134 
5.7 Acknowledgements ...................................................................................... 134 
6 ANTI-VIRAL ANTIBODY PROFILING BY HIGH DENSITY PROTEIN 
ARRAYS ..................................................................................................................... 135 
6.1 Abstract ......................................................................................................... 135 
6.2 Introduction .................................................................................................. 136 
6.3 Experiments .................................................................................................. 140 
6.3.1 Serum Samples ...................................................................................... 140 
6.3.2 HD-viral-NAPPA Fabrication ............................................................... 141 
6.3.3 Protein Expression................................................................................. 142 
6.3.4 Serum Profiling on HD-viral-NAPPA .................................................. 143 
6.3.5 RAPID ELISA....................................................................................... 144 
6.3.6 Statistical Analysis ................................................................................ 145 
6.4 Results .......................................................................................................... 147 
6.4.1 Quality of Protein Display on HD-viral-NAPPA .................................. 147 
6.4.2 Quality of Serum Profiling on HD-viral-NAPPA ................................. 149 
6.4.3 Higher Sensitivity in Detecting Antibodies on HD-NAPPA ................ 150 
6.4.4 Anti-viral Antibodies of Three Common Viruses in JIA ...................... 153 
6.4.5 Profiles of Anti-viral Antibodies in JIA and T1D Samples .................. 154 
 x 
CHAPTER                                                                                                                      Page  
6.5 Discussion ..................................................................................................... 156 
6.6 Conclusions .................................................................................................. 161 
6.7 Acknowledgements ...................................................................................... 161 
7 CONCLUSIONS AND FUTURE WORK .......................................................... 162 
7.1 Conclusion .................................................................................................... 162 
7.2 Future Work .................................................................................................. 164 
7.2.1 Enriching the Gene Collection to Cover the Full Human Proteome ..... 164 
7.2.2 Longitudinal Samples for AAb and Virus Study .................................. 165 
7.2.3 Post-translational Modifications (PTMs) of Autoantigens ................... 166 
7.2.4 Integration with T1D Microbiome and Virome .................................... 167 
REFERENCES ............................................................................................................... 169 
APPENDIX 
A IRB APPROVAL INFORMATION ....................................................................... 196 
B COPYRIGHT PERMISSIONS ............................................................................... 198 
 
 
 xi 
LIST OF TABLES 
Table                                                                                                                               Page 
3 - 1 Sample Characteristics of Each Stage ...................................................................... 55 
3 - 2 List of 26 Candidate AAbs by Wilcoxon Rank-Sum Test ....................................... 63 
3 - 3 List of 25 Candidate AAbs by pAUC Analysis ........................................................ 64 
4 - 1 Sample Characteristics of Each Cohort…………………………………………….83 
4 - 2 Statistics of Candidates from Screening-based Approach ........................................ 90 
4 - 3 Statistics of Candidates from Knowledge-based Approach ..................................... 92 
4 - 4 Cellular Functions of Six AAbs ............................................................................... 97 
4 - 5 Prevalence of Identified AAbs in IA-2A and GADA Subgroups ............................ 97 
5 - 1 Sample Characteristics……………………………………………………………109 
5 - 2 Characteristics of Viruses ....................................................................................... 110 
5 - 3 Frequencies of Antibody Responses to Studied Viruses ........................................ 125 
5 - 4 Sero-positivity of EBV in Gender and Age Subgroups .......................................... 126 
5 - 5 Infection Rate and Vaccination Information of Studied Viruses ........................... 130 
5 - 6 Antibody Responses to VCA and EA Antigens of EBV ........................................ 132 
6 - 1 Sample Characteristics of T1D Sample Set……………………………………….141 
6 - 2 Sample Characteristics of JIA Sample Set ............................................................. 141 
6 - 3 List of Viruses in This Study .................................................................................. 148 
 
 
 
 xii 
LIST OF FIGURES 
Figure                                                                                                                             Page 
2 – 1 Stages in the Development of Diabetes Mellitus ....................................................... 8 
2 - 2 How T1D Arises ......................................................................................................... 9 
2 - 3 Intracellular Distribution of Major T1D-associated Autoantigens ........................... 12 
2 - 4 Model of β-cell Damage Leading to β-cell Autoimmunity ...................................... 14 
2 - 5 Mechanisms ofVirus Induced Diabetes .................................................................... 30 
2 - 6 Nucleic Acid Programmable Protein Array (NAPPA) ............................................. 40 
3 - 1 Scheme of NAPPA and Strategy of AAb Screening……………………………….57 
3 - 2 Reproducibility of Protein Expression on NAPPA .................................................. 62 
3 - 3 Visual Comparison of Candidate AAbs ................................................................... 65 
3 - 4 Jitter Plots of Serological Immunoreactivity to Candidate AAbs ............................ 67 
3 - 5 Validation of Candidate AAbs Using LIPS Assay ................................................... 69 
4 - 1 Study Design………………………………………………………………………..84 
4 - 2 Quality of DNA Staining, Protein Display and Serum Profiling on NAPPA .......... 88 
4 - 3 Sero-reactivity to Known T1D-associated Autoantigens on NAPPA ...................... 89 
4 - 4 Network Analysis of Sero-positive Proteins on NAPPA ......................................... 91 
4 - 5 Sero-reactivity to IA-2 and GAD65 ......................................................................... 93 
4 - 6 Comparison of RAPID ELISA with NAPPA and LIPS assay ................................. 94 
4 - 7 Novel AAbs from Two Approaches ......................................................................... 95 
4 - 8 Prevalence of Identified AAbs in Age Subgroups.................................................... 98 
5 - 1 Study Design………………………………………………………………………112 
 xiii 
Figure                                                                                                                             Page 
5 - 2 Quality of DNA and Protein Display……………………………………………..118 
5 - 3 Inter-spot Correlation of IgG and IgA Profiling ..................................................... 119 
5 - 4 Reproducibility of Anti-viral Antibody Profiling ................................................... 120 
5 - 5 Reproducibility of RAPID ELISA ......................................................................... 121 
5 - 6 Concordance of Antibody Response to Viral Proteins ........................................... 122 
5 - 7 Heatmaps of IgG and IgA Sero-reactivity .............................................................. 124 
6 - 1 Antibody Profiling on HD-viral-NAPPA…………………………………………144 
6 - 2 Quality of Protein Display on HD-viral NAPPA ................................................... 149 
6 - 3 Quality of Serum Profiling on HD-NAPPA ........................................................... 150 
6 - 4 Higher Sensitivity in Detecting Anti-viral Antibodies on HD-NAPPA ................. 152 
6 - 5 Anti-viral Antibodies to PB19, RUBA and EBV ................................................... 154 
6 - 6 Profiles of Anti-viral Antibodies in JIA and T1D Patients .................................... 155 
 
 1 
CHAPTER 1  
1 OBJECTIVES AND CONTRIBUTION 
1.1 Significance and Objectives 
Type 1 diabetes (T1D) is one of the most common chronic autoimmune diseases 
during childhood. It is characterized by immunologically mediated destruction of insulin-
producing pancreatic islet β-cells (van Belle et al., 2011). The incidence rate of T1D is 
increasing at an annual rate of 3% particularly in those under the age of 10 years 
(Onkamo et al., 1999). Currently, there is no cure for T1D. T1D patients suffer from 
lifetime dependence of exogenous insulin injection accompanied by microvascular and 
macrovascular complications which are burdensome to both the individual and society 
(van Belle et al., 2011). 
Genetic, immunological and environmental factors have been implicated in T1D 
development (Atkinson, 2012). Genetic factors include single nucleotide polymorphisms 
(SNPs) in human leukocyte antigen (HLA) and non-HLA genes. Autoreactive T-cells 
play a primary pathological role in T1D. Autoantibodies (AAbs) produced by B-cells 
targeting self-proteins is one significant hallmark during disease progression. Family 
history, HLA genotypes and AAbs can be combined to predict T1D risk. Discovering 
new AAbs may help improve risk prediction, stratify patients with different clinical 
courses, explain disease pathogenesis, identify cellular immune response antigens and 
provide candidates for prevention trials. There are some evidences showing a link 
between environmental factors and T1D pathogenesis. Viral infection is of particular 
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interest (Knip and Simell, 2012). Uncovering viruses that are associated with T1D 
development will aid in the understanding of T1D pathophysiology. 
However, the challenge of discovering novel T1D-associated AAbs and viruses 
lies in the lack of high-throughput screening tools. The advert of the proteomic era gives 
us new opportunities to tackle these problems using protein mircoarrays. Hence, the goal 
of this doctoral dissertation project is to track the humoral immune response including 
AAbs and anti-viral antibodies in T1D by protein arrays in order to identify new T1D-
associated AAbs and viruses. The specific aims of the projects are: 
i)  Perform a proteome-scale, two-stage serological AAb screening against 
6,000 human proteins by Nucleic Acid Programmable Protein Array (NAPPA). The aim 
is to identify and validate novel AAbs in T1D. The candidate AAbs will be validated by 
an orthogonal immunoassay. The role of new AAbs in improving T1D diagnostic in 
combination with the major known T1D-associated AAbs will be evaluated. 
ii)  Conduct a comprehensive study for T1D-associated AAbs by a screening-
based approach using NAPPA including 10,000 human proteins and a knowledge-based 
approach using individual immunoassay to test 126 pancreas enriched genes from 
literature and bioinformatics analysis. The aim is to enrich the T1D “autoantigenome” 
and provide new insights into T1D pathophysiology in an unprecedented breadth and 
width.  
iii)  Immunoproteomic profiling of anti-viral antibodies to 646 viral antigens 
in 42 new-onset T1D patients and 42 age-gender matched healthy controls. This will 
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allow us to compare the antibody positive rate of the studied viruses and individual viral 
antigens. The goal is to identify viral strains that are associated with T1D. 
iv) Characterize high density (HD)-NAPPA platform including its sensitivity, 
reproducibility and application in profiling anti-viral antibodies in autoimmune diseases. 
The signal to background (S/B) ratio will be compared between the standard NAPPA and 
HD-NAPPA. The aim is to demonstrate HD-NAPPA as a platform to profile anti-viral 
antibodies in future applications. 
1.2 Scientific Contributions 
Based on the results of the above projects, all of the four objectives have been 
achieved successfully. The scientific contributions are as the following: 
(i) A proteome-scale, two-stage serological AAb screening against 6,000 
human proteins was performed and identified 26 novel AAbs including a known T1D-
associated AAb (ZnT8A). An orthogonal immunoassay named Luciferase 
ImmunoPrecipotation System (LIPS) assay was developed and used to validate these 
candidate AAbs. A dual specificity typrosine-phosphorylation-regulated kinase 2 
(DYRK2) was validated with 36% sensitivity at 98% specificity. The AUC for a 
combination of DYRK2 AAb (DYRK2A) and the classical IA-2 AAb (IA-2A) was 0.90 
compared to 0.72 for DYRK2A and 0.64 for IA-2A alone. This is the first systematic 
screening for novel AAbs against large number of human proteins by protein arrays in 
T1D.   
(ii) A comprehensive search for novel AAb biomarkers in T1D using a 
screening-based approach by NAPPA and a knowledge-based approach by enzyme-
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linked immunosorbent assay (ELISA) was performed. Six AAbs were identified and 
validated with sensitivities ranged from 16% to 27% at 95% specificity. Their prevalence 
in T1D cases complements to the major known T1D-assocaited AAbs and varied in 
different age subgroups.  
(iii) Seroreactivity to 646 viral antigens was assessed in 42 new-onset T1D 
patients and 42 age-gender matched healthy controls. Prevalence of anti-viral antibodies 
agreed well with the infection rates of the corresponding virus based on the previous 
epidemiological studies. Antibody positive rate of Epstein-Barr virus (EBV) was 
significantly higher in cases than controls (OR 6.6; 95% CI 2.0-25.7) while the other 
viruses did not differ between the two groups. The EBV and T1D association was 
significant in both genders and age subgroups (<=12 and >12). These results suggest a 
potential role of EBV in T1D development. 
(iv) HD-NAPPA showed higher S/B ratio compared with standard NAPPA. 
HD-NAPPA also showed high reproducibility of protein display and serum profiling with 
average correlation coefficients within or between printing batches at 0.91 and 0.95, 
respectively. Common as well as unique antibody reactivity patterns were observed in 
T1D and juvenile arthritis. 
With these results, two papers were published. One manuscript is in revision and 
one more manuscript in preparation for publication. All of them are listed below: 
1. Miersch, S.*, Bian, X.*, Wallstrom, G., Sibani, S., Logvinenko, T., 
Wasserfall, C. H., Schatz, D., Atkinson, M. A., Qiu, J., Labaer, J. (2013). Serological 
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autoantibody profiling of type 1 diabetes by protein arrays. J Proteomics. 94, 486-96. 
PMID: 24148850. (*Co-first authorship) 
2. Bian, X., Wallstrom, G., Wasserfall, C. H., Wang, J., Barker, K., Wang, 
H., Atkinson, M. A., Schatz, D., Qiu, J., Labaer, J. Identification of novel autoantibodies 
in type 1 diabetes by protein arrays. In preparation. 
3. Bian, X., Wallstrom, G., Davis, A., Wang, J., Park, J., Throop, A., Steel, 
J., Yu, X., Wasserfall, C. H., Atkinson, M. A., Schatz, D., Qiu, J., Labaer, J. 
Immunoproteomic profiling of Virus Antibodies in New-Onset Type 1 Diabetes on 
Protein Arrays. In revision. 
4. Bian, X., Wiktor, P., Kahn, P., Brunner, A., Khela, A., Karthikeyan, K., 
Barker, K., Wasserfall, C. H., Gibson, D., Rooney, M. D., Qiu, J., LaBaer, J. Anti-Viral 
Antibody Profiling by High Density Protein Arrays. Proteomics. 2015 Mar 11. doi: 
10.1002/pmic.201400612. [Epub ahead of print]. PMID: 25758251. 
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CHAPTER 2 
2 INTRODUCTION 
2.1 Type 1 Diabetes 
2.1.1 Overview  
Type 1 diabetes (T1D), which is referred as insulin-dependent diabetes, is 
characterized by progressive autoimmune destruction of insulin-producing pancreatic β-
cells (Atkinson, 2012). Type 2 diabetes (T2D), also named as noninsulin-dependent 
diabetes, is another major subtype of diabetes. T2D patients are resistant to the effects of 
insulin rather than the lack of insulin. Both of them suffer from a high blood glucose 
level. The boundary between these two subtypes is not as black-and-white nowadays 
(Odegaard and Chawla, 2012). Some autoantibody (AAb) positive T1D children are 
obese, which is a common characteristic of T2D patients. Alternatively, some latent adult 
onset diabetic (LADA) patients are positive for T1D-associated AAbs usually AAb to 
GAD65 (Falorni and Calcinaro, 2002). Although T1D only accounts for 5-10% of 
diabetes population (Atkinson, 2012), it affects individuals at their most productive age. 
So there is an emerging need to understand its natural history of disease development, 
improve current diagnostic tools and develop effective therapeutic strategies for T1D. 
T1D is a growing and global health problem. According to the statistics from 
Juvenile Diabetes Research Foundation (JDRF) (http://jdrf.org/about-jdrf/fact-sheets/jdrf-
and-diabetes-statistics/), as many as three million Americans were diagnosed with T1D. 
More than 15,000 children and 15,000 adults were diagnosed with T1D each year in 
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United States (US), respectively. Among people who are living with T1D, 85% are adults 
and 15% are children. Nearly 14.9 billion US dollars were spent on the healthcare of T1D. 
The symptoms of T1D include extreme thirst, frequent urination, increased 
appetite, sudden weight loss and sugar in urine. A lot of children developed severe 
ketoacidosis before T1D diagnosis. T1D is often diagnosed by the symptoms, fasting 
blood glucose test, oral glucose tolerance test (OGTT) and hemoglobin A1c (HbA1c) test. 
T1D and T2D are distinguished based on the age of diagnosis and doctors’ expertise. At 
the time of diagnosis, > 80-90% of pancreatic β-cells of T1D patients were destroyed 
(Atkinson, 2012). T1D patients need daily insulin injections and can live almost normal 
lives. However, it may still cause some effects at the microvascular and macrovascular 
level. It will lead to hyperglycemia or hypoglycemia if the blood glucose level is not 
carefully monitored (van Belle et al., 2011). There is a great impetus to have better 
understanding of this disease. 
2.1.2 Natural History of T1D 
The first model of the T1D natural history was proposed by George Eisenbarth in 
1986 (Eisenbarth, 1986) (Figure 2-1). This model suggests individuals with genetic 
predisposition are exposed to putative environmental triggers which will finally lead to β-
cell autoimmunity. During the process of autoimmune destruction, autoreactive T-cells 
are capable of destroying β-cells. AAbs are produced by autoreactive B-cells. The loss of 
pancreatic β-cells results in the reduction of insulin production which is reflected by the 
decreased C-peptide levels.  
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This model has been a benchmark and served the T1D community for years. The 
details in this model was enriched by ongoing research in the T1D field (van Belle et al., 
2011) (Figure 2-2). During the initiation stage, cytokine expression is triggered by 
environmental factors. It further up-regulates the expression of major histocompatibility 
complex (MHC) I molecules on the antigen presenting cells (APCs). CD4
+
 T-cells will 
activate B-cells to produce AAbs against specific antigens. CD8
+
 T-cells are involved in 
direct killing of β-cells to release new epitopes. There is a short period of honeymoon 
phase after epitope spreading due to the stimulation of β-cell proliferation.  
 
 
2 - 1 Stages in the Development of Diabetes Mellitus 
Adapted from (Eisenbarth, 1986).  Reproduced with permission from (scientific 
reference citation), Copyright Massachusetts Medical Society. 
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2.1.3 Genetic Factors 
As suggested by the classic model of T1D natural history, genetic predisposition 
is a primary T1D risk factor. A number of genomic wide associations studies (GWAS) 
revealed the linkage of human leukocyte antigen (HLA) regions on chromosome 6p21 
with T1D. These include the HLA-DR3/4 and DQ2/8 class II antigens. Besides HLA 
genes, other genes contributing to T1D are involved in insulin production, metabolism, 
immunity, protection from β-cell apoptosis and some with unknown functions (Atkinson, 
2012). INS encodes insulin which is a major known T1D-associated autoantigen for both 
 
 
2 - 2 How T1D Arises 
Adapted from  (van Belle et al., 2011). Permission not required for reproduce in a 
dissertation. 
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B-cells and T-cells. It is not surprising that single nucleotide polymorphisms (SNPs) in 
INS results a higher susceptibility of T1D. PTPN22 encodes tyrosine-protein phosphatase 
non-receptor type 22. It regulates T-cell receptor signaling by dephosphorylation of the 
Src family kinases LCK and FYN (Steck et al., 2009). CTLA4, which is short for 
cytotoxic T lymphocyte-associated protein 4, is a major negative regulator of T-cell 
responses (Pozzilli et al., 1996). The depth of genetic association studies was extended to 
epigenetic and transcriptome level.  
2.1.4 Immunological Contributors 
T1D is an autoimmune disease with various immunological contributors including 
CD8
+ 
T-cells, natural killer (NK) cells, CD4
+
 T-cells, regulatory T-cells and B-cells. 
Cytotoxic/CD8
+ 
T-cells that escaped from negative selection in the thymus are the 
primary killers of pancreatic β-cells. One way of their action is that they recognize β-cells 
as non-self and release cytotoxins including perforin, granzymes and granulysin. These 
cytotoxins are serine proteases and will trigger the caspase cascade in the apoptosis 
pathway in β-cells. Another way of their action is that they express FAS ligand on the 
cell membrane which will interact with FAS molecule on the β-cells to recruit the death-
induced signaling complex (DISC) and further induce apoptosis. NK cells act similarly as 
cytotoxic T-cells by releasing cytotoxins to destroy β-cells. As shown in the natural 
history of T1D, CD4
+
 T-cells activated by APCs will further activate B-cells to produce 
AAbs against specific antigens. The function of regulatory T-cells is to suppress 
autoreactive T-cells or B-cells. B-cells not only produce AAbs, as a feedback, they are 
also APCs and can further present antigenic epitopes to cytotoxic T-cells. 
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2.1.5 Environmental Triggers 
There are several evidences that suggest the involvement of environmental factors 
in T1D development: first, the incidence of T1D cases has been increasing at 3% a year 
which cannot be explained by genetic deposition alone (Onkamo et al., 1999); second, the 
concordance of monozygotic twins in developing T1D is around 66% (Redondo et al., 
2008); third, in some countries, T1D shows seasonal and regional outbreaks which is 
similar to an infectious disease (Peng and Hagopian, 2006).  
There are several possible environmental triggers: viruses, bacteria, dietary 
factors and psychosocial factors (Peng and Hagopian, 2006). Among these, viral 
infections have attracted of particular interest among. A variety of viruses have been 
implicated in the β-cell autoimmunity. Bacteria especially symbiotic microorganisms 
reside in the human gastrointestinal tract play a role in the metabolic process in T1D 
(Knip and Simell, 2012). Dietary factors include cow’s milk consumption, breastfeeding, 
caloric and vitamin D intake. The impact of these factors in T1D is still controversial 
based on previous studies. They might be involved in initiation, acceleration or inhibition 
of T1D progression by some unknown mechanisms (Peng and Hagopian, 2006). 
Increased psychosocial stress has been connected with increased T1D risk. The stress 
could be direct to the mother of children who develop T1D or children themselves (Peng 
and Hagopian, 2006). The identification of environmental factors associated with T1D 
development will lead to a better understanding of disease pathogenesis. 
2.2 T1D-associated Autoantigens 
2.2.1 Known T1D AAbs 
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AAbs produced by B-cells are hallmarks of T1D development. Islet cell 
antibodies (ICAs) to pancreatic islet cells were found by immunofluorescence staining of 
human pancreatic tissue using sera from patients with multiendocrine deficiencies 
associated organ specific autoimmunity (Bottazzo et al., 1974). Insulin antibodies (IAA) 
were present in insulin-dependent diabetics before insulin treatment (Palmer et al., 1983). 
AAb to a 64 kDa protein from human pancreatic islet was detected in 23 of 28 ICA 
positive individuals, 4 of 5 ICA negative but IAA positive individuals, 26 of 31 newly 
diagnosed T1D patients (Atkinson MA, 1990). This 64 kDa protein was identified as the 
GABA-synthesizing enzyme named glutamic acid decarboxylase (GAD) (Baekkeskov et 
al., 1990). Protein tyrosine phosphatase-like IA-2 (islet cell antigen 512) was identified as 
the insulin-dependent diabetes-related 37/40K autoantigen in 1995 (Bonifacio et al., 
1995a). ZnT8 was the most recent identified major T1D-associated autoantigen. It was 
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Adapted from (Arvan et al., 2012). Permission was requested from Cold Spring 
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discovered by analyzing genes highly expressed in pancreas using DNA microarray. 
AAbs to the candidate proteins were measured by radioimmunoprecipitation assay (RIA) 
in T1D patients and healthy controls (Wenzlau et al., 2007). The sensitivities of AAbs to 
these four major T1D-associated autoantigens are around at 60%-80% in new-onset T1D 
patients. 
  Insulin is the central regulator that maintains metabolic hemostasis (Figure 2-3). It 
is highly expressed in the pancreatic β-cells. After transcription and translation from 
mRNA, the (pro-) pre-insulin polypeptide is transported to the endoplasmic reticulum 
(ER) by the 24-residue signal peptide. (Pro-) pre-insulin is folded by forming three 
disulfide bonds and the signal peptide is cleaved. It is further cleaved by peptidase to 
generate mature insulin and release C-peptide. The mature insulin is stored in the 
secretory granules (Steiner and Oyer, 1967). Insulin expression is regulated by the 
promoter of insulin gene and responds to glucose stimuli. GAD65 is an enzyme that 
catalyzes the reaction to produce the neurotransmitter GABA. It is a soluble protein 
primary expressed in the cytosol of neuroendocrine cells (Baekkeskov et al., 1990). 
GAD67 is an isoform of GAD65. They are both expressed in human brains, but only 
GAD65 is expressed in human islets. IA-2 is a protein phosphotyrosine phosphatase that 
does not possess phosphatase activity. IA-2, together with IA-2β are transmembrane 
proteins localized at the membrane of insulin secretory granules (Arvan et al., 2012). 
ZnT8 belongs to a zinc transporter protein family with 10 members (ZnT1-10). It is a six-
pass transmembrane protein that resides in the membrane of insulin secretory granules. 
ZnT8 is responsible for the processing and packing of insulin into these granules 
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(Cousins et al., 2006). One proposed hypothesis of T1D pathogenesis is the increased 
demand of β-cell proteins due to the increased metabolic stress leads to the generation of 
antigenic proteins from protein misfolding (Figure 2-4). Meanwhile, autoreactive T-cells 
recognizing these abnormal epitopes can kill β-cells to release more antigenic epitopes 
and initiate the autoimmune process (Arvan et al., 2012). 
The value of four major T1D-assocciated AAbs is well acknowledged. Their 
contribution in predicting T1D risk depends on factors such as genetic background, age, 
gender, family history and country. The 5-year risk is almost 80% when combining four 
major known AAbs in the Diabetes Prevention Trial of Type 1 Diabetes (DPT-1) study 
(Winter and Schatz, 2011). The addition of ZnT8A with GADA, IA-2A, or IAA results a 
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5-fold increase of the risk prediction from 7.3% to 36.8% among the Diabetes and 
Autoimmunity Study in the Young (DAISY) participants (Winter and Schatz, 2011). 
These four autoantigens were also explored as potential candidates for T1D therapeutics. 
DPT-1 trial investigated the preventive effects of oral insulin intake in the relatives of 
patients with diabetes (Group., 2002). Gene therapy using plasmid-encoded (Pro-) insulin 
successfully reduced (Pro-)insulin-specific CD8
+
 T cells in T1D patients (Roep et al., 
2013). Another two clinical studies looked at the therapeutic role of GAD protein in 
preserving C-peptide level among recently diagnosed T1D patients (Ludvigsson et al., 
2008b; Ludvigsson et al., 2012).  
Besides these major T1D-associated AAbs, many minor ones were reported in 
T1D. AAb to insulin receptor was reported in one T1D case (Elias et al., 1987). Among 
two GAD isoforms, AAb response in T1D is primary to the GAD65 isoform, AAb to 
GAD67 added little to IDDM detection (Hagopian WA, 1993). IA-2β (phogrin) is a 
homologue of IA-2. They are both expressed in neuroendocrine cells. AAb to IA-2β had 
lower sensitivity than IA-2 antibody (IA-2A) (Lu J, 1996). AAb to a 58 kDa ICA was 
detected in non-obese diabetic (NOD) mice but not in the other mice strains. This antigen 
was found to be expressed in neuroblastoma cells and identified as peripherin (Boitard et 
al., 1992). AAb to ICA69 was identified by immunoprecipitation of human islet 
expression library using sera of prediabetic patients (Pietropaolo et al., 1993). 
Sensitivities of AAb to ICA69 varied from 4.17% to 21% depending on different studies 
(Kerokoski et al., 1999; Lampasona V, 1994; Martin et al., 1995). Another study reported 
AAbs from T1D patients recognized a 51 kDa antigen. By screening the expression 
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library derived from rat insulinoma cells, the 51 kDa protein was identified as aromatic-
L-amino-acid decarboxylase (DCC) (Rorsman et al., 1995). However, there were no 
follow-up studies on this AAb. The GM2-1 ganglioside islet autoantigen was reported to 
be a target of AAbs in the ICA positive relatives of T1D patients (Dotta et al., 1997b). It 
is expressed in secretory granules but not β-cell specific (Dotta et al., 1998). Glima 38 is 
a glycosylated islet cell membrane protein. AAb to glima 38 was detected in 19% of 
newly diagnosed T1D patients (Aanstoot et al., 1996). Another study investigated the 
association of AAb to glima 38 with IA-2A and ICAs. It was found AAb to glima 38 was 
detected in 38% of T1D patients, 35% of prediabetic siblings and 0% in control subjects 
(Winnock et al., 2001). AAb to glucose transporter 2 (GLUT2) was found in new-onset 
T1D patients. It may be involved in the process of the blockage of glucose uptake by 
binding to GLUT2 (Inman et al., 1993). Serum from T1D patients was reactive with rat 
GLUT2 at the molecular weight of 60 kDa (Pehuet-Figoni et al., 2000). AAbs to heat 
shock proteins (Hsp) including Hsp60 and Hsp70 was described in multiple studies by 
enzyme-linked immunosorbent assay (ELISA) in T1D (de Graeff-Meeder et al., 1993; 
Gruden et al., 2009; Ozawa et al., 1996). The sex-determining region Y-related protein 
SOX13, also named as ICA12, was first described as a T1D autoantigen in 2000 
(Kasimiotis et al., 2000). Several follow-up studies investigated its prevalence in Indian, 
Swedish and Korean diabetes patients (Fida et al., 2001; Park et al., 2003; Tandon et al., 
2002; Torn et al., 2002). However, an opposite conclusion which claimed AAb to ICA12 
was unlikely to be a useful marker for pre-clinical T1D patients challenged the validity of 
this AAb (Lampasona et al., 2001). Human DNA topoisomerase II (Top II) was 
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characterized as an autoantigen in IDDM patients in 1996 (Chang et al., 1996). It was 
reported by the same group that the positivity of anti-TopII was 50.2% and 55.2% in two 
studies, respectively (Chang et al., 2004; Shiau et al., 2000). AAbs to carbonic anhydrase 
II and lactoferrin was reported in three different studies and had variable sero-prevalence 
(di Cesare et al., 2004; Hardt et al., 2008; Taniguchi et al., 2001). Importin β was 
identified as a novel autoantigen in T1D autoimmunity by screening random peptide 
libraries by phage display (Ola et al., 2006). CD38 is named as ADP-ribosyl 
cyclase/cyclic ADP-ribose hydrolase 1. AAb to CD38 was first described in Caucasian 
patients with diabetes (Pupilli et al., 1999). Different approaches such as immunoblot 
analysis or fluid radioimmunoassay were used to measure AAbs to CD38 and resulted in 
discrepancies in its sensitivity (Antonelli et al., 2002; Mallone et al., 2001; Mallone et al., 
2002; Pupilli et al., 2005; Sordi et al., 2005). In 2008, a systematic study investigated the 
presence of AAbs to 56 secretory vesicle-associated proteins and identified VAMP2 and 
NPY as novel minor T1D AAbs with 21% and 9% sensitivity, respectively (Hirai et al., 
2008a). CCL3 was reported to be the target of AAb with 87.4% sensitivity by a fluid 
phase radioassay (Shehadeh et al., 2009). However, it was later proved not to be markers 
of T1D when measured by a commercial ELISA kit (Ziegler AG, 2011). Desin and filtrin 
are presented in both the kidney podocytes and pancreatic islet cells. It was found AAbs 
to desin and filtrin were prevalent in 33% and 11% of T1D patients (Rinta-Valkama et al., 
2007). Only a few studies explored both the protein level of autoantigens and the AAbs to 
autoantigens. Reg1α was described in other autoimmune diseases such as rheumatoid 
arthritis and systemic lupus erythematosus (Fujishiro et al., 2012). Reg1α protein level 
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was found to be significant higher in newly diagnosed T1D patients and anti-Reg1α 
antibodies were prevalent in 47% of T1D patients (Astorri E, 2010). AAb to aminoacyl-
tRNA synthetase (aaRS) was detected in 37.9% of T1D patients compared with 1.54% of 
the non-diabetic controls (Park et al., 2010). Luciferase immunoprecipitation systems 
(LIPS) assay was a recently developed method to profile AAbs. Pancreatic duodenal 
homeobox 1 (Pdx1) is a transcription factor that regulates β-cell development and 
function (McKinnon and Docherty, 2001). AAb to Pdx1 (PAA) was found in 21% of the 
patients who were triple positive of the major T1D-associated AAbs (Donelan et al., 
2013). Serological Proteome Analysis (SERPA) is a method to profile T1D AAbs from 
human pancreatic β-cells by two-dimensional gel electrophoresis (2DE) followed by 
immunoblotting. The AAb to Rab GDP dissociation inhibitor beta (GDIβ) was further 
validated by radiobinding assay (RBA) (Massa et al., 2013). AAb like anti-serpin B13 
was found to be protective to autoimmune destruction by reducing inflammation in 
pancreatic islets (Baldzizhar et al., 2013). The dual specificity tyrosine-phosphorylation-
regulated kinase 2 (DYRK2) was identified by a non-biased screening using an 
innovative protein array platform followed by LIPS assay for validation (Miersch et al., 
2013). A Korean group performed a large scale screening for novel AAbs. Anti-EEF1A1 
and anti-UBE2L3 antibodies were validated by an independent sample set (Koo et al., 
2014).  
Among these reported AAbs, few were validated in an independent sample set in 
an independent study by orthogonal assays. Some are not T1D specific but also presented 
in other autoimmune diseases (Raju et al., 2005). Most of the follow-up studies were 
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done by the same group who made the discovery. Inconsistent conclusions resulted from 
differences in the samples used (prediabetic, new-onset, long lasting or latent 
autoimmune diabetes of adults) and the technology applied (RIA, ELISA, 
immunoblotting, LIPS assay, protein array or luminex assay). Nonetheless, the 
enrichment of T1D AAb repertoire will benefit T1D research in the long term. 
2.2.2 Methods for Identifying Novel AAbs 
Methods for identifying novel autoantigens for B or T-cells are largely different. 
The methods used for identifying novel AAbs can be divided into two categories: 
screening/non-targeted or knowledge/targeted based approaches.  
The screening/non-targeted approaches include: immunohistochemistry (IHC) 
staining of pancreatic tissue section, immunoprecipitation of phage display library 
constructed from brain or pancreatic islet tissues of human or mice, immunoprecipitation 
of phage display library made of peptides covering all human proteome together with 
next generation sequencing (NGS) technology, SERPA and protein microarray. Islet cell 
antigens were detected using IHC staining by applying patient sera on human pancreatic 
islet tissue sections (Bottazzo et al., 1974). There are several disadvantages associated 
with this method. It is hard to obtain pancreatic tissue sections. The process to prepare the 
tissue sections is time consuming and labor intensive. In addition, it is difficult to 
quantify the signal of fluorescence staining. nPOD which is short for the network for 
pancreatic organ donors with diabetes, was established and funded by JDRF 
(http://www.jdrfnpod.org/). It provides pancreatic tissues to T1D researchers and has 
great impact worldwide (Campbell-Thompson et al., 2012). Juvenile Diabetes Foundation 
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(JDF) unit is a standard to quantify the level of ICAs (Bonifacio et al., 1990). To uncover 
the protein identities of ICAs, a screening technology was developed using serum from 
T1D patients to precipitate phage displayed proteins from islet cells of human or mice. 
Several AAbs were discovered in this way including IA-2 (ICA512), ICA69 and importin 
β (Bonifacio et al., 1995a; Ola et al., 2006; Pietropaolo et al., 1993). Phage display was 
combined with NGS to screen T1D-associated AAbs. Using this method, a phage display 
library displaying peptides covering the whole human proteome was constructed (Larman 
et al., 2013). No specific AAb was discovered. However, they revealed a prematurely 
polyautoreactive phenotype in T1D patients compared with their matched controls. 
SERPA was used as a proteomic tool to identify novel AAbs in T1D. Proteins from 
pancreatic tissues were separated by 2DE. T1D specific candidate AAbs were identified 
by applying T1D patient serum on the membranes transferred from 2DE gels. Candidate 
AAbs were cloned and validated by RBA (Massa et al., 2013). Protein microarray 
enables high-throughput screening of AAb to individual antigen proteins. Shane Miersch 
used a novel protein array platform and validated a minor T1D-associated AAb by LIPS 
assay (Miersch et al., 2013). A group from Korean identified two novel AAbs by high-
density protein microarrays (Koo et al., 2014). 
The knowledge/targeted approaches include: RBA using pure proteins, western 
blotting, immunoprecipitation, ELISA and luminex assay. Most AAbs identified in the 
early days were focused in the landscape of pancreatic islets. It was already known that 
T1D patients had ICAs against pancreatic islet tissue sections and insulin is one of the 
most abundant β-cell specific proteins. It was reasonable to check the presence of AAbs 
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to insulin in T1D patients. The suspicion was confirmed by measuring insulin antibodies 
using a radiolabeled soluble insulin binding assay before insulin treatment (Palmer et al., 
1983). The rationale to measure it before treatment is because insulin treatment may elicit 
antibodies to exogenous insulin which may not be distinguishable from endogenous 
insulin. Since ICA stains the whole human pancreatic tissue, it is reasonable to search for 
more proteins in the pancreatic islets as the source of AAb targets. Western blotting was 
used to identify specific proteins that are recognized by patient serum. A 64 kDa islet 
antigen from human pancreatic tissue was identified and had high prevalence in T1D 
patients (Atkinson MA, 1990). This 64 kDa protein was later proved to be GAD65 by 
immunoprecipitation of GAD prepared from brain and islet with anti-64 kDa antibody 
from T1D patients (Baekkeskov et al., 1990). ELISA was used to profile AAbs to 
purified proteins. Several AAbs were identified using ELISA including HSP60, HSP70, 
carbonic anhydrase II, lactoferrin and Aminoacryl-tRNA synthetase (di Cesare et al., 
2004; Gruden et al., 2009). Luminex assay is a method to measure AAbs in a multiplexed 
manner. It was applied to quantify AAb to serpin in the serum of NOD mice (Baldzizhar 
et al., 2013). 
2.2.3 Methods for Measuring Known AAbs 
The identification of novel AAbs by various approaches described above, allows 
for more efforts to develop and standardize assays used for quantifying these AAbs for 
clinical or research purposes. The most common methods to measure T1D AAbs include: 
RIA, LIPS assay and meso-scale discovery (MSD) platform. 
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RIA is a classical assay to measure major T1D-associated AAbs. In this assay, 
radiolabeled antigens are produced by in vitro transcription and translation using Rabbit 
Reticulocyte Lysate (RRL) expression system. Serum samples from T1D patients are 
incubated with antigen proteins and pulled down by protein A/G coated beads. After 
washing away non-specific bindings, AAb levels are quantified by measuring the 
radioactivity. Diabetes Autoantibody Standardization Program (DASP) is a program to 
improve the measurement of T1D-associated AAbs. The aim of this program is to 
improve laboratory methods, evaluate and compare assay performance in different labs. 
Experiment materials such as plasmids used for in vitro protein expression, sample 
processing procedures and experimental protocols were standardized (Bingley et al., 2003; 
Burbelo et al., 2010; Schlosser et al., 2010). 
LIPS assay was developed by Peter D. Burbelo at National Institute of Health 
(NIH) (Burbelo et al., 2005b). In this assay, genes encoding antigens of interest are 
cloned into a mammalian expression vector appended with a C-terminal renilla luciferase 
tag. Antigen proteins are expressed in mammalian cell lines and harvested for incubation 
with patient serum samples. Antigen-antibody complexes are formed and captured by 
protein A/G beads. The substrate coelecterazine is added to produce luminescent signal. 
It was shown that LIPS assay had high sensitivity in measuring AAb to IA-2, GAD65 and 
high reproducibility between RIA and LIPS (Burbelo et al., 2008). The method was 
adapted and modified in which they use a T7 promoter-based plasmid to encode antigen 
proteins that allows for cell-free expression of antigen proteins. This modified version of 
LIPS assay had similar performance in measuring IA-2A (Miersch et al., 2013). One 
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advantage of LIPS over RIA is the avoidance of radioactive materials. Because of its 
similarity and consistency with the more commonly used RIA, researchers were trying to 
develop and standardize it as a high-throughput platform to profile AAbs in T1D (Marcus 
et al., 2011). 
 MSD provides an alternative and multiplexed immunoassay platform for 
quantifying AAbs in T1D. It was developed as a nonradioactive and bivalent assay to 
measure insulin antibodies. In this assay, 96-well plates with electrodes were coated with 
streptavidin. Biotinylated and sulfo-TAG labeled insulin was incubated with serum 
samples from T1D patients. Biotinylated insulin was captured by streptavidin on the 
plates and pulled down insulin antibodies together with Sulfo-TAG labeled insulin. 
Electrochemiluminescent signal was produced when the Sulfo-TAG was close to the 
bottom of the plates. This assay has successfully demonstrated in its ability to measure 
persistent insulin in individuals with differential risk (Yu et al., 2012). It was also used to 
measure AAbs to GAD65 to identify high risk individuals. The advantage of MSD 
platform is that it has been approved by the Food and Drug Administration (FDA) for 
preclinical studies. 
Many other assay platforms were developed to improve the measurement of 
known T1D-associated AAbs. A time-resolved immunofluorometric dual-label assay was 
developed to detect AAbs to GAD65 and IA-2 simultaneously (Ankelo et al., 2007). 
Triple chimeric islet autoantigen IA2-ZnT8WR was used to measure AAbs to IA-2 and 
ZnT8 with two different polymorphisms (ZnT8W and ZnT8WR) (Yu et al., 2010). 
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2.2.4 Autoantigens Recognized by T-cells  
For years, AAbs were thought to be the “smoke of fire” and not play a role in 
T1D pathogenesis. Whereas autoantigens recognized by T-cells including CD4
+
 or CD8
+
 
T-cells are more important. CD4
+ 
T-cells are the heart of this disease. The breakage of 
immune tolerance to pancreatic β-cells of CD4+ T-cells is the key during T1D 
progression. CD8
+ 
T-cells also play a pivotal role in the process of autoimmune 
destruction. The identification of autoreactive T-cells may provide targets for diagnostic 
and therapeutic purpose of T1D. 
Most of the reported T-cell autoantigens were not specified to be reactive to CD4
+ 
or CD8
+
 T-cells as determined by T-cell proliferation assay or cytokine production assay. 
One early study showed peripheral blood mononuclear cells (PBMCs) of T1D patients 
responded to fractionated human pancreatic islet cell proteins. T-cell proliferation was 
observed in T1D patients but not in controls (Brooks-Worrell et al., 1996). PBMCs had a 
proliferative response to GAD65 in insulin-dependent diabetes (Atkinson et al., 1992). 
Autoreactive T-cells specific for ICAs including GAD65 and ICA512 were present 
during the prediabetic period (Durinovic-Bello et al., 1996). T-cell response to IA-2 was 
characterized in T-cell lines. Some of the T-cell lines responded to an immunodominant 
region in IA-2 (Hawkes et al., 2000). ZnT8 is a major AAb target in T1D. It was 
demonstrated that PBMCs from T1D patients were stimulated to produce IFNγ in 
response to a peptide pool from ZnT8 by Enzyme-Linked ImmunoSpot (ELISPOT) assay 
(Dang et al., 2011). Besides the major T1D-associated autoantigens, one study reported a 
recombinant fragment of JUNB (amino acids 1-180) stimulated peripheral blood T-cell 
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proliferation in 71% of new-onset T1D patients (Honeyman et al., 1993). T-cell 
proliferation responding to HSP60, HSP70 and HSP90 was profiled in children newly 
diagnosed with T1D. Epitopes of HSP70 and HSP60 were recognized by T-cells in 85% 
of the 25 children tested in this study (Abulafia-Lapid et al., 2003). RegII is a protein 
predominantly expressed in β-cells. Proteins from Reg family were overexpressed in 
islets of a patient who died after sudden onset of T1D. Reg-specific T-cells can transfer 
diabetes in NOD mice (Gurr et al., 2007). 
Some autoantigens were clearly described that can stimulate both CD4
+ 
and CD8
+
 
T-cells. Glucose-6-phosphatase (G6PC2) is one of them. Also named as IGRP, it is 
highly expressed specifically in pancreatic islets. The gene was first cloned in 1996 
(Arden et al., 1999). In one study, NOD mice immunized with peptides from IGRP 
showed a dominant CD4
+
 T-cell response and had a preventive role during disease 
development(Mukherjee et al., 2005). In another study, IGRP-reactive T-cells were 
detected in the islets and peripheral blood ex vivo by a tetramer assay (Lieberman et al., 
2003).  
Autoantigens recognized by CD8
+
 T-cells were investigated more because their 
direct involvement in β-cell destruction. GAD-specific cytotoxic T-cells may play a 
critical role in the initiation events inT1D (Panina-Bordignon et al., 1995). One study 
reported the insulin peptide B10-18 was presented by HLA-A2 (*0201). Cytotoxic T-cells 
recognizing this epitope was detected and correlated with recurrent of autoimmunity after 
islet transplant (Pinkse et al., 2005). A more recent study found cytotoxic T-cells 
recognizing a 10-mer signaling peptide of pre- (pro-) insulin killed β- cells in a glucose 
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dependent manner (Skowera et al., 2008). T-cell clones from T1D patients responded to 
proteins from insulin secretory enriched fractions of a hamster insulinoma cell line 
(Chang et al., 1995). Lots of studies tried to identify antigenic epitopes that can stimulate 
cytotoxic T-cells. In one study, peptides from islet amyloid polypeptide (IAPP), IGRP 
and IA-2 were presented by HLA-A (*0201) in T1D patients. Stimulation of IFNγ 
production was measured by ELISA (Ouyang et al., 2006). A quantum dot coupled major 
histocompatibility complex (MHC) multimer assay was used to measure the presence of 
CD8
+
 T-cells restricted to the insulin, pre- (pro-) insulin, IA-2, GAD65 and IGRP 
epitopes (Velthuis et al., 2010). Islet-specific CD8
+
 T-cell IFNγ enzyme-linked 
immunospot (ISL8Spot) assay was developed to quantify CD8
+
 T-cell response to ICAs 
including HLA-A2 restricted β-cell epitopes derived from pre- (pro-) insulin, GAD and 
IGRP (Mallone et al., 2007). 
There are some autoantigens that showed reactivity to CD4
+ 
T-cells. Imogen 38, 
also named as 28S ribosomal protein S31, is expressed in the mitochondrial and was 
identified as a novel autoantigen recognized by diabetic T-cell clone (1C6) in one newly 
diagnosed T1D patient by T-cell proliferation assay (Arden et al., 1996). It was reported 
later by another group that alteration of peptide of imogen 38 could inhibit antigen 
specific reactivity of Th1 clone (Geluk et al., 1998). A natural processed peptide WE14 
from chromogranin A was reported to be recognized by CD4
+
 T-cells in NOD mice 
(Stadinski et al., 2010). Mouse islet protein fraction containing islet amyloid polypeptide 
(IAPP) can stimulate the diabetogenic CD4
+
 T-cell clone BDC-5.2.9 to produce IFNγ 
(Debug et al., 2011).  
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In general, the identification of autoantigens for T-cells is much more challenge 
than for B-cells. T-cell assays need the interaction between T cell receptors (TCRs), 
peptides from autoantigens and MHC encoded by HLA genes. B-cells, CD4
+
 and CD8
+
 
T-cells may recognize same autoantigens. It is feasible to screen the autoantigens for B-
cells using an easier approach and test their validity as autoantigens for T-cells by a more 
complicated method. Many T-cell autoantigens were initially discovered in NOD mice 
not in human. It is worthy to test whether they are valid in human. A systematic survey of 
autoantigens for T-cells is needed with detailed epitope mapping, interaction with 
specific HLA genotypes and T-cell clones, their frequency and dynamics during T1D 
progression.  
2.2.5 Methods for Identifying Autoantigens Recognized by T-cells  
Methods for discovering and monitoring T-cell autoantigens are much more 
complicated than for B-cells. Four strategies could be used to identify T-cell autoantigens. 
First, pancreatic β-cells are one of the most specialized cells in human body. Many 
pancreas enriched genes are potential targets for T-cell autoimmunity; Second, 
autoantigens recognized by B-cells are another source for T-cell autoantigens as they may 
share some common epitopes; Third, β-cell autoantigens could be identified by analyzing 
mRNA expression using cDNA subtraction libraries or DNA microarrays. Forth, using an 
“inverse translation” approach, antigens found in NOD mouse can be tested in human 
(Haskins et al., 1989). 
The T-cell proliferation assay is a method to measure the proliferation of activated 
T-cells. In this assay, PBMCs are stimulated with specific antigens and incubated with 
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3
H-Thymidine. The proliferation signal is measured by the incorporation of radioactive 
nucleotide in DNA by a CPM reader. The stimulation index (SI) is calculated by using 
the mean CPM of the experimental wells divided by the mean CPM of control wells 
(Kruisbeek et al., 2004). 
The ELISPOT assay is a method to detect a single antigen responsive T-cell 
within a population of PBMCs. It provides information about the specific cytokines that 
are secreted by T-cells after antigen stimulation and the frequency of reactive T-cells 
within the test population. In this assay, a PVDF membrane microtiter plate was coated 
with a capture antibody which binds specifically to the cytokines that will be measured. 
PBMCs from either T1D patients or healthy controls are seeded into individual wells 
together with different antigens. Cytokines secreted by reactive T-cells are captured by 
the capture antibody in the wells. A biotin labeled detection antibody that binds to the 
specific cytokine is applied and is followed by a streptavidin conjugated enzyme that can 
catalyze substrate reaction to produce signals. Each spot in the well represents a cytokine-
secreting cell (Czerkinsky et al., 1983).  
The FluoroSpot assay is a modified form of the ELISPOT assay. Instead of 
measuring one cytokine, FluoSpot assay measures the secretion of two or more cytokines 
in one well by coating two or more capture antibodies. The secreted cytokines can be 
captured simultaneously in the same well and detected by different fluorescently labeled 
secondary antibodies (Gazagne et al., 2003).This method is more attractive than 
ELISPOT assay when there is limited cell amount and many cytokines need to be 
measured. 
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The MHC tetramer assay is a method to detect and quantify antigen-specific T-
cells in blood samples. In this assay, fluorophore labeled streptavidin beads are coated 
with biotin labeled MHC molecules and form a tetramer. The tetramers are incubated 
with PBMCs and peptide antigens. If these three form a complex, the fluorophore-labeled 
cells can be separated by a flow cytometer. Higher percentage of fluorophore positive 
complexes indicates a higher prevalence of antigen-specific T-cells (Altman et al., 1996). 
One study showed increased frequencies of T-cells against four novel epitopes in human 
pre- (pro-) insulin in new-onset patients compared with controls (Unger et al., 2011). 
Diab-Q-kit is essentially similar to the tetramer assay, however, the streptavidin beads are 
labeled with quantum dots instead of fluorophores. 
The assay throughput for identifying and monitoring T-cell autoantigens is limited 
because of the intricate nature of these assays. T-cell activation needs the interaction 
between MHC molecules, peptides from antigens and TCRs. All three are important in 
activating autoreactive T-cells during T1D progression. The third factor such as epitopes 
of autoantigens, HLA genotypes of APCs or T-cell clones can be studied if the 
information of any of the other two was known. Continuously monitoring autoreactive T-
cells can be used to track disease progression. These T-cell clones are also potential 
therapeutic targets in T1D. 
2.3 Role of Viral Infection in T1D 
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2.3.1 Mechanisms of Virus Induced Diabetes 
Viral infection is one of the most important environmental factors in T1D. It was 
implicated in the etiology of T1D more than 100 years ago (Knip and Simell, 2012). 
Viruses act in different mechanisms to induce T1D autoimmunity (Figure 2-5). Some 
viruses infect β-cells directly and cause β-cells cytolysis. In this case, β-Cells are 
destructed through the necrosis pathway. Infection of β-cells also leads to some indirect 
autoimmune effects including expression of viral antigens, cytokines, HLA molecules 
and alteration of β-cell antigens. All these lead to an increased inflammation signal. As a 
result, immune cells begin to recognize β-cells as non-self. More often, systemic viral 
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infection will activate immune response and breakdown immune tolerance. Some viral 
antigens show sequence similarity with known T1D-associated β-cell antigens. This is 
called molecular mimicry. The immune response to viral antigens cross reacts with β-cell 
autoantigens. All these different paths will lead to β-cell damage and clinical T1D (Jun 
and Yoon, 2004; Yoon, 1995). 
2.3.2 Viruses Reported to Be Associated with T1D 
A number of viruses have been implicated to be associated with T1D in either 
animal models or viral epidemiologic studies in human. These viruses encompassed 
different genome types (dsRNA, ssRNA(+), ssRNA(-), dsDNA). Different approaches 
were used to investigate T1D and viral associations. The most often reported T1D-
associated viruses are: enterovirus, epstein-barr virus (EBV), human cytomegalovirus 
(HCMV), human endogenous retrovirus, mumps virus, rubella virus and rotavirus. 
Enterovirus is ssRNA(+) virus that belongs to the family of Picornaviridae. There 
are 12 species and more than 100 serotypes under enterovirus genus (Oberste et al., 1999). 
Coxsackivirus (CV) is among one of the 12 species. Enterovirus infection affects millions 
of people worldwide. The symptoms of infection are usually mild. However, if viruses 
were spread to the central nervous system of newborns, it may cause severe problems. 
Complement fixation assay was used to measure the neutralization antibodies to seven 
coxsackvirus strains including A2, A5, A10, A16, B3, B4 and B5 in 123 patients with 
recent-onset T1D, 155 patients with two years’ duration of T1D and 250 normal 
individuals in 1969. It was found that the titers of antibodies to coxsackievirus B (CVB), 
especially B4 strain, were higher in recent-onset patients than patients with longer 
 32 
duration and healthy controls (Gamble et al., 1969). A follow-up study examined the 
diabetes incidence in individuals 5 years after they were tested positive for 
coxsackievirus B4 (CVB4) infection (Dippe et al., 1975). CVB4 strain was isolated from 
the pancreas of a child with sever diabetic ketoacidosis (Yoon et al., 1979). It provided a 
direct evidence of coxsackievirus infection in pancreatic cells. Enterovirus was shown to 
infect cultured β-cells (Ylipaasto et al., 2004). CVB4 infection can induce the 
development of antibodies to a 64 kDa autoantigen in mice (Gerling et al., 1991). CVB4 
infection also induces cytokine production in pancreatic cell cultures through toll-like 
receptor 4 (Triantafilou and Triantafilou, 2004). In human pancreatic tissue, it was 
observed that CVB4 infection was specific to β-cells but not causing direct β-cell 
destruction. The infection induced inflammation mediated by NK cells (Dotta et al., 
2007). Enterovirus is notorious in T1D at both the epidemiology and molecular level. 
More systematic clinical studies were performed to explore their associations. 
Enterovirus infection was found to be associated with the development of β-cell 
autoimmunity and the initiation of β-cell destruction in the Finnish Diabetes Prediction 
and Prevention (DIPP) study (Lonnrot et al., 2000). The same conclusion was reached 
from another study by detecting enterovirus RNA in blood samples (Oikarinen et al., 
2011). A recent study surveyed neutralization antibodies to 41 different enterovirus 
serotypes in 183 DIPP AAb positive children and 360 AAb negative controls. The results 
support CVB1 is associated with induction of β-cell autoimmunity (Laitinen OH, 2014). 
Another study published by the same group further conformed CVB1 as a diabetogenic 
virus type (Oikarinen et al., 2014). However, two other prospective studies failed to show 
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the association of enterovirus infection and T1D (Fuchtenbusch et al., 2001; Graves et al., 
2003). These two studies are the BABYDIAB study in Germany and the Diabetes 
Autoimmunity Study in the Young (DAISY) in US.  
EBV, named as human herpesvirus 4 (HHV-4), is a dsDNA virus that belongs to 
the family of Herpersviridae. There are 8 species in this family. EBV infection is 
associated with cancers and autoimmune diseases including Hodgkin’s lymphoma, 
Burkitt’s lymphoma, systemic lupus erythematosus and multiple sclerosis (Maeda et al., 
2009). EBV infection can induce fulminant onset of diabetes (Burgess et al., 1974b). 
PCR reaction was used to search for EBV genome in T1D patients (Foy et al., 1995; Foy 
et al., 1994). It was reported EBV infection was not associated with islet cell and insulin 
AAb seroconversion by profiling antibody response to EBV nuclear antigens (Elliott RB, 
1995a). Antibody levels to viral capsid antigen (VCA) and early antigen (EA) was 
profiled by a commercial ELISA kit and it was found lower VCA IgG class antibody 
levels in T1D patients (Hyoty et al., 1991). EBV infection can stimulate cytokine 
production in the host (Hornef et al., 1995). EBV may be involved in T1D pathogenesis 
by the mechanism of molecular mimicry. It was reported that antibody reactivity to an 
epitope in one EBV protein was also presented in the human HLA-DQ8 protein 
(Parkkonen et al., 1994a). 
HCMV, also known as human herpesvirus-5 (HHV-5), is a dsDNA virus that 
belongs to the family of Herpersviridae. It was reported that a diabetic case had 
congenital cytomegalovirus infection in 1979 (Ward et al., 1979). Using molecular 
probes specific for HCMV genome, the viral genome was found in 22% in diabetic 
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patients and 2.6% in healthy controls (Pak et al., 1988). Another study reported that there 
was no detectable cytomegalovirus DNA in the pancreas of recent-onset T1D patients 
(Elliott RB, 1995a). A peptide derived from the DNA-binding protein from HCMV can 
stimulate autoreactive T-cells. This peptide showed sequence similarity with GAD65 
which is a major T1D-associated autoantigen (Roep BO, 2002). 
Human endogenous retrovirus was implicated inT1D. Human endogenous 
retrovirus K18 encodes a superantigen which is a candidate autoantigen for T1D (Conrad 
et al., 1997). However, the following studies showed contradictory conclusions from this 
first report. The human endogenous retroviral strain was named as insulin dependent 
diabetes mellitus (IDDM)K (1,2)22  and it was not specific for T1D but also presented in 
healthy controls (Kim et al., 1999). The genomic DNA or mRNA of (IDDM)K (1,2)22 
was not detectable in T1D patients (Muir A, 1999). Another study used reverse 
transcription-polymerase chain reaction (RT-PCR) to detect viral mRNA in six patients 
and controls and found no difference between these two groups (Jaeckel et al., 1999). 
Mumps virus is a ssRNA(-) virus that belongs to the family of Paramyxovirida. 
Mumps virus can infect human pancreatic β-cell cultures as proved by 
immunohistochemical staining of mumps proteins (Prince et al., 1978). It was reported 
that the T1D patients showed a significantly lower prevalence and reduced titers of 
antibodies to mumps (Toniolo et al., 1985). IgA class antibody response to mumps virus 
was higher in T1D patients than healthy controls, while no difference was found in IgG 
or IgM responses (Hyoty et al., 1985). In the Italian Insulin-dependent Diabetes Registry 
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study, a significant association was found between mumps and rubella virus with T1D, 
but not measles virus (Ramondetti et al., 2012).  
Besides, some studies reported the association between rotavirus and rubella virus 
infections with T1D. Many of the studies on the same virus generated conflicted 
conclusions. This may be due to the limited sample size, different methods to determine 
viral infections or geographical differences of sample locations. A systematic study is 
needed to evaluate the role of viral infections in T1D. 
2.3.3 Methods for Studying Viral and T1D Association 
To investigate the viral and T1D association, one way is to determine the 
prevalence of viral infections during T1D progression. Viral infection not only results in 
acute infection-related symptoms, the host innate and adaptive immune system work 
cooperatively to fight against infection. Anti-viral antibodies are produced during this 
course. Different approaches could be used to detect the presence of viral proteins, 
genome or anti-viral antibodies. The same method to detect AAbs can be used to detect 
anti-viral antibodies including RIA, ELISA, LIPS and luminex assay. There are some 
unique methods to detect anti-viral antibodies including plaque reduction neutralization 
assay and complement fixation assay. 
Plaque reduction neutralization assay is a method to detect neutralizing antibodies 
in serum against a specific serotype of this virus. In this assay, a serum sample is mixed 
with a virus stock at different serial dilutions. After incubation, the serum and virus 
mixture is applied to a monolayer of the host cells of this virus on agar plates. If the 
sample has no neutralizing antibodies, the viruses in the mixture will infect the host cells 
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and form plaques on the monolayer. Conversely, if the sample has neutralizing antibodies 
that bind to the viral particles, it will be blocked from infecting host cells. As a result, the 
number of plaques will be reduced. The percentage of inhibition is calculated by dividing 
the number of plaques with serum incubation by without serum incubation. A high 
percentage of inhibition is considered positive for anti-viral antibodies. A recent study 
adapted this method to profile neutralizing antibodies to 41 enterovirus serotypes 
(Laitinen OH, 2014). 
The complement fixation assay is another method to detect the presence of 
specific antibodies in serum samples. In this assay, a serum sample is incubated with a 
standard complement protein and viral antigens. If the serum sample has anti-viral 
antibodies, antibody-antigen complexes will be formed and destroy the complement 
component. When sheep red blood cell (sRBC) and anti-sRBC complex will be applied, 
since the complement that can react with anti-sRBC and sRBC complex is already 
depleted, the sRBC will stay intact and the reaction shows no red color. Conversely, if 
there are no anti-viral antibodies in the serum, the complement will not be depleted. It 
will react with anti-sRBC and RBC complexes and lyse the RBCs, resulting red color in 
the reaction. Viral antibodies to coxsackievirus, influenza and mumps virus were 
determined by this method (Gamble et al., 1969). 
Some studies sought to detect viral protein in the pancreatic tissue by IHC 
staining. Others tried to detect viral genomes by PCR or IHC. The emerging NGS 
techniques opened new revenues to sequence the T1D samples for diabetogenic viral 
strains (Lee et al., 2013). 
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2.4 Protein Microarray 
2.4.1 Overview 
Protein array is defined as an array of proteins displayed on a tiny microscopic 
slide. The function and binding activity of displayed proteins can be analyzed in a high-
throughput manner. The concept of protein array was first brought up by Roger Ekins in 
1989 (Ekins, 1989). The first mature protein array platform was developed by Gavin 
MacBeath in 2000. He printed as many as 10,800 spots on one slide and demonstrated 
protein-protein interactions using purified proteins (MacBeath and Schreiber, 2000). 
Heng Zhu and his colleagues produced another mature protein array by purifying and 
printing 5,800 yeast proteins on slides in 2002 (Zhu et al., 2001). The binding activity of 
calmodulin and phospholipid to yeast proteins were investigated on this array. After that, 
more and more innovative protein array platforms were emerging. Based on their 
characteristics, they can be divided into three categories: analytical protein array, reverse 
phase protein array and functional protein array. 
Analytical protein array is also known as capture array. Capture antibodies or 
aptamers that can bind specifically to proteins are printed. Protein mixture such as cell 
lysate is labeled with fluorescence and applied on the slides to determine and compare 
protein abundance in different samples (BB., 2005). It can be used to analyze proteins 
that are associated with disease status (Orchekowski et al., 2005). Some limitations of 
this technology include: epitope destruction during the process of labeling targeted 
protein; sensitivity, specificity and availability of high quality capture antibody; difficulty 
in detecting low abundance proteins. 
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Reverse phase protein array is a platform that prints cell lysate or fractionated cell 
lysate on glass slides. Fluorescently labeled antibodies can be used to detect proteins of 
interest. Cloud Paweletz used this platform to identify molecular markers and pathway 
targets in patients during the progression of prostate cancer (Paweletz et al., 2001). This 
platform is also highly dependent on the availability of good antibodies. 
Functional protein array is known as target protein array. Proteins are displayed 
on slides that allow for the investigation of their biochemistry activity including protein-
protein, protein-DNA, protein-RNA, protein-drug interaction, protein enzymatic assay 
and protein translational modifications (PTMs). The first use of this platform is by Gavin 
MacBeath in 2000. Based on the source of printed proteins, the functional protein array 
could be further categorized as cell-dependent protein array and cell-free protein array. 
Cell-dependent protein array requires the expression and purification of individual 
proteins from a cell culture system such as bacteria, yeast, insect or mammalian cells. 
Cell-free protein arrays use an in vitro transcription and translation system to produce 
target proteins from their DNA templates. There are several classical cell-free protein 
array platforms. Protein in situ array (PISA) is platform that use PCR-generated DNA 
fragment to produce proteins by a cell-free protein expression system. Expressed proteins 
are spotted and immobilized on slide surface by a capture agent (He and Taussig, 2001). 
This method was adapted and modified. DNA is first printed on the slides before the cell-
free expression reagent is printed. Proteins are captured in situ and can be detected by the 
specific antibodies (Angenendt et al., 2006). The DNA array to protein array (DAPA) 
was developed in 2007 by a group in UK (He et al., 2008). In this platform, DNA that 
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encodes proteins of interest is printed on a glass slide. A second slide is coated with 
capture agent. These two slides are assembled together with a cell-free expression reagent 
soaked membrane in the middle. The synthesized proteins can be captured by the capture 
agent on the other slide. DNA slides can be reused as long as it is not degraded. Nucleic 
Acid Programmable Protein Array (NAPPA) is another major cell-free proteins array. It 
will be introduced with details in next sections with high density (HD)-NAPPA. 
2.4.2 Nucleic Acid Programmable Protein Array 
NAPPA, Nucleic Acid Programmable Protein Array, was first described in 2004 
(Figure 2-6). Instead of printing purified proteins, NAPPA is produced by printing 
cDNAs in a plasmid that is appended with a C-terminal GST tag together with an anti-
GST capture antibody. Proteins are transcribed and translated from plasmid DNA and 
captured by the anti-tag antibodies. Proteins displayed on the slides can be used for 
functional studies such as binding assays (Ramachandran et al., 2004). In 2008, 1,000 
unique human cDNAs was printed on NAPPA in duplicate on one slide. Proteins with 
variable sizes can be expressed, displayed with high day to day reproducibility 
(Ramachandran et al., 2008). 
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NAPPA has several advantages over the traditional protein arrays: 1) Replaces 
printing proteins with the more reliable and less expensive process of printing DNA; 2) 
Avoids the need to express, purify and store proteins; 3) Displays better than 95% of 
sequence-verified full-length proteins. We have demonstrated its utility in assessing sero-
reactivity to membrane proteins on NAPPA (Montor et al., 2009); 4) Protein display 
levels are consistent from protein to protein with 93% of proteins within two-folds of the 
mean. The binding between antibody and antigen is concentration dependent. On 
traditional protein-printed protein arrays, the amount of protein displayed on each spot 
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often varies as much as 3 orders of magnitude due to the naturally large variation in 
protein purification yields. This makes it difficult to interpret whether a weaker signal is 
due to low/no protein amount on the array or low/no antibody concentration in plasma 
sample. The consistent display of proteins on NAPPA arrays will make data 
interpretation much easier; 5) Assures protein integrity by using both mammalian 
expression machinery and chaperone proteins to synthesize and fold proteins. 
NAPPA has a broad application in immunoprofiling of serological antibodies, 
protein-DNA and protein-protein interactions and PTMs. Humoral immune response to 
infectious agents including viruses and bacteria can be analyzed on NAPPA (Ceroni et al., 
2010; Montor et al., 2009). NAPPA was widely used as an AAb biomarker discovery 
platform in cancers and autoimmune diseases (Anderson et al., 2015; Anderson et al., 
2011; Anderson et al., 2010; Gibson et al., 2012; Wright et al., 2012). Recently, PTMs 
like AMPylation were profiled on NAPPA (Yu et al., 2014c). 
2.4.3 High Density-NAPPA 
HD-NAPPA is a new technology that helps NAPPA to achieve a much higher 
density (Takulapalli et al., 2012). HD-NAPPA is built on silicon nanowell substrates. 
Nanowells are generated on silicon substrates by different etching techniques including 
wet or plasma etching (Wiktor et al., 2015). The density of array increases with the 
decrease of well size. As a proof of concept, HD-NAPPA can reach as high as 24,000 
features per slide. The regular HD-NAPPA has 14,000 spots per slide (Takulapalli et al., 
2012). To mimic the glass surface of standard NAPPA, a thin film of silicon dioxide is 
thermally grown the surface of silicon nanowells. Aminopropyl-triethoxy-silane (APTES) 
 42 
is coated on top to generate a monolayer for NAPPA chemistry. Printing mix is dispensed 
into individual wells by high-speed electronic Piezo printer. Using this platform, a lot less 
DNA is consumed compared with standard NAPPA. HD-NAPPA showed less diffusion, 
the capability of detecting antigen-antibody binding and protein-protein interaction 
(Takulapalli et al., 2012). HD-NAPPA has great potential in future applications of 
functional proteomic studies. 
2.5 Rationale of This Dissertation Study 
2.5.1 AAb Biomarker Discovery 
AAbs are produced by autoreactive B-cells during T1D progression. The major 
T1D-associated autoantigen include insulin, GAD65, IA-2 and ZnT8 (Atkinson MA, 
1990; Bonifacio et al., 1995a; Palmer et al., 1983; Wenzlau et al., 2007). A number of 
minor T1D-associated AAbs were identified by various approaches. The number of T1D-
associated AAbs may be much higher than currently known. Diabetic individuals who are 
positive for ICA staining yet remain negative for the four known T1D-associated AAbs, 
indicating the existence of yet-to-be discovered AAbs (Wang J, 2007). Also, a proportion 
of patients are negative for both ICA and the known biochemical AAbs with no apparent 
difference in clinical performance compared with AAb positive T1D patients suggesting 
different disease subtypes (Hameed et al., 2011). One possible explanation is that AAbs 
in this group may target antigen proteins outside the landscape of the pancreatic islet, 
which give us a hint that a whole proteome screening may help to identify additional 
AAbs. In addition, some AAbs may appear at different stages of the disease such as the 
pre-diabetic period. Because their levels might not persist, they may not have been 
 43 
detected in blood samples taken at the time of diagnosis or in clinically active patients. 
Some of these AAbs might be specific to certain individuals emphasizing the 
heterogeneous nature of the disease (e.g., different rates of progression, etiological 
factors, genetic backgrounds) (Achenbach et al., 2013; Achenbach et al., 2004). 
Furthermore, these AAbs might have been missed by the traditional assay methods used 
for AAb discovery. Additional AAbs may provide values in the following aspects:  
(1) Identifying individuals at risk: Prevention of T1D will only be possible if 
individuals with high risk for progression to T1D (especially in the general population) 
can be identified. The incidence of T1D in the general population is around 22/100,000 in 
US. The majority of T1D cases are diagnosed in non-relatives, with 85% of new T1D 
cases occurring in individuals with no known family history (Hamalainen and Knip, 2002; 
Knip et al., 2010). Biomarkers are needed that can improve our prediction models and 
enable the selection of subjects with, for example, high 5-year risk of disease onset. Such 
markers could be deployed immediately to identify high risk subjects for intervention 
trials (Marino et al., 2011). Currently a large percentage of subjects based on our current 
risk prediction model might not develop an insulin requirement within 5 years, even 
among relatives of T1D subjects (Winter and Schatz, 2011). Identifying markers that are 
present prior to the development of our currently used AAbs could improve the risk 
prediction models. 
(2) Stratifying patients with different clinical courses: Individuals who 
progress to T1D do so at different rates. The currently used AAb biomarkers do not 
explain the variations in progression rates towards clinical T1D. The mechanisms 
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regulating the progression rates of rapid or slow progressors in an AAb positive 
population are not well understood, yet they are crucial to ensuring that the most 
appropriate interventions are developed (Achenbach et al., 2013; Wasserfall and 
Atkinson, 2006). Once high risk individuals are identified, prevention strategies would 
benefit from additional biomarkers that provide a more detailed description of that 
individual’s status with respect to disease progression rates. 
(3) Improving our understanding of autoimmune destruction: The existence of 
the known T1D-associated AAbs indicates autoimmune destruction (Bonifacio and 
Ziegler, 2010). Yet we still lack a detailed understanding of the molecular mechanisms of 
T1D pathogenesis.  Current T1D models explain the natural history but not mechanisms 
of the disease development.  The etiopathogenesis remains elusive due to our limited 
ability to observe and monitor beta-cell destruction directly (Atkinson, 2012). An 
improved understanding of disease etiology, especially what events trigger the 
conversion from genetic high risk to serological high risk, will help strategies aimed at 
preventing or delaying disease progression. Finding biomarkers that are linked to these 
events or even mark them temporally, will clearly aid in this regard. 
(4) Identifying cellular immune response antigens: Cellular immune response 
plays an important role in T1D development. Because the difficulties associated with the 
identification of T-cell autoantigens, assays measuring antibody responses to 
autoantigens are usually used as surrogates for identification of T-cell antigens with the 
assumption that antigens that are presented by B cells will also stimulate T cell responses. 
Therefore, the identification of autoantigens that can elicit autoantibodies may provide 
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candidates for research in their role in cellular immune response, which may be more 
relevant to immune destruction in T1D. 
(5) Providing candidates for prevention trials: Autoantigens may provide 
candidates for developing T1D prevention strategies. Ongoing clinical trials are 
conducted by TrialNet to study the daily intake of oral insulin capsules or injections of 
GAD protein to delay the disease in at risk relatives of people with T1D or preserve 
insulin production respectively.  DiaPep277, a synthetic peptide from human heat shock 
protein (Hsp60, a minor T1D autoantigen) was found to preserve endogenous insulin 
secretion up to 18 months (Raz et al., 2007). It is now in the phase III clinical trial. New 
autoantigens may also be fed into similar clinical trials. 
However, the rate of discovering new AAbs has been limited by the throughput of 
the techniques used in the past. This suggests the need for new tools that can adequately 
test a broad antigen space, as well as the need to apply those tools to well-characterized 
samples. Ideally, such tools must be high-throughput and multiplexed to allow the 
generation of a comprehensive picture of antibody repertoire in many subjects at many 
time points. Yet, they must also be cost-effective to enable the discovery of leads for 
further confirmation. We believe the rapid advancement of “omics technologies” will 
help move this field forward. A protein array-based immunoproteomics approach is 
powerful to characterize humoral immunoprofile against human proteomes to identify 
novel T1D-associated AAbs. We believe that the identification of a panel of novel T1D-
specific AAbs will help to connect the nodes in T1D etiology, provide candidates for 
detailed pathophysiology study and develop preventive approaches based on these targets.   
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2.5.2 Viral and T1D Association Study 
Interplay between genetic, immunological and environmental factors contributes 
to T1D development (Eisenbarth, 1986; Herold et al., 2013), yet it is still poorly 
understood. Among various environmental factors, viral infections have attracted 
particular interest (Craig et al., 2013b; Roivainen and Klingel, 2010). One hypothesis 
holds that in susceptible individuals, the antiviral response leads to cross-reactivity 
against host antigens in the β-cells, ultimately leading to β-cell destruction.  A number of 
viral genes have been found to share similar amino acid sequences with the known T1D-
associated autoantigens (Roep BO, 2002). These findings provide support for the 
“molecular mimicry” theory of the role of viral infection in T1D development 
(Coppieters et al., 2012). An improved understanding of the contributions of different 
environmental risks (especially viral infections) may help devise novel prevention 
strategies in T1D. 
Different approaches were applied to determine viral infection in T1D. The broad 
availability of DNA sequencing technologies in conjunction with the ease of amplifying 
nucleic acids has motivated DNA-based approaches to study the role of viral infection in 
T1D. RT-PCR is a traditional way to detect viral genomes from the stool samples or nasal 
swabs through the amplification of viral genes with gene-specific primers (Saito et al., 
1989). While clearly very powerful, this approach demands that the nucleic acids are still 
persistent in the blood or tissue at the time of sample collection. In the context of the 
cross-reactivity hypothesis, many of the pathogenic events may occur after the virus is no 
longer present. Viremia can be as short as a few days (Lee et al., 2013). Moreover, the 
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high cost of NGS technology, and the need to test many samples make deep sequencing-
based studies less amicable to epidemiological studies. Finally, the sensitivity of PCR-
based detection also varies based on the choice of pathogen genes to be amplified and 
some mutations in the pathogen genomes also affect amplification efficiency. PCR is 
susceptible to false positive results due to contamination or non-specific amplification.  
As noted above, the humoral response to viral antigens can be detected long after 
viremia has ended and the modern ability to test the immune response against the entire 
viral proteome will provide additional important clinical information about the 
individual’s immune status beyond simply demonstrating a history of infection. 
2.5.3 Advantages of NAPPA 
Our NAPPA approach to profile AAbs and anti-viral antibodies is innovative by 
the following aspects: 
(1) Our innovative protein array allows us to study the immune repertoire 
during T1D development. On this platform, we can: 1) assess the serological antibody 
profile to thousands of human and viral antigen proteins simultaneously and require as 
little as 4µl serum/plasma samples per array; 2) compare the sero-reactivity to known 
T1D-associated antigens on the same array; 3) track the antibody repertoire changes 
during the course of T1D progression; 4) profile both IgG and IgM or IgA antibodies in a 
multiplexed way. 
(2) The consistent levels of proteins across the array give every protein a fair 
chance for detection by antibodies in serum. The issue of a broad dynamic range of 
protein concentrations in serum is not relevant here. 
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(3) The potential of linking multiple antigens to improve predictive value can 
be explored. It is highly possible that the prevalence of each of the novel AAbs will be 
lower than the known four, i.e., a relatively small fraction of patients may respond to 
each antigen.  Thus, a biomarker test based on a single antigen would demonstrate poor 
sensitivity.  An integrated panel of multiple T1D-specific antibodies will increase the 
predictive value. 
(4) The identification of additional AAbs will improve our ability to 
understand their role in T1D pathogenesis from network and/or bioinformatics analysis.  
(5) The identification of additional AAbs may potentially benefit proteomics 
studies on other platforms and search for these AAbs in serum. 
From an “omics” perspective, AAb profile from this study can complement with 
other proteomic discoveries. The anti-viral antibody profile can be integrated with 
mirobiome and virome studies in T1D. The complete host humoral immunoprofile 
against human and viral proteomes will provide new insights into T1D pathophysiology. 
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CHAPTER 3  
3 SEROLOGICAL ANTIBODY PROFILING OF TYPE 1 DIABETES BY 
PROTEIN ARRAYS 
3.1 Abstract 
The need for biomarkers that illuminate the pathophysiology of type 1 diabetes 
(T1D), enhance early diagnosis and provide additional avenues for therapeutic 
intervention is well recognized in the scientific community. A proteome-scale, two-stage 
serological autoantibody (AAb) screening followed by an independent validation study 
was performed. In the first stage, the immunoreactivity was compared between T1D 
cases and healthy controls against ~6,000 human proteins using the Nucleic Acid 
Programmable Protein Array (NAPPA). Genes identified with higher signal intensities in 
patients were challenged with a larger sample set during the second stage. Statistical 
analysis revealed 26 novel AAbs and a known T1D associated AAb. During validation, 
the presence of AAbs to dual specificity tyrosine-phosphorylation-regulated kinase 2 
(DYRK2) was verified using the Luciferase Immunoprecipitation System (LIPS) assay 
(36% Sensitivity, 98% specificity). The area under the curve (AUC) for a combination of 
DYRK2 AAb (DYRK2A) and the classical T1D AAb IA-2 AAb (IA-2A) was 0.90 
compared to 0.72 for DYRK2A and 0.64 for IA-2A alone. This is the first systematic 
screening for seroreactivity against large number of human proteins in T1D patients. The 
application of protein microarrays to identify novel AAbs in T1D, expanded the current 
T1D “autoantigenome” was demonstrated and it will help fulfill the goal of searching for 
novel biomarker candidates for T1D in the future.
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3.2 Introduction 
Early studies of diabetes demonstrated the seroreactivity of individuals with T1D 
to islet cells in pancreatic cryosections (Atkinson et al., 1990), suggesting an AAb-
mediated autoimmune component in this disease. The identification and study of AAbs 
associated with T1D (Baekkeskov et al., 1990; Bonifacio et al., 1995a, b; Bottazzo et al., 
1974; Palmer et al., 1983; Wenzlau et al., 2007), has confirmed their roles as biomarkers 
with value in diagnosis (Wasserfall and Atkinson, 2006), prognosis, patient treatment 
stratification (Christie et al., 2002), tolerizing therapies as well as providing insights into 
the pathophysiology of disease (Ludvigsson et al., 2008a). AAbs against insulin, glutamic 
acid decarboxylase 65 (GAD65), protein tyrosine phosphatase receptor N (IA-2) and zinc 
transporter member 8 (ZnT8) antigen proteins in T1D have a combined clinical 
performance enabling the detection of >90% of T1D (Wenzlau et al., 2007). The known 
T1D-associated AAbs are frequently used for research studies and increasingly used in 
clinical management for purposes such as identifying individuals with T1D risk, 
stratifying patients with different disease course and improving our understanding of 
autoimmune destruction (Achenbach et al., 2013; Bonifacio and Ziegler, 2010; Pozzilli, 
2002). Despite this, known T1D associated AAbs against antigens like insulin and 
GAD65 are not diabetes specific. Insulin AAb (IAA) appears in insulin autoimmune 
syndrome while GAD65 AAb (GADA) appears in Stiff-Man Syndrome (Raju et al., 
2005). In addition, many diabetic individuals positive for islet cell antibody (ICA) 
staining are negative for all known anti-islet AAbs (Wang et al., 2007), suggesting the 
existence of additional, yet-to-be-identified AAbs. Comprehensive identification of AAbs 
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targeted in T1D will help fully characterize the heterogeneity of disease represented in 
the “autoantigenome” that may enable enhanced diagnostics, personalized therapies and a 
fundamental understanding of diabetes pathology. 
AAb discovery in T1D has been slow with the identification of four major AAbs 
over the past four decades. Previous AAb biomarkers were discovered based on either the 
known understanding of T1D pathogenesis (e.g., IAA) using radioimmunoassay (RIA) or 
immunoprecipitation of autoantigens from cell lysates by patient serum. With the 
development of genomics and bioinformatics, ZnT8 was identified as a major T1D AAb 
by analyzing pancreatic gene expression profiles followed by RIA (Wenzlau et al., 2007). 
No large-scale screening of individual proteins at the proteome level has been conducted 
to search for new T1D AAb biomarkers perhaps due to the lack of appropriate high-
throughput proteomic techniques. 
The advent of proteomics technologies like protein microarrays has provided 
attractive opportunities to profile AAb against a large number of human proteins in T1D.  
Protein microarrays in particular are an invaluable tool for simultaneous interrogation of 
thousands of proteins and possess immense potential as a non-biased discovery tool to 
identify AAbs targeting self-antigens. They have been used in a variety of systematic and 
organ-specific autoimmune diseases including autoimmune hepatitis (Song et al., 2010), 
rheumatoid arthritis (Hueber et al., 2005), multiple sclerosis (Quintana et al., 2008) as 
well as in various cancers including breast cancer (Anderson et al., 2011), lung cancer 
(Madoz-Gurpide et al., 2008), colon cancer and colorectal cancer (Babel et al., 2009; 
Nam et al., 2003).  
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Conventional protein microarrays printed from purified proteins, however, suffer 
from practical limitations including the substantial cost and time associated with 
purifying proteins from sizable libraries that can make large scale screening cost-
prohibitive. The wide range of protein concentrations deposited and limited shelf lives 
due to the instability of purified proteins, can further compromise the array utility.  
Recent conceptual advances achieved with the NAPPA platform have circumvented these 
primary challenges associated with conventional protein microarrays by printing cDNA 
encoding plasmids instead of purified proteins (LaBaer and Ramachandran, 2005). 
Plasmids encoding genes with a C-terminal affinity tag are co-printed on the array along 
with anti-tag antibody allowing for the cell-free expression and immediate capture of 
thousands of functional proteins with a wide range distribution of protein sizes on glass 
slides (LaBaer and Ramachandran, 2005). Slides are stable at room temperature for at 
least one year and can be expressed at the time-of-use. NAPPA has been applied in a 
variety of AAb discovery studies such as breast cancer and arthritis (Anderson et al., 
2011; Gibson et al., 2012). 
In the present study, the first large scale use of protein microarrays in profiling of 
AAbs in T1D was reported by conducting a two-stage, sequential serological 
immunoreactivity screening and an independent validation study. The two stages of 
screening resulted in the identification of 26 candidate AAbs including ZnT8 (p<0.005, 
FDR<10%). Candidate genes were selected for further validation via LIPS assay in an 
independent serum set (Burbelo et al., 2005a). Using this assay, AAb to DYRK2 showed 
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36% sensitivity at 98% specificity, thus demonstrating the use of protein microarrays in 
the search for novel T1D associated AAbs
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3.3 Experiments 
3.3.1 Serum Samples 
T1D serum samples included in the study were obtained from individuals 
diagnosed with T1D, according to American Diabetes Association (ADA) criteria, at 
College of Medicine, the University of Florida. Peripheral blood samples were drawn 
from the antecubital vein and serum was prepared according to a standardized protocol 
before freezing serum aliquots at -80
o
C. Control samples were drawn and prepared in the 
identical fashion to T1D patients and selected to be age-matched to the patient set. 
Control samples were considered to be at low risk of T1D with absence of known T1D-
associated AAbs and T1D family history. Independent sample sets were used in each 
stage of study. Neither patients nor control samples were known to have any other 
underlying autoimmune disease. All samples were collected with written informed 
consent, under the guidelines of the Institutional Review Boards (IRB) at the University 
of Florida, the Harvard Medical School and Arizona State University through the entire 
study. The detailed sample information is indicated in Table 3-1. 
 
 
 
 
 
 
 
 
 55 
3 - 1 Sample Characteristics of Each Stage 
  
Total 
Gender 
Male 
(%) 
 
Age 
Mean+SD  
(Median) 
 
Years from Diagnosis 
Mean+SD  
(Median) 
 
First-stage screening 
 
T1D 6.7% 
50 17.6±10.4 
(14.4) 
 
6.7±8.4 
(4.0) 
 
Healthy 13.3% 
20 24.3±9.6 
(23.4) 
 
N/A 
 
Second-stage 
screening 
 
T1D 40.0% 
74 21.1±11.3 
(17.0) 
 
5.5±7.7 
(2.3) 
 
Healthy 20.0% 
75 18.5±12.1 
(15.5) 
 
N/A 
 
Validation Stage 
 
T1D 46.7% 
46 17.2±11.0 
(13.0) 
 
6.8±8.5 
(3.5) 
 
Healthy 66.7% 
46 17.7±11.5 
(15) 
 
N/A 
 
 
3.3.2 Array Production and Quality Assessment 
Human genes used in this study were obtained from DNASU 
(http://dnasu.asu.edu/DNASU/). NAPPA was produced and the quality of DNA printing 
and protein expression were controlled as previously described (Burbelo et al., 2005a; 
Miersch and LaBaer, 2011; Qiu and LaBaer, 2011; Sibani and LaBaer, 2011). The 
correlation of protein expression within one printing run or two printing runs was 
compared to determine the reproducibility of slides production. 
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3.3.3 Profiling of Serum AAbs 
Serum AAb profiling on NAPPA was performed as previously described 
(Anderson et al., 2011). Briefly, once slides quality had been confirmed, expressed slides 
were challenged with serum samples, HRP-linked anti-human IgG secondary antibodies 
and developed by Tyramide Signal Amplification (TSA) (Clutter et al., 2010). All slides 
were scanned by a ScanArray ProScanArray HT scanner (Perkin Elmer) at the same 
settings. Individual spot signal intensities were quantified using Microvigene Image 
Analysis Software V2.9.9.2. Slide images were vetted to remove visually defective 
features (i.e. with scrapes, smudges, dust particles, or obvious contribution of signal from 
adjacent features).   
3.3.4 Study Design and Data Analysis  
Screening efforts were structured in two stages (Figure 3-1). In the first stage of 
screening, 50 cases and 20 control serum were used to screen >6,000 unique proteins 
across three arrays. Signal intensities were normalized by first subtracting the background 
signal estimated by the 25
th
 percentile of the negative control (printing mix alone without 
plasmid DNA) on each slide and then scaling data of each slide to the same overall 
median intensity and median absolute deviation. Normalized signal intensities were 
analyzed  by comparing the 90
th
 percentiles of case and control samples using three 
statistical tests: Quantile regression (Koenker, 2001), Fisher’s exact test and a binomial 
proportion test. The antigens that did not exhibit statistically significant (p<0.05) 
differential reactivity in cases versus controls according to any of the three tests were 
eliminated. The remaining antigens were ranked by the difference between the summed  
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3 - 1 Scheme of NAPPA and Strategy of AAb Screening 
(a) Nucleic acid programmable protein array (NAPPA) - spotted plasmids are printed 
along with a capture antibody, expressed in situ using a cell free expression system, 
and the protein of interest is captured by an anti-tag antibody. 
(b) Protein displaying-microarray slides are challenged with serum from either patient 
or control individuals.  The difference in immunoreactivity is determined by tyramide-
amplified signals from the HRP-labeled anti-human IgG secondary antibody.  
Antigens that repeatedly show a higher intensity in patients than controls are 
considered candidate T1D autoantigens. Red dots represent high reactivity, yellow 
dots represent medium reactivity; green dots represent low reactivity. 
(c) Three stages of AAb discovery strategy: First stage screening: A large number of 
expressed antigen genes were challenged with a smaller number of sera samples to 
eliminate uninformative genes; Second stage screening: Antigens that exhibited higher 
responses among patient serum were challenged with a larger number of patient and 
control serum samples to scale down the number of candidates for validation; 
Validation stage: Top candidates from microarray analysis were validated by an 
independent luminescent immunoprecipitation (LIPS) method. 
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signals of cases versus controls above the 90
th
 percentile of the controls. ~750 antigens 
from three arrays were advanced to the second stage screening.  
In the second stage, 74 case and 75 control sera were screened using the ~750 
antigen genes identified from the first stage. After background subtraction, Wilcoxon 
Rank-Sum Test and the partial AUC at 95% specificity (pAUC95) were applied in the 
analysis of normalized data to rank genes that have differential reactivity between patient 
and control group. The sensitivity and p-values of each candidate was generated.  The 
rationale to include two statistical methods to analyze the second-stage screening data 
was to be more inclusive with autoantibody biomarker candidates for validation. 
During the validation stage, the sensitivity and specificity of the combination of 
IA-2A and DYRK2A was investigated by constructing a classification rule using logistic 
regression (David W. Hosmer, 2013; Li et al., 2002; Rai et al., 2002). Leave one out 
cross validation was used to assess the performance of the logistic regression classifier. 
Specifically, disease status for each sample was predicted using a logistic regression 
classifier that was trained using the remaining samples. These cross validation predictions 
were then used to conduct receiver operator characteristic (ROC) analysis and calculate 
the AUC for the combination of IA-2A and DYRK2A. 
3.3.5 Validation of Candidates by LIPS Assay 
The liquid-phase, LIPS assay was used to verify a selection of candidate AAbs 
from the second stage screening (Burbelo et al., 2008). C-terminal renilla luciferase 
fusion products (Ag-cRuc) for each antigen were generated using a modified pRL-CMV 
vector (Promega), engineered to contain a gateway-compatible death cassette (available 
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at DNASU) and T7 promoter. Gateway compatibility enabled the rapid and accurate 
transfer of candidate genes from entry vectors into the expression vector.  The 
incorporation of T7 promoter to pRL-CMV parental vector allows the choice of 
expression in either mammalian cells via the CMV promoter or in vitro by cell free 
expression via T7 promoter, thus increasing ease, speed and versatility. Where available, 
entry clones encoding the autoantigen candidate genes were used to generate the 
expression clones by a LR recombination reaction. In all other instances, inserts were 
cloned into a pDON221 entry vector by PCR amplification and homologous 
recombination using BP Clonase II (Invitrogen) and then into the pRL-CMV vector using 
LR Clonase II (invitrogen). Plasmid DNA encoding the antigen-cRuc was purified and 
sequence verified from single colonies and stored as glycerol stocks. 
For expression, plasmid DNA encoding antigen-cRuc was mixed at a ratio of 2 
μg/ 20 μL in rabbit reticulocyte lysate (RRL) supplemented with 10 µg/mL tRNA for 
protein expression at 30
o
C for 90 min. Expression of each clone was verified by 1) 
luciferase activity of RRL-expressed antigen (3X10
5
 to 1X10
6
 ALU / µL lysate) versus 
the same volume of no DNA control retic); 2) western blot using anti-renilla antibody or 
antigen specific antibody. For assay of serum responses, serum samples were diluted at a 
1:10 ratio in buffer A (50 mM Tris, pH 7.5, 100 mM NaCl, 5 mM MgCl2, 1% Triton X-
100) and prepared in a 96 well plate. 50 µL diluted antigen-cRuc protein was incubated 
with 10 µL diluted serum sample and 4 0µL buffer A at 4
 o
C overnight with gently 
shaking at 500rpm on a plate shaker (Eppendorf). The antigen and serum mixture was 
transferred to a Millipore HTS filter plate (Millipore, Bedford, MA) with 5  of 30% slurry 
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protein A/G beads (Pierce Biotechnology, Rockford, IL) and incubated at RT for 2 hours. 
After intense wash with 8X of 100 µL buffer A each time and 2X of 200 µL PBS, the 
luminescent intensity of each sample was quantified in duplicate by reading on a Glomax 
Luminometer (Promega) with a 5 second integration time following automated injection 
of 50 μL of coelenterazine substrate. Jitter plots were then generated from log 
transformed raw luminescent signal intensities using R software to enable the comparison 
of patient and control population immunoreactivity to candidate autoantigens. Sensitivity 
for each AAb was calculated at the 98% specificity. 
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3.4 Results 
3.4.1 Array Production and Quality Assessment 
High quality NAPPA arrays comprised proteins displayed at high level are keys to 
a successful serum screening study. Prior to serum challenge, protein display on NAPPA 
was quality assessed by anti-tag antibodies, confirming the robustness of protein 
expression. Signal intensities for protein levels on the array were similar to those 
previously estimated to be in the average magnitude of 9 femtomoles per feature 
(Ramachandran et al., 2008). Importantly, scatter plots of signal intensities of anti-tag 
staining from replicate arrays revealed correlation coefficients of >0.84 from two 
randomly selected slides within a print run or between two print runs attesting the 
reproducibility of slide printing and protein display, further confirming the suitability for 
serum screening (Figure 3-2).  
3.4.2  Screening Strategy  
Screening efforts were structured in two stages. During the first stage, >6,000 
unique proteins, printed across three arrays were challenged with serum from 50 T1D 
patients and 20 healthy controls. The goal was to facilitate the second stage by 
eliminating uninformative antigens. Thus any antigens that showed no immune response 
in either group (i.e., most antigens) or no appreciable difference in response were 
eliminated. During the second stage, ~750 candidate genes identified from the first stage 
were printed in duplicate and challenged with an independent sample set of 74 patients 
and 75 healthy controls to confirm the reproducibility of enhanced immunoreactivity and 
to further scale down the number of candidate AAbs for independent validation.  
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The advantages of this two-stage screening experimental design are three-fold: 1) 
It minimized the cost of screening against such a large initial group of antigens; 2) It 
ultimately reduced the logistical burden of handling large numbers of slides during 
screening and 3) It limited the potential for overfitting of the data. 
In the first stage screening, statistical analysis revealed approximately 12% of 
these ~6,000 proteins displayed enhanced reactivity when challenged with patient sera as 
opposed to that from healthy controls. During the second stage, both the case and control 
 
 
3 - 2 Reproducibility of Protein Expression on NAPPA 
(a) Pseudo-colored image of anti-GST staining on two expressed slides to assess the 
level of protein display: slides were developed with a mouse monoclonal anti-GST to 
an epitope distinct from that used for antigen capture enabling assessment of protein 
expression, capture and display and confirming reproducibility.  
(b) Plots of signal intensities from all spots for two arrays within or between printing 
batches showed R >0.84.   
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samples were independent of the samples used in the first stage. Raw screening data were 
produced and normalized after removing the within block and pin effects. Analysis of the 
normalized signal intensity by the Wilcoxon Rank-Sum Test identified 26 proteins whose 
median antigen reactivity was higher in patients than in controls (p<0.005) (Table 3-2). 
3 - 2 List of 26 Candidate AAbs by Wilcoxon Rank-Sum Test 
 
 
Second Stage Screening Candidates Ranked by Wilcoxon Rank-Sum Test 
  
PAUC-
95 
PAUC-
95 p-
value 
PAUC-
95 q-
value 
Median 
of 
Patients 
Median 
of 
Controls 
Wilcoxon 
Rank-Sum 
p-value AUC Sensitivity Specificity 
TBCA 0.0130 0.0000 0.0010 1.29 1.19 0.0000 0.72 32.00% 94.59% 
DOM3Z 0.0064 0.0453 0.1920 0.27 0.21 0.0003 0.66 27.03% 94.59% 
TTC4 0.0038 0.0382 0.1905 1.07 1.02 0.0004 0.66 9.33% 94.59% 
Slc30A8-NC 0.0037 0.1229 0.2411 2.14 1.88 0.0004 0.66 16.00% 94.59% 
LIMK2 0.0063 0.0139 0.1266 1.23 1.12 0.0005 0.66 20.00% 94.59% 
CAPN11 0.0149 0.0000 0.0007 1.71 1.61 0.0005 0.66 36.49% 94.37% 
TSPAN31 0.0043 0.0389 0.1905 0.96 0.91 0.0006 0.65 9.33% 94.52% 
PEA15 0.0112 0.0000 0.0032 0.89 0.84 0.0006 0.65 25.33% 94.59% 
CDK6 0.0046 0.0542 0.1967 1.02 1.00 0.0007 0.65 14.67% 94.59% 
DYRK2 0.0046 0.0233 0.1647 0.81 0.73 0.0008 0.65 12.00% 94.52% 
GPR120 0.0038 0.1187 0.2411 1.27 1.18 0.0011 0.64 17.33% 94.59% 
POU2F1 0.0048 0.0808 0.2188 1.36 1.27 0.0014 0.64 18.67% 94.59% 
CDK4 0.0062 0.0452 0.1920 1.75 1.61 0.0018 0.64 20.27% 94.44% 
KCNK13 0.0077 0.0134 0.1266 1.11 1.06 0.0019 0.64 24.00% 94.52% 
FOXM1 0.0025 0.2340 0.2901 0.81 0.77 0.0021 0.64 10.67% 94.59% 
CDKN1A 0.0045 0.1307 0.2411 1.71 1.59 0.0022 0.64 23.29% 94.59% 
HOXB7 0.0085 0.0022 0.0603 1.27 1.21 0.0025 0.63 22.97% 94.59% 
ARF6 0.0006 0.5963 0.4706 1.24 1.11 0.0026 0.63 2.67% 94.59% 
GTF2A1 0.0133 0.0000 0.0007 0.97 0.93 0.0033 0.63 26.67% 94.59% 
HTR1E 0.0089 0.0033 0.0716 1.35 1.28 0.0034 0.63 28.00% 94.44% 
IL13RA2 0.0081 0.0024 0.0603 1.01 0.99 0.0040 0.63 24.00% 94.44% 
CDC2 0.0019 0.2352 0.2901 1.03 0.99 0.0040 0.63 5.33% 94.59% 
SERPINH1 0.0060 0.0542 0.1967 1.10 1.08 0.0045 0.62 21.33% 94.52% 
KLK3 0.0024 0.2166 0.2812 1.56 1.45 0.0046 0.62 10.67% 94.44% 
TBRG4 0.0061 0.0082 0.1168 1.57 1.51 0.0048 0.62 15.07% 94.59% 
ZFP64 0.0067 0.0137 0.1266 1.30 1.23 0.0048 0.62 18.92% 94.59% 
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Similarly, analysis of the normalized antibody-dependent signal intensity resulted 
in the identification of 25 proteins that displayed differential immunoreactivity when the 
statistical significance of the partial area under the curve at 95% specificity (pAUC95) 
was tested to be higher in T1D patients than controls (p<0.005) (Table 3-3). 
3 - 3 List of 25 Candidate AAbs by pAUC Analysis 
  Second Stage Screening Ranked by PAUC95 
  
PAUC-
95 
PAUC-
95 p-
value 
PAUC-
95 q-
value 
Median 
of 
Patients 
Median 
of 
Controls 
Wilcoxon 
Rank-
Sum p-
value AUC Sensitivity Specificity 
CAPN11 0.0149 0.0000 0.0007 1.71 1.61 0.0005 0.66 36.49% 94.37% 
GTF2A1 0.0133 0.0000 0.0007 0.97 0.93 0.0033 0.63 26.67% 94.59% 
ARG2 0.0130 0.0000 0.0010 1.29 1.19 0.0000 0.72 32.00% 94.59% 
PEA15 0.0112 0.0000 0.0032 0.89 0.84 0.0006 0.65 25.33% 94.59% 
SFRS7 0.0090 0.0003 0.0261 1.03 1.03 0.3008 0.52 22.67% 94.59% 
LASS2 0.0090 0.0003 0.0261 1.19 1.16 0.0239 0.59 24.00% 94.59% 
ZNF683 0.0090 0.0004 0.0290 1.88 1.83 0.0240 0.59 21.33% 94.44% 
LGMN 0.0087 0.0005 0.0316 1.74 1.66 0.0061 0.62 21.33% 94.59% 
STK32A 0.0083 0.0007 0.0374 1.25 1.17 0.0050 0.62 18.67% 94.52% 
LATS1 0.0082 0.0007 0.0374 1.70 1.62 0.0216 0.60 18.67% 94.52% 
TNRC5 0.0079 0.0009 0.0398 1.41 1.35 0.1402 0.55 18.92% 94.59% 
ZBED1 0.0080 0.0011 0.0400 1.67 1.62 0.0401 0.58 17.81% 94.59% 
APCS 0.0079 0.0011 0.0400 1.09 1.08 0.1326 0.55 22.97% 94.59% 
CDK3 0.0090 0.0011 0.0400 1.76 1.69 0.1549 0.55 22.67% 94.59% 
ZNF323 0.0078 0.0013 0.0437 0.83 0.85 0.3450 0.52 20.00% 94.52% 
FOXA1 0.0084 0.0020 0.0603 1.17 1.15 0.0242 0.59 21.62% 94.52% 
HOXB7 0.0085 0.0022 0.0603 1.27 1.21 0.0025 0.63 22.97% 94.59% 
PDIA3 0.0068 0.0023 0.0603 0.92 0.92 0.6667 0.48 14.67% 94.59% 
ZBTB25 0.0070 0.0024 0.0603 1.32 1.27 0.0190 0.60 15.49% 94.52% 
IL13RA2 0.0081 0.0024 0.0603 1.01 0.99 0.0040 0.63 24.00% 94.44% 
LOC91461 0.0076 0.0026 0.0624 1.32 1.28 0.0313 0.59 22.67% 94.44% 
IKBKB 0.0072 0.0027 0.0624 0.90 0.92 0.2924 0.53 16.22% 94.59% 
HTR1E 0.0089 0.0033 0.0716 1.35 1.28 0.0034 0.63 28.00% 94.44% 
PRKCB1 0.0075 0.0039 0.0819 1.22 1.21 0.0870 0.56 21.62% 94.59% 
CRH 0.0078 0.0045 0.0911 1.43 1.43 0.1973 0.54 21.33% 94.52% 
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3 - 3 Visual Comparison of Candidate AAbs 
Array images challenged with serum sample from different patients that deemed 
positive by statistical analysis were adjusted to identical black and color thresholds to 
enable visual comparison. Differences were readily perceived upon visual examination 
of immunoreactivity of candidate features between patient and control serum-
challenged slides.  Intensity scale = red > orange > yellow >green.   
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To enable the visual comparison of immunoreactivity obtained from the second-
stage screening, image scans of serum challenged slides were adjusted to be pseudo-
colored in identical black and full color threshold scale. Slides with duplicate features 
designated as seropositive in different patients by statistical analysis were compared to a 
slide challenged with control serum with similar median signal intensities (Figure 3-3). 
Visually discernible differences for the antigens calpain-11 (CAPN11), CDK3, astrocytic 
phosphoprotein (PEA15) and sphingosine-1-phosphate receptor 3 (SIPR3) suggested that 
the normalization scheme employed did not distort the data in a manner that either 1) 
creates signal differentials that do not exist or 2) destroys true signal differentials.  In 
order to provide a visual representation of signal intensities of candidate antigens across 
all samples, jitter plots were generated from normalized and log-transformed signal 
intensities to illustrate the comparison of immunoreactivity of known T1D associated 
AAbs as well as the novel ones in patient and control groups (Figure 3-4). 
3.4.3 AAb Candidates Identified from the Second-stage Screening 
Known T1D AAbs, such as ZnT8-NC (Slc30A8), GAD65 and IA-2, were 
included as positive controls on the second stage screening array. The display levels of 
these antigens were confirmed by anti-GST staining of arrays (data not shown). In this 
protein microarray assay, the median signal of known AAb to ZnT8-NC (Slc30A8) in 
patient group was significantly higher than the control group (p<0.0004) from the 
Wilcoxon Rank-Sum test (Table 3-2); however, none of the other three known AAbs to 
insulin, IA-2, or GAD65 exhibited statistically significant increases reactivity toward 
patient sera. The absence of immunoreactivity to those three known T1D associated 
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AAbs may reflect a differential performance of solid-phase immune-profiling techniques 
in the detection of some epitopes. Nevertheless, the additional 25 additional candidate 
AAbs besides ZnT8-NC (Slc30A8) were identified using the unbiased screening strategy. Some of 
these autoantigens are known to be expressed in the pancreas or enriched in islet cells 
 
 
3 - 4 Jitter Plots of Serological Immunoreactivity to Candidate AAbs 
Each dot represents the signal from one patient or control serum to the indicated 
antigens; the solid lines indicate median signal intensities of patient (n=74) or control 
group (n=75). The upper line across both patient and controls groups, indicates the 
95
th
 percentile of control signal. 
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such as PEA-15 and DYRK2 (Kuliawat et al., 2004; Miele et al., 2007). 
3.4.4 Validation of Candidate AAbs 
Candidate AAbs were selected based on the significance of differential reactivity 
(as indicated by p-value) and their potential roles in beta-cell physiology for validation in 
an independent serum set (46 patients and 46 controls) by LIPS assay (Burbelo et al., 
2005a). LIPS assay was employed as a validation platform because it was a solution 
based assay platform orthogonal to protein array and the performance of LIPS on the 
known T1D associated AAbs (GAD65 and IA-2) was similar to the widely accepted RIA 
in clinical T1D studies. The published LIPS assay expression vector pRL-CMV was 
modified so that it was compatible with Gateway® Cloning, allowing us to transfer the 
candidate genes into the modified vector easily and to produce candidate antigens by the 
RRL IVTT system (Figure 3-5) consistent with the antigen production used throughout 
this study and in most reported RIA assays (Burbelo et al., 2009). The modified pRL-
CMV vector was first tested on IA-2, a known T1D-associated AAb. LIPS assay 
confirmed IA-2 with a sensitivity of 54% at 98% specificity, comparable to the 
performance of LIPS assay and commonly used RIA assay reported (Burbelo et al., 2008). 
Besides IA-2, nine sequence-verified candidate genes (PEA15, CAPN11, DYRK2, 
CDK1,CDK3, CDK4, CDK6, TBCA, GCK) including candidates from supplement 
statistical analysis (Table 3-2) and previous published T1D associated autoantigens were 
cloned into the modified pRL-CMV expression vector with c-terminal luciferase fusion 
and immunoreactivity to these antigens were measured by LIPS. Luminescent data for 
each sample collected were from the average of the replicate measurements.  Average 
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patient signals that exceed the 98
th
 percentile of control signals were considered to exhibit 
positive reactivity.  
One candidate AAb, DYRK2 showed 36% sensitivity at 98% specificity (Figure 
3-5); whereas, the other nine candidates showed lower sensitivities (Data not shown). It is 
possible the failure to validate these latter candidates may be due to the platform 
difference. The performance of DYRK2 was confirmed by several repeated assays (Data 
 
 
3 - 5 Validation of Candidate AAbs Using LIPS Assay 
(a) Schematic representation of LIPS assay. 
(b,c) LIPS assay confirmed the performance of IA-2 and DYRK2 with 54% and 36% 
sensitivity at 98% specificity respectively.  The solid lines represent the median signal 
of patient (n=46) and control group (n=46), the dash line indicates the 98% percentile 
of signal intensities from control group. 
(d) ROC curves for IA-2 and DYRK2 alone and the combination of the two. 
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not shown). The addition of DYRK2A improved the AUC for IA-2A from 0.64 to 0.90. 
DYRK2A has an AUC of 0.72 on its own. The combination of DYRK2A and IA-2A has 
a sensitivity of 72% at 98% specificity.
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3.5 Discussion 
The rapid rise in diabetes incidence imposes a substantial economic burden on 
health care systems worldwide (Scully, 2012). Primarily affecting children and young 
adults, T1D is characterized by the progressive destruction of insulin producing 
pancreatic beta cells and imposes a lifelong responsibility to maintain glucose 
homeostasis through regular insulin injections. It is believed the autoimmune reactions 
mediated by B cells and T cells play an important role in disease pathogenesis and 
autoantibodies to self-proteins are good predictors for disease diagnosis and progression.  
Historically, four autoantigens (Insulin, GAD65, IA-2, ZnT8) have been reported as 
major targets of AAb with individual sensitivity more than 55%. The combination of 
these four AAbs detects >90% of T1D patients (Wenzlau et al., 2008). Nevertheless, the 
prevalence of individuals that are ICA positive but negative for all four known AAbs is 
not rare at all ages and thus provides impetus for the discovery of novel AAbs that are not 
yet identified (Hameed et al., 2011; Wang et al., 2007). Minor T1D-associated AAbs with 
low sensitivity and specificity such as carboxypeptidase-H (Castano et al., 1991), ICA69 
(Pietropaolo et al., 1993), GM2-1(Dotta et al., 1997a), microsomal hepatic protein 
(Pehuet-Figoni et al., 2000), SOX13 (Kasimiotis et al., 2001), HSP70(Abulafia-Lapid et 
al., 2003), topoisomerase II (Chang et al., 2004), VAMP2 and NPY (Hirai et al., 2008a) 
were reported continuously and provide deeper understanding of T1D pathogenesis in 
addition to the four major ones. The above AAb biomarker discovery studies relied upon 
a targeted strategy and restricted inquiry to the landscape of the pancreas using low-
throughput experimental techniques such as phage display, ELISA and RIA.  
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The value of AAbs in prediction and diagnosis of T1D is well-established; 
however, their pathogenic role is contentious (Baekkeskov et al., 2000). AAbs, generated 
during the influx of immune cells into the peri-islet space, are most often considered 
byproducts of a pre-existing underlying pathology, rather than a causative agent 
themselves. A comprehensive knowledge of the ‘autoantigenome’ in T1D will 
undoubtedly assist in generating and testing hypotheses aimed at answering questions 
regarding mechanisms of beta cell damage and the temporal expression patterns of 
autoantibodies that aid in disease characterization. A systematic profiling of serological 
AAbs will expand the current ‘autoantigenome’ in T1D and illuminate T1D pathogenesis. 
To date, no unbiased, proteome scale and high-throughput AAb discovery studies 
have been published for T1D. The development and successful use of new discovery 
technologies such as protein microarrays offer a valuable opportunity to design non-
biased, data-driven studies to profile serum AAbs to a large number of human proteins in 
a high-throughput manner. The innovative protein array platform, NAPPA, has been used 
successfully in identifying circulating antibodies in infectious diseases, autoimmune 
diseases and cancers (Anderson et al., 2011; Ceroni et al., 2010; Gibson et al., 2012). In 
this study, the establishment of a NAPPA protein array based high-throughput pipeline of 
AAb discovery in T1D is the basis of the success in identifying DYRK2 as a novel minor 
T1D-associated AAb. 
The high-throughput discovery pipeline involved two large screening process 
followed by a targeted solution-based validation study. Although a known T1D-
associated AAb-ZnT8 was among the final candidate list, neither GAD65 nor IA-2 were 
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identified presumably due to the differences in the manner in which responses to those 
antigens are typically measured. Nevertheless, several candidate AAbs identified are 
known to play critical roles in beta cell physiology and are associated with exocytotic 
machinery. PEA15 was implicated in the regulation of glucose induced insulin secretion 
through the inhibition of potassium channel expression and (Miele et al., 2007), STX6 
has been shown to function in the process of endosomal maturity and its delivery to 
lysosomes and may further influence the secretory pathway in live pancreatic beta-cells 
(Kuliawat et al., 2004). Several ubiquitously expressed cyclin-dependent kinases (CDKs) 
were identified in the list including CDK3, CDK4 and CDK6. Studies in human and mice 
have revealed that beta cell replication and proliferation can be stimulated by the over-
expression of either CDK4 or CDK6 without evidence of cell death, loss of function or 
aberrant differentiation (Fiaschi-Taesch et al., 2009; Marzo et al., 2008), but how they 
would be targeted in the pancreas as autoantigens is unclear. In addition, candidates that 
show no strong connection with diabetes such as S1PR3 and endoplasmic reticulum to 
nucleus signaling 2 (ERN2) were also identified. The diversity of functions of the 
identified AAb candidates demonstrated the power of the unbiased screening strategy. 
To confirm these findings, an initial step was taken in validating the above AAb 
candidates in an independent serum sample set using an orthogonal liquid-phase assay 
originally developed by Peter D. Burbelo (Burbelo et al., 2009). To adapt this assay 
platform for compatibility with the IVTT system, the expression vector was modified and 
engineered with a Gateway™-compatible cassette to simplify the process of gene transfer 
and T7 promoter to enable antigen production in an RRL IVTT system. Candidate 
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antigens were selected for validation based on their classification performance and 
putative roles in beta-cell biology. 
DYRK2 was validated with a 36% sensitivity at 98% specificity, further analysis 
indicate that DYKR2 complements IA-2 by a moderate increase in sensitivity, whereas it 
did not complement GAD65. IA-2A has a sensitivity of 54% at 98% specificity on its 
own. The widely accepted linear regression model was used to combine the two markers 
and generate the ROC curve. The addition of DYRK2A improved the AUC for IA-2A 
from 0.64 to 0.90. An important next step will be to validate the performance of the 
DYRK2A and IA-2A combination in future studies on independent sample sets.   
The identification of minor AAbs like DYRK2 and future characterization of the 
correlation of their seropositivity with other clinical features may benefit other aspects of 
clinical patient management (e.g. stratification) and advance our understanding of disease 
etiology and heterogeneity. DRYK2 is a member from novel dual specificity protein 
kinase family and has been implicated in the glucose metabolic pathway as responsible 
for the phosphorylation and inactivation of glycogen synthase (Skurat and Dietrich, 2004). 
DYRK2 is highly expressed in the pancreas based on protein atlas data and has been 
implicated in the apoptosis pathway in response to severe DNA damage through the 
activation of the p53 signaling (Yoshida, 2008). Moreover, a Genome wide association 
study (GWAS) found that DYRK2 is significantly associated with type 2 diabetes in 
Mexican Americans (Hayes et al., 2007). Its role in T1D pathogenesis requires further 
investigation. 
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Other candidates from screening were not validated in the LIPS assay, which may 
reflect differences in the detection methods. Antigen conformation and / or binding 
characteristics of autoantibody markers to their target antigens that can be identified in a 
solid-phase assay may be very different from those identified in a liquid-phase assay.  
The original rationale for choosing a liquid phase validation platform included using a 
method that had previously been shown to work for two classical T1D AAbs and to 
ensure the markers reported can perform on two orthogonal validation platforms. It is 
expected that some markers will only perform well on one platform but not both. This 
may explain why some of the markers discovered on the arrays did not validate in the 
liquid phase assay. Some classical autoantibodies in T1D have been reported to behave 
differently on different platforms. For example, it has been reported that insulin antibody, 
a known T1D autoantibody, showed lower sensitivity, specificity and AUC in liquid 
phase assays compared with a solid phase ELISA assay (Schlosser et al., 2010; Yu et al., 
2012). On the other hand, IA-2A performs better when measured by the liquid phase RIA 
than on the solid phase ELISA platform (Torn et al., 2008). It is possible that some 
conformational epitopes of antigen proteins might be blocked by the capture antibody in 
the array platform. In the liquid LIPS assay platform, these epitopes were exposed and 
recognized by serum autoantibodies. On the other hand, the array platform might display 
some epitopes that are not exposed in a liquid phase assay. Assessment of sero-reactivity 
to these candidates on different platforms such as the multiplexed self-assembling bead 
arrays on the luminex platform (Wong et al., 2009), plate-based programmable ELISAs 
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(Gibson et al., 2012) or targeted small content NAPPA arrays (Anderson et al., 2011) 
may shed light on the behavior of these antigens presented in different formats.
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3.6 Conclusions 
In conclusion, a discovery pipeline was developed that enables the first large scale 
proteome scale searching for AAb biomarkers in T1D on an innovative protein array 
platform using a two-stage screening strategy, resulting in the discovery of minor AAb-
DYRK2 (36% sensitivity at 98% specificity), thus, demonstrating the applicability of 
NAPPA to AAb discovery in T1D and providing impetus to expand this technology to 
the whole human proteome with the established pipeline. 
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CHAPTER 4  
4 IDENTIFICATION OF NOVEL AUTOANTIBODIES IN TYPE 1 DIABETES 
BY PROTEIN ARRAYS 
4.1 Abstract 
Autoantibodies (AAbs) produced during the development of type 1 diabetes (T1D) 
are valuable in predicting risk, stratifying patients with different clinical courses, 
explaining disease pathogenesis and providing candidates for prevention trials. We 
performed a comprehensive profiling of humoral autoimmunity in T1D by human protein 
arrays and enzyme-linked immunoassay (ELISA). Analysis of reactive antigens revealed 
similar pathways were enriched in both patient and healthy control groups. At the 
individual antigen level, we identified and validated six AAbs with sensitivities ranged 
from 16% to 27% at 95% specificity. Their prevalence in T1D cases complements the 
major known T1D-assocaited AAbs and varies in different age subgroups. Our study 
enriched our knowledge of T1D “autoantigenome/autoantibody-ome” and provided new 
insights in T1D pathophysiology into unprecedented breadth and width. 
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4.2 Introduction 
The rapid rise of incidence rate poses a huge challenge to find a cure for T1D 
(Onkamo et al., 1999). Upon diagnosis, more than 80-90% of pancreatic β-cells have 
been destroyed (Atkinson, 2012). While cellular immune response plays a dominant role 
in β-cell autoimmune destruction, antibodies against self-proteins, i.e. AAbs, are 
produced during disease progression. They were used for predicting T1D risk and 
selecting high risk subjects for prevention trials (Marino et al., 2011). Immune-
therapeutic strategies were under development by targeting autoantigens recognized by 
AAbs (Ludvigsson et al., 2012). 
AAbs to Insulin, GAD65, IA-2 and ZnT8 were identified as major T1D-
associated AAbs (Baekkeskov et al., 1990; Bonifacio et al., 1995a; Palmer et al., 1983; 
Wenzlau et al., 2007). A number of minor AAbs were discovered by various approaches 
(de Graeff-Meeder et al., 1993; Hirai et al., 2008b; Kasimiotis et al., 2000; Pietropaolo et 
al., 1993; Winnock et al., 2001). The rate of discovering new AAbs has been greatly 
limited by the throughput of technologies. Phage displayed libraries were constructed 
from human or mouse pancreatic tissue and immunoprecipitated by T1D patient sera 
(Pietropaolo et al., 1993; Winnock et al., 2001). Immunoassays such as 
radioimmunoprecipitation (RIA) or ELISA are targeted approaches to test antigens one a 
time (de Graeff-Meeder et al., 1993; Hirai et al., 2008b; Kasimiotis et al., 2000). One 
hypothesis of β cell autoimmunity is the increased biosynthetic activity of proinsulin 
leads to the increase of misfolded proteins in the endoplasmic reticulum (ER)  in β cells 
(Eizirik et al., 2009). When the ER faces sustained stress, the autoreactive cytotoxic T 
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cells that recognize abnormal epitopes will destroy β cells and release more antigenic 
epitopes to initiate a process called “epitope spreading” (Fonseca et al., 2009). The 
number of T1D-associated AAbs may be much higher than currently known. Diabetic 
individuals who are positive for Islet Cell Antigen (ICA) staining yet remain negative for 
the four known T1D-associated AAb biomarkers (Wang J, 2007). Also, a proportion of 
patients are negative for both ICA and the known biochemical AAbs with no apparent 
difference in clinical performance compared with AAb positive T1D patients suggesting 
different disease subtypes (Hameed et al., 2011). One possible explanation is that AAbs 
in this group may target antigen proteins outside the landscape of the pancreatic islet, 
which give us a hint that a whole proteome screening is needed to identify additional 
AAbs that will give us a complete picture of humoral autoimmunity in T1D. 
However, we still have a limited understanding on global antibody response in 
T1D. A global profiling of AAbs and the identification of their eliciting autoantigens in 
T1D will aid in the construction of molecular pathways that explain the pathological 
events during autoimmunity and disease onset. The advent of the proteomics era opened 
new avenues to search for new AAbs in T1D. Phage immunoprecipitation sequencing 
(PhIP-Seq) is a technology that couples phage display with next generation sequencing 
(NGS). It was applied to screen peptide and AAb interactions and revealed a prematurely 
polyautoreactive phenotype in T1D patients (Larman et al., 2013). Serological proteome 
analysis (SERPA) is a method to identify patient specific antigen proteins using a 
proteomic approach (Massa et al., 2013). Protein microarrays provide an ideal tool to 
profile global antibody response to a large number of proteins in a high-throughput 
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manner in T1D. An innovative cell-free protein array platform named Nucleic Acid 
Programmable Protein Array (NAPPA) was used to screen 6,000 human proteins and 
identified a minor T1D-associated AAb (Miersch et al., 2013). Two additional novel 
AAbs were discovered by high-density protein microarrays in 2014 (Koo et al., 2014).  
In this study, we performed a comprehensive search for T1D-associated AAbs by 
a screening-based approach using NAPPA including 10,000 human proteins and a 
knowledge-based approach using an individual immunoassay to test 126 pancreas 
enriched genes from literature and bioinformatics analysis. We performed network 
analysis and compared global antibody response in T1D patients and controls. Six AAbs 
were discovered and validated in independent sample set. Their value of complementary 
to the known T1D-associated AAbs and their prevalence in different age subgroups were 
analyzed.  
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4.3 Experiments 
4.3.1 Study Samples 
All samples were collected with written informed consent under the guidelines of 
the Institutional Review Boards (IRB) at the University of Florida. T1D samples were 
obtained from new-onset patients within three months of diagnosis according to the 
American Diabetes Association (ADA) criteria. Peripheral blood samples were drawn 
from the antecubital vein and serum was prepared before freezing as aliquots at -80
o
C. 
Control samples were prepared in the identical fashion and selected to be age-gender 
matched to the patients. Controls had no T1D family history and were considered to be at 
low risk for T1D with absence of known T1D-associated AAbs except for two 
individuals are positive for GADA and one is positive for IA-2A. Neither patients nor 
control samples were known to have any other underlying autoimmune disease. 
Characteristics of study subjects including age, gender and status of known T1D-
associated AAbs were presented as median, mean, standard deviation (SD) and 
percentage (Table 4-1). 
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4 - 1 Sample Characteristics of Each Cohort 
    
Screening Based 
  
Knowledge  Based     
Characteristics   Cohort1 Cohort2     Cohort4   Cohort3 
  T1DM HC T1DM HC T1DM HC T1DM HC 
Number of 
Subjects 40 40 *60 60 46 46 *96 96 
Age                 
Mean+ SD 15.0+6.5 15.0+6.6 14.0+7.6 14.2+7.4 14.0+8.4 14.0+8.1 14.0+7.3 14.0+7.1 
Median 13 13 12 12 11 12 12 12 
Gender                  
Male (%) (14)35.0% (14)35.0% (28)47.5% (29)48.3% (20)43.5% (21)45.7% (41)43.2% (42)43.8% 
GADA positive (36)90.0% 0 (50)83.3% (2)3.3% (40)87.0% (2)4.3% (82)85.4% (2)2.1% 
IA-2A positive (26)65.0% 0 (40)66.7% (1)1.7% (31)67.4% (1)2.2% (62)64.6% (1)1.0% 
 
4.3.2 Study Design 
This study adapted screening-based and knowledge-based approaches to search 
for novel AAbs in T1D (Figure 4-1). In the screening-based approach, we profiled AAbs 
against 10,000 human proteins in cohort 1 (40 cases and 40 controls) on 5 arrays sets 
during the discovery stage. We selected 39 AAbs to verify their differential sero-
reactivity in cohort 1 by ELISA.19 AAbs had >10 sensitivity at 95% specificity during 
the verification stage. They were tested in an independent set of cohort 4 (60 cases and 60 
controls) and further confirmed in cohort 3 (96 cases and 96 controls) by ELISA. In the 
knowledge-based approach, 126 pancreas enriched genes were selected by literature 
search (Hirai et al., 2008b; Ludvigsson et al., 2012; Wenzlau et al., 2007) and 
bioinformatics analysis. AAbs to these proteins were profiled in cohort 4 (46 cases and 
46 controls) by ELISA. 14 AAbs showed >10% sensitivity at 98% specificity were 
confirmed in cohort3. 
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4 - 1 Study Design 
(1) Screening-based approach: i. Discovery: samples from cohort 1 were screened 
against 10,000 human proteins across 5 NAPPA array sets; ii. Verification: 39 
candidate autoantigens were verified using samples from cohort1 by RAPID ELISA; 
iii. Validation: 19 candidate autoantigens were validated using samples from cohort2 
by RAPID ELISA; iv. Confirmation: 19 candidate autoantigens were confirmed using 
samples from cohort3 by RAPID ELISA.  
(2) Knowledge based approach: i. Discovery: 126 pancreas enriched genes (literature, 
bioinformatic) were tested in samples from cohort4 by RAPID ELISA; ii. 
Confirmation: 14 candidate autoantigens were tested in samples from cohort3 by 
RAPID ELISA. 
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4.3.3 NAPPA Production and Quality Assessment  
10,000 human genes obtained from DNASU (http://dnasu.asu.edu/DNASU/) (Seiler 
et al., 2014) were printed on 5 array sets (GST1, GST2, GST3, GST4 and Flag) (Miersch 
and LaBaer, 2011). Plasmids encoding human proteins have either a C-terminal 
glutathione S-transferase (GST) or N-terminal Flag fusion tag in frame with the protein. 
Proteins were expressed by an in vitro transcription and translation (IVTT) system. 
Expressed proteins with fusion tag can be easily captured on slides by the co-printed anti-
tag antibodies (Ramachandran et al., 2008). Known T1D-associated AAbs (Insulin, IA-2, 
GAD65 and ZnT8) were printed as positive controls for serum profiling. Both DNA 
printing and protein display on NAPPA was quality assured as described (Miersch et al., 
2013).  
4.3.4 Profiling of AAbs on NAPPA 
As described (Bian et al., 2015), printed slides were blocked in SuperBlock 
Buffer (Thermo Fisher Scientific, MA) at room temperature (RT) for 1 hour (hr) on the 
shaker. Then slides were rinsed five times with deionized (DI) water and placed in a 
metal slide rack (Amazon, WA) for drying by centrifugation at 1,000 rpm for 3 min at RT. 
160 μL human HeLa cell lysate-based protein expression system (Thermo Fisher 
scientific, MA) was injected into HybriWell (Grace BIO-LABS, OR) sealed slides and 
incubated in the oven (EchoTherm, CA) at 30°C for 1.5 hrs for protein expression and 
15°C for 30 min for protein capture. Expressed slides were washed 10 times with water 
and dried by centrifugation at 4°C, 1,000 rpm for 3 min. Slides were placed in the 
hybridization chamber of HS 4800™ Pro hybridization station (Tecan, Männedorf, 
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Switzerland) and programed with 1 h blocking with 5% milk-PBST (0.2% Tween), 16 
hrs of 160 µL 1:50 diluted serum at 4°C followed by 1 hr incubation of 160 µL 1:500 
diluted Alexa Fluor 647® Goat Anti-Human IgG (Jackson ImmunoResearch 
Laboratories, PA). Slides were washed, dried and scanned by Tecan scanner under 
consistent settings. A pool sample was prepared by mixing equal volumes of samples 
from each patient and control. The pool sample was run as technical replicates on every 
serum screening day.  
Normalized signal intensity was generated using the raw signal intensity divided 
by the medium signal intensity of each array. Strong sero-reactivity resulted in saturated 
signals of the local spot with diffusion to the neighboring spots. The presence of diffusion 
was defined as a ring. Differences in ring counts between the case and control group were 
used as selection criteria for candidate AAbs for ELISA verification. 
4.3.5 Rapid Antigenic Protein in situ Display (RAPID) ELISA 
As described (Bian et al., 2015), 96-well ELISA plates (Corning Life Sciences, 
CA) were coated with 50 µL 10 µg/mL anti-GST antibody (GE Healthcare, PA) in 
coating buffer (0.5 M carbonate bicarbonate buffer, pH 9.6) overnight at 4°C. On the next 
day, coated plates were washed five times with 100 µL PBST and blocked with 100 µL 
5% milk-PBST for 1.5 hrs. Meanwhile, 40 ng/μL protein encoding plasmid was 
expressed in the human HeLa cell lysate-based protein expression system at 30°C for 1.5 
hrs in the oven. Expressed proteins were diluted in milk-PBST at 1:50. 50 µL diluted 
antigen was captured in each well at RT for 1 hr on a shaker at 500 rpm. Plates were 
washed with five times of PBST. Each well was incubated with 50 µL 1:200 diluted 
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serum at RT for 1 hr, washed again and incubated with 50 µL 1:10,000 diluted HRP 
labeled Goat Anti-Human IgG (Jackson ImmunoResearch Laboratories, PA) at RT for 1 
hr. Plates were incubated on a shaker at 500 rpm. Finally, the plates were washed and 
incubated with 50 µL 1-Step Ultra TMB - ELISA Substrate for 10 min (Thermo Fisher 
scientific, MA) for detection and 50 µL 2M sulfuric acid to stop the reaction. OD450 was 
measured by Envision® Multilabel Reader (PerkinElmer, MA). 
4.3.6 Statistical Analysis 
Network analysis was conducted on antigens that showed sero-positivity in at 
least two individuals (either cases or controls) using Cytoscape version 3.2.0. The 
pathway function were enriched as modules and annotated by ReactomeFIPlugIn. The 
size of the nodes indicates the frequency of individual antigens with sero-positivity. The 
color of the nodes indicates the percentage of sero-positivity in cases. Sensitivity and 
specificity of candidate AAbs were determined by RAPID ELISA. Heatmaps were 
generated in MultiExperiment Viewer version 4.9 (http://www.tm4.org/mev.html). Graphs 
and plots were drawn in GraphPad Prism 6.
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4.4 Results 
4.4.1 Quality of Protein Array and Serum Profiling 
We constructed five array sets (GST1, GST2, GST3, GST4 and Flag) with ~2,000 
features on each array. Pico-green staining showed DNA printed on the array was 
uniform. The correlation coefficient of protein display and serum profiling was 0.92 and 
0.97, respectively. The high reproducibility of protein display demonstrated the high 
quality of our protein arrays. The high reproducibility of serum profiling proved the 
robustness of our serum screening practice (Figure 4-2). 
 
4 - 2 Quality of DNA Staining, Protein Display and Serum Profiling on NAPPA 
(A) Representative slide images of DNA staining, protein display and serum profiling. 
DNA staining is pesudo-colored in green, protein display and serum profiling is 
pesudo-colored in rainbow color (Blue, yellow and red indicate low, medium and high 
signal intensity).  
(B) Scatter plot of signal intensities of two protein display slides on the left and two 
serum profiling slides on the right. 
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4.4.2 Screening-based Approach by NAPPA 
Sero-reactivity to known T1D-associated AAbs (IA-2, GAD65 and ZnT8) was 
visually distinguishable from other antigens which showed negative sero-reactivity on the 
same array. The healthy control sample did not show any responses to any of these 
antigens (Figure 4-3), clearly proving the validity of our array platform in profiling 
serological AAbs in T1D.  
 
We selected 39 candidate AAbs based on their sero-reactivity on protein arrays 
for verification by RAPID ELISA in the same sample set used in screening (cohort1). 19 
candidates were confirmed by ELISA with >10% sensitivity at 95% specificity (Table 4-
2). 
 
IA-2(601-
979)
GST1                        GST2                         GST3                           GST4                          FLAG
T1D Cases
IA-2
Healthy Control
GAD65
ZnT8
IA-2
IA-2
GAD65 GAD65
IA-2
GAD65
IA-2
ZnT8
 
 
4 - 3 Sero-reactivity to Known T1D-associated Autoantigens on NAPPA 
Slide images showed the apparent sero-reactivity to the known T1D-associated 
autoantigens (IA-2, GAD65 and ZnT8) on five NAPPA array sets (four printed with 
genes with GST tag, one printed with genes with flag tag). 
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4 - 2 Statistics of Candidates from Screening-based Approach 
    Cohort1 Cohort2 Cohort3 
Antigen Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity 
PTPRN2 0.25 0.95 0.20 0.95 0.22 0.95 
MLH1 0.15 0.95 0.33 0.95 0.27 0.95 
MTIF3 0.15 0.95 0.20 0.95 0.25 0.95 
PPIL2 0.20 0.95 0.18 0.95 0.19 0.95 
NUP50 0.15 0.95 0.17 0.95 0.16 0.95 
TOX4 0.20 0.95 0.12 0.95 0.13 0.95 
FIGN 0.13 0.95 0.12 0.95 0.13 0.95 
C9orf142 0.18 0.95 0.05 0.95 0.11 0.95 
ZNF280D 0.13 0.95 0.08 0.95 0.11 0.95 
HES1 0.10 0.95 0.15 0.95 0.11 0.95 
TOX 0.30 0.95 0.07 0.95 0.09 0.95 
CTBP1 0.25 0.95 0.08 0.95 0.09 0.95 
POLR1D 0.15 0.95 0.07 0.95 0.09 0.95 
TAF11 0.15 0.95 0.03 0.95 0.08 0.95 
PHF15 0.15 0.95 0.05 0.95 0.07 0.95 
STMN3 0.10 0.95 0.05 0.95 0.06 0.95 
TCEAL4 0.13 0.95 0.03 0.95 0.05 0.95 
FILIP1 0.10 0.95 0.03 0.95 0.04 0.95 
BANK1 0.10 0.95 0.02 0.95 0.02 0.95 
 
4.4.3 Network Analysis of Sero-positive Proteins on NAPPA 
1,204 antigens showed sero-positivity in at least one of the cases or controls. 
Network analysis was conducted on the 558 antigens that showed sero-positivity in at 
least two individuals (either cases or controls) using Cytoscape. It generated 21 modules 
including 135 nodes and 274 edges. Although no difference was found between cases and 
controls at the pathway level, representative pathways enriched were β-cell development, 
class I MHC mediated antigen processing & presentation, B-cell activation, T-cell 
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receptor signaling pathway, viral infections, TGFβ signaling, metabolism, glucose 
transport  and insulin pathway (Figure 4-4).  
4.4.4 Knowledge-based Approach by RAPID ELISA 
In the knowledge-based approach, AAbs to126 pancreas enriched genes selected 
by literature search and bioinformatics analysis were profiled by RAPID ELISA in 
cohort4. The aim of this step is to discover the sero-reactive antigens and to scale down 
the number of proteins for confirmation in cohort3. 14 candidate AAbs that has >10% 
sensitivity at 98% specificity in cohort4 were further selected for validation in cohort3 
(Table 4-3).  
 
 
4 - 4 Network Analysis of Sero-positive Proteins on NAPPA 
The size of the nodes indicates the frequency of individual antigens with sero-
positivity. The color of the nodes indicates the percentage of sero-positivity in cases. 
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4 - 3 Statistics of Candidates from Knowledge-based Approach 
    Cohort4 Cohort3 
Antigen Sensitivity Specificity Sensitivity Specificity 
QRFPR 0.11 0.98 0.20 0.95 
CTRC 0.13 0.98 0.15 0.95 
SNX6 0.13 0.98 0.15 0.95 
SYTL4 0.17 0.98 0.13 0.95 
ELA2A 0.11 0.98 0.13 0.95 
IGRP 0.11 0.98 0.11 0.95 
PAX6 0.11 0.98 0.11 0.95 
HMGN3 0.20 0.98 0.10 0.95 
STXBP1 0.22 0.98 0.09 0.95 
REG3G 0.15 0.98 0.09 0.95 
SCG5 0.13 0.98 0.06 0.95 
RCBTB2 0.13 0.98 0.05 0.95 
ASB9 0.13 0.98 0.04 0.95 
PPY 0.13 0.98 0.02 0.95 
 
4.4.5 RAPID ELISA as an Individual Immunoassay to Profile AAbs 
Protein microarray (NAPPA) offers a great high-throughput screening tool to 
profile AAbs against thousands of antigen proteins. RAPID ELISA is more suitable to 
profile AAbs to a smaller number of candidates using a large number of serum samples in 
a plate format. Before applying RAPID ELISA as an individual immunoassay to test and 
validate AAb candidates, we compared its performance with an RIA based clinical assay 
in measuring antibody response to known T1D-associated AAbs (IA-2 and GAD65). The 
clinical assay achieved 64.6% sensitivity at 96.96% specificity for IA-2A and 85.4% 
sensitivity at 97.92% specificity for GADA. Our in-house RAPID ELISA obtained 69.8% 
and 66.7% sensitivity at 95% specificity for IA-2A and GADA, respectively (Figure 4-5). 
Using the above cutline, 51 and 55 subjects were positive by both assays for IA-2A and 
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GADA, respectively. 16 subjects were positive only by ELISA and 11 were only positive 
by clinical assay for IA-2A. 9 subjects were positive only by ELISA and 27 were positive 
only by clinical assay for GADA (Figure 4-5).  
 
 
4 - 5 Sero-reactivity to IA-2 and GAD65 
(A) Jitter plots of sero-reactivity of IA-2 and GAD65 by clinical test and ELISA. 
(B) Venn diagram shows the overlap of individuals with positive sero-reactivity to IA-
2 or GAD65 in clinical test and ELISA. 
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In addition, we compared the sero-reactivity to IA-2 by RAPID ELISA and 
NAPPA in cohort1. The relative absorbance of RAPID ELISA and normalized signal 
intensity of NAPPA agreed well (Figure 4-6). We further compared RAPID ELISA with 
LIPS assay which was used in our previous publication (Miersch et al., 2013). AAb 
response to NUP50 was measured in cohort2. The relative absorbance of RAPID ELISA 
and luminescent signal of LIPS assay matched well (Figure 4-6). RAPID ELISA also has 
 
 
4 - 6 Comparison of RAPID ELISA with NAPPA and LIPS assay 
(A) Bar plots of sero-reactivity to IA-2 measured by RAPID ELISA and NAPPA in 
cohort1. 
(B) Bar plots of sero-reactivity to NUP50 measured by RAPID ELISA and LIPS 
Assay in cohort2. 
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high intra-assay and inter-assay reproducibility (data not shown). Due to the high 
sensitivity in detecting serum AAbs and the large overlap of sero-positivity with the 
clinical assay, NAPPA and LIPS assay, RAPID ELISA was proved as a superb individual 
immunoassay to profile AAbs.  
4.4.6 Novel AAbs from Two Approaches 
In the knowledge-based approach, 7 out of 15 candidates showed >10% 
sensitivity at 95% specificity in the independent sample set (cohort3). Of note, AAb to 
 
 
4 - 7 Novel AAbs from Two Approaches 
(A) Visual representative images of sero-reactivity to PTPRN2, MLH1, PPIL2 and 
NUP50 in one case-control pair. 
(B) Jitter plots of sero-reactivity in cohort3. 
(C) Heatmap of sero-reactivity in cohort3. 
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QRFPR, also named G-protein coupled receptor 103, had 20% sensitivity (Table 4-3). In 
the screening-based approach, AAbs to five antigens (PTPRN2, MLH1, MTIF3, PPIL2 
and NUP50) showed >15% sensitivity at 95% specificity cohort3 (Table 4-2).  
Among these, PTPRN2/IA-2β is an isoform of a major T1D-associated AAb 
(PTPRN/IA-2) (Lu et al., 1996). Although it was described a long time ago, the fact that 
we detected it in our non-biased screening further proved the power of our protein array 
platform in searching for AAb biomarkers. Representative slide images showed the 
apparent sero-reactivity to PTPRN2, MLH1, PPIL2 and NUP50 on NAPPA in the case 
sample but not in the control (Figure 4-7). The antibody response to MTIF3 was not 
strong on the array which may be due to the lower titer of this antibody in the serum 
which is consistent with the observation by RAPID ELISA. Notably, PPIL2 was printed 
on two array sets (GST1 and GST3) and showed up on both sets (data not shown). Jitter 
plots and heatmap were generated based on the relative absorbance data of RAPID 
ELISA in cohort3 (Figure 4-7).  
The cellular functions of six AAbs were listed in Table 4-4. PTPRN2 and QRFPR 
were implicated in the biology of T1D (Granata et al., 2014; Lu et al., 1996). MTIF3 
gene contains one of the established BMI-associated loci on obesity-related traits in 
French population (Goumidi et al., 2014).  
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4 - 4 Cellular Functions of Six AAbs 
 
4.4.7 Characteristics of Identified AAbs 
The complementary of novel AAbs to the known T1D-associated AAbs was 
evaluated. The prevalence of novel AAbs ranged from 13.43% to 29.85% of the 29 IA-
2A-negative T1D patients. Similarly, the prevalence was 9.38% to 25.00% of the 32 
GADA-negative T1D patients (Table 4-5).  
4 - 5 Prevalence of Identified AAbs in IA-2A and GADA Subgroups 
  IA-2A positive IA-2A Negative GADA Positive GADA Negative 
  n=67 n=29 n=64 n=32 
Prevalence of anti-PTPRN2 26.87%(18) 10.34%(3) 21.86(14) 21.86%(7) 
Prevalence of anti-MLH1 29.85%(20) 20.69%(6) 28.13%(18) 25.00%(8) 
Prevalence of anti-MTIF3 23.88%(16) 27.59%(8) 28.13%(18) 18.75%(6) 
Prevalence of anti-PPIL2 17.91%(12) 20.69%(6) 23.44%(15) 9.38%(3) 
Prevalence of anti-NUP50 13.43%(9) 20.69%(6) 15.63%(10) 15.63%(5) 
Prevalence of anti-QRFPR 19.40%(13) 20.69%(6) 18.75%(16) 9.38%(3) 
 
Gene Tissue Specificity Subcellular Location General Funcion 
PTPRN2 Brain and pancreas Cytoplasmic vesicle Transmembrane receptor 
MLH1 Lymphocytes, spleen, testis, thyroid,  Nucleus DNA repair 
MTIF3 Highest  in thymus, pancreas and testis Mitochondrion Translation initiation 
PPIL2 Highest  in thymus, pancreas and testis Nucleus 
Chaperone, ubiquitin ligase 
activity 
NUP50 Ubiquitous. Nucleus 
Nuclear pore complex 
component 
QRFPR Pancreas Membrane Neuopeptide Y receptor activity 
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The prevalence of AAbs among three age subgroups (<=12, 13-20 and >20 years) 
was investigated in the cases of cohort3. Antibody response to IA-2 and GAD65 remain 
high (57%-74%) in three age subgroups with slight decrease in individuals older than 20. 
Sero-reactivity to MLH1 and MTIF3 showed a dramatic decrease in age group (>20 
years). The prevalence of AAbs to PTPRN2, PPIL2, NUP50 and QRFPR were increased 
in >20 age group (Figure 4-8). 
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4 - 8 Prevalence of Identified AAbs in Age Subgroups 
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4.5 Discussion 
To our knowledge, this is the most comprehensive study that profiled the global 
humoral response in T1D. We accomplished this by a screening-based approach using 
NAPPA including 10,000 human proteins and a knowledge-based approach using ELISA 
to test 126 pancreas enriched genes. 
In the screening-based approach, sero-reactivity of the known T1D-associated 
AAbs was apparently distinguishable on the arrays probed with a T1D patient sample 
from a healthy control sample. However, the number of antigens that showed positive 
sero-reactivity was nearly the same between the patient and control groups. Network 
analysis revealed sero-positive antigens were enriched in pathways like β-cell 
development, class I MHC mediated antigen processing & presentation, B-cell activation, 
T-cell receptor signaling, viral infections, TGFβ signaling, metabolism, glucose transport 
and insulin signaling. Overall, there was no difference in the pathways enriched between 
cases and controls. One possible explanation is autoimmune destruction in T1D is a 
global effect rather than targeting specific pathways. The major known T1D-assocaited 
AAbs were not enriched in the same signaling pathway, either. In healthy controls 
without T1D, proteins in different pathways were more or less sero-positive by the 
accumulation of historical humoral responses.  
In addition to array-based profiling to search for candidate T1D specific 
antibodies, we have also performed a comprehensive assessment of antigens 
overexpressed in pancreas at the gene level. Of the four major known T1D-assocaited 
AAbs, insulin is highly expressed in pancreatic β-cells that regulate metabolic hemostasis. 
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GAD65 is expressed primary in the cytosol of neuroendocrine cells that distributed in the 
islet and neurons. IA-2 is localized at the membrane of insulin secretory granules (Lu et 
al., 1996).  ZnT8 was discovered by analyzing genes that are highly expressed in 
pancreas (Wenzlau et al., 2007).  Besides the protein array based screening approach, we 
also profiled AAbs to protein candidates that are highly expressed in pancreas. We relied 
on a RAPID-ELISA platform as an individual assay to assess the performance of 
individual antigens including antigen candidates from screening-based approach and 
antigens enriched in pancreas from bioinformatics analysis. Like NAPPA, RAPID-
ELISA also uses in vitro produced antigens to circumvent the challenges of human 
antigen production in vivo. The results of RAPID ELISA agreed well with liquid-based 
clinical RIA assay and LIPS assay (Figure 4-5). 
Using ELISA, we were able to confirm that 19 AAbs had a performance of >10% 
sensitivity at 95% specificity. 5 were validated with performance >15% sensitivity at 
95% specificity in an independent sample set (Table 4-2). The identification of PTPRN2 
as the best performer proves the validity of our discovery approach. PTPRN2 belongs to 
the same family of PTPRN (IA-2) and has been reported before. IA-2β/PTPRN2 was 
directly linked with β cell biology (Lu et al., 1996).  MLH1, a DNA mismatch repair 
protein, was frequently mutated or deleted in cancer (Bronner et al., 1994). MTIF3 is a 
mitochondrial translation initiation factor and NUP50 is a nuclear pore complex protein. 
They both the have highest expression in thymus, pancreas and testis. MTIF3 was 
implicated in obesity-related traits in French population (Goumidi et al., 2014). NUP50 
and PPIL2 were rarely described in T1D. QRFPR, also known as GPR103, it is a G-
 101 
protein-coupled receptor and enriched in the membrane of pancreas islet cells. GPR103 
contains seven transmembrane domes and functions as the ligand of RFamide peptides. 
Binding of RFamide peptides with GPR103 promote the survival of pancreatic β-cells 
and human pancreatic islets, but different peptides exert opposite effects on insulin 
secretion (Granata et al., 2014).  
In addition, AAbs to a dozen of other antigen proteins showed >10% sensitivity at 
95% specificity (Table 4-3). SNX6 is on the membrane of cytoplasmic vesicle and 
involved in intracellular trafficking. SYTL4 is participated in exocytosis (Jacobsson G, 
1994). IGRP/G6PC2 is an enzyme that hydrolyzes glucose-6-phosphate to glucose in the 
ER (Arden et al., 1999).  It was reported as the target of pathogenic CD8
+
 T cells in T1D 
(Lieberman et al., 2003). This is the first time of describing it as an AAb target. 
Our study clearly demonstrated the success of using a data driven 
immunoproteomics approach to profile global humoral response in T1D. There are two 
previous reports on T1D AAbs using protein arrays, including one from our group and 
another from a group in Korean (Koo et al., 2014; Miersch et al., 2013). We examined 
three reported AAbs (anti-DYRK2, anti-EEF1A1 and anti-UBE2L3) by RAPID ELISA 
in cohort3. None of them showed reproducible sensitivity as previous report (data not 
shown). The inconsistent result may be due to the differences in the study samples. In this 
study, we used samples from new-onset patients of 4-31 years old with a median age of 
11. Cases and controls were pair-matched. In our previous paper, the subjects were older 
and with longer duration (>6 years) of T1D. In the study published on Diabetes Journal 
(Koo et al., 2014), the average age of T1D patients used in discovery phase is 42 years 
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old with a standard deviation of 16 years. As T1D is a juvenile autoimmune disease and 
T1D patients need insulin treatment as soon as diagnosis, we believe samples from 
subjects with younger age and shorter duration of disease will be better for AAb study.
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4.6 Conclusions 
We successfully profiled the global humoral response in T1D. A comprehensive 
search for novel AAbs biomarkers in T1D using a screening-based approach by NAPPA 
and a knowledge-based approach by ELISA was performed. Six AAbs were identified 
and validated with sensitivities ranged from 16% to 27% at 95% specificity. Their 
prevalence in T1D cases complement to the major known T1D-assocaited AAbs and 
varied in different age subgroups. 
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CHAPTER 5 
5 IMMUNOPROTEOMIC PROFILING OF ANTI-VIRAL ANTIBODIES IN 
NEW-ONSET TYPE 1 DIABETES USING PROTEIN ARRAYS 
5.1 Abstract 
The rapid rise in the incidence of type 1 diabetes (T1D) suggests the potential 
involvement of environmental factors including viral infections. The association between 
viral infections and T1D was evaluated by profiling anti-viral antibodies using a high-
throughput immunoproteomics approach in new-onset T1D patients. A viral protein array 
was constructed comprising the complete proteomes of seven viruses reported to be 
associated with T1D and additional open reading frames (ORFs) from other common 
viruses. Sero-reactivity to 646 viral antigens was assessed in 42 new-onset T1D patients 
and 42 age-gender matched healthy controls (mean age 12.7 years, 50% males). 
Prevalence of anti-viral antibodies agreed well with the infection rates of the 
corresponding virus based on epidemiological studies. Antibody positive rate of Epstein-
Barr virus (EBV) was significantly higher in cases than controls (OR 6.6; 95% CI 2.0-
25.7) while the other viruses did not differ between the two groups. The EBV and T1D 
association was significant in both genders and age subgroups (<=12 and >12). These 
results suggest a potential role of EBV in T1D development. The innovative 
immunoproteomic platform is useful for understanding the role of viral infections in T1D 
and other disorders where associations between viral infection and disease are unclear. 
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5.2 Introduction 
T1D is a chronic heterogeneous disease characterized by the progressive 
autoimmune destruction of pancreatic β cells. The incidence of T1D is rising by an 
average of 3-5% in recent years that cannot be fully explained by genetic predisposition 
alone (Onkamo et al., 1999). Moreover, the concordance rate for developing T1D among 
monozygotic twins is around 40% (Kumar et al., 1993). Hence, it is likely that 
environmental factors play a significant role during T1D development (Eringsmark 
Regnell and Lernmark, 2013). Among various environmental factors considered relevant 
to T1D are those of nutrition and psychosocial factors; yet, viral infections have attracted 
particular interest (Craig et al., 2013a; Roivainen and Klingel, 2010).  
Although there are a number of studies indicating viral effects on T1D 
pathogenesis, the exact mechanistic explanations for how viruses contribute to T1D 
etiology are still unknown. Viral infection or presence may act as a longitudinal factor 
during the process of the induction of single islet antibody, or the simulation from single 
islet antibody to multiple islet antibodies, or the progression from β cell autoimmunity to 
clinical onset of T1D (Schneider and von Herrath, 2014a). Several studies reported that 
the initial development of autoantibodies and progression to multiple autoantibodies 
occurred at an early age. Subsequently, individuals progress to clinical T1D at different 
paces during which viral infections may act as an accelerator (Chmiel R, 2015; Parikka et 
al., 2012). For example, enterovirus infection was shown to increase progression to 
clinical onset in the Diabetes and Autoimmunity Study in the Young (DAISY) study 
(Stene et al., 2010). Given the complexity to understand the role of viral infections in 
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T1D, it is valuable to tackle this important scientific question by assessing sero-reactivity 
to many viruses/viral antigens in many samples collected longitudinally, from birth to 
disease onset. 
Many viruses have been implicated in T1D in both animal models and humans 
with varying levels of evidence. Historically, the prevalence of viral infections in T1D 
was explored by genomic and immunological approaches that only support the study of 
one viral protein or one type of virus at a time (Banatvala et al., 1985; Gamble et al., 
1969). Viral DNA or mRNA was detected by PCR or in situ hybridization (ISH) in a 
relatively low-throughput manner (Foy et al., 1995; Pak et al., 1988). At the protein level, 
immunohistochemical (IHC) staining and electron microscopy was used to stain and 
observe viral proteins (Dotta et al., 2007; Ylipaasto et al., 2004). Both ISH and IHC 
require the use of pancreatic sections from rare pancreatic tissue followed by tedious 
sample processing procedures. Many serological studies investigated the presence of 
antibodies to viruses. M-antibody enzyme-linked immunosorbent assay (ELISA) has 
been a classic way to profile IgM antibodies in T1D patients (Banatvala et al., 1985). The 
plaque assay, which measures the presence of neutralization antibodies against the whole 
virus, is another method to profile serological antibodies to specific viral serotypes 
(Laitinen OH, 2014; Oikarinen et al., 2014). The complement fixation test utilizes 
complement activation and the lysis of red blood cells to indicate the presence of certain 
viruses (Gamble et al., 1969). Recent advances in next generation sequencing (NGS) 
technology have opened new venues for studying the role of viral infection in T1D 
development (Lee et al., 2013). 
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Despite these efforts, the understanding of the association between viral infections 
and T1D development is still not clear. A lack of quantitative and high-throughput 
technologies has limited the ability to study the role of viral infections in disease 
comprehensively. Conflicting reports have stemmed from observations based on limited 
sample sizes (Craig et al., 2013a). Previous studies focusing on single viral protein or 
single viral species fail to provide a complete picture of infection and antibody responses 
at the systems level. Protein microarrays provide an ideal tool for multiplexed screening 
of specific antibodies in sera against thousands of different viral proteins printed on a 
standard microscope slide.   
The aim of this study was to assess the prevalence of anti-viral antibodies to 646 
viral proteins from 23 T1D-related and other common viruses in new-onset T1D patients 
and age-sex matched healthy controls. By examining antibody responses to hundreds of 
individual viral antigens at the proteome level, the goal is to provide a complete picture 
of infection at a dimension never achieved before. Antibody positive rates of studied 
viruses were determined and compared between T1D cases and controls. Specific 
antibody responses on the array were validated by a confirmatory ELISA. The past onset 
nature of T1D samples may prevent us from drawing conclusions of whether the virus is 
pathological in induction of β cell autoimmunity or acceleration of clinical T1D. 
Nonetheless, this is first comprehensive study of antibody response to a large number of 
viral species at the individual viral protein level in T1D. The successful application of 
protein array platform to a large number of samples collected longitudinally before or 
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after seroconversion will provide a better understanding of viral infection and T1D 
development.
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5.3 Experiments 
5.3.1 Serum Samples 
All samples were collected with written informed consent with the approval of 
Institutional Review Boards (IRB) at the University of Florida. Serum samples were 
obtained from new-onset T1D patients within three months of diagnosis. Control samples 
were prepared in the identical fashion as T1D patient samples and selected to be age-sex 
matched. Control samples were tested to be negative for major known T1D 
autoantibodies (AAbs) (IA-2A, GADA and ZnT8A). Peripheral blood samples were 
drawn from the antecubital vein and serum was prepared and stored as aliquots at -80
o
C. 
All individuals were free of other autoimmune diseases at the time of collection. The 
sample information is shown in Table 5-1. 
5 - 1 Sample Characteristics 
Characteristics New Onset Patients (n=42) Healthy Controls (n=42) 
Age     
Mean+ SD 12.64+4.94 12.83+4.96 
Median 11.5 12 
Gender      
Male(%) (21)50% (21)50% 
GADA positive (33)78.57% 0 
IA-2A positive (18)54.54% 0 
ZnT8A positive (20)47.62% 0 
 
5.3.2 Selection of Viral Strains 
Based on literature mining, viruses from seven different genera that have been 
implicated in T1D, which include Enterovirus (Coxsackievirus B4), Human endogenous 
retrovirus K (IDDMK1,2-22), Rubivirus (Rubella virus), Rubulavirus (Mumps virus), 
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Rotavirus (Rotavirus A), Cytomegalovirus (Human cytomegalovirus) and 
Lymphocryptovirus (Epstein-Barr virus) were identified. These viruses encompassed a 
variety of genome types (ssRNA+, ssRNA-, dsRNA and dsDNA). Selection of viral 
strain from each genus was based on their relevance to T1D as well as the availability of 
viral genome template (Conrad et al., 1997; Craig et al., 2013a; Forrest et al., 1969; Foy 
et al., 1995; Gamble et al., 1969; Honeyman et al., 2000; Pak et al., 1988; Yoon et al., 
1979). Additional viral genes were from other common viruses to further enrich in the 
collection (Table 5-2). 
5 - 2 Characteristics of Viruses 
Virus Species Abbre. Family Genome ORF clones 
% of  
complete 
ORFeome 
*Human Cytomegalovirus 
HCMV/HHV-
5 Herpesvirinae dsDNA 164 100% 
*Esptein-Barr virus EBV/HHV-4 Herpesvirinae dsDNA 85 100% 
*Coxsackievirus B CVB Picornaviridae ssRNA+ 12 100% 
*Rubella virus RUBA Togaviridae ssRNA+ 6 100% 
*Mumps virus MuV Paramyxoviridae ssRNA- 9 100% 
*Human endogenous retrovirus K HERK Retroviridea ssRNA- 4 100% 
*Rotaviruses RV Reoviridae dsRNA 12 100% 
Hepatitis B virus HBV Herpesviridae dsDNA 10 100% 
Human Papillomavirus16 HPV16 Papillomaviridae dsDNA 8 100% 
Human Papillomavirus18 HPV18 Papillomaviridae dsDNA 8 100% 
Chikungunya virus CHIKV Togaviridae ssRNA+ 9 100% 
Semliki Forest virus SFV Togaviridae ssRNA+ 9 100% 
Sindbis virus SINV Togaviridae ssRNA+ 9 100% 
Influenza A virus (H1N1) n/a Orthomyxoviridae ssRNA- 10 100% 
Influenza A virus (H3N2) n/a Orthomyxoviridae ssRNA- 10 100% 
Varicella-zoster virus VZV Herpeviridae dsDNA 68 93.10% 
Simian virus 40 SV40 Polyomaviridae dsDNA 6 85.71% 
Vaccinia virus VACV Poxviridae dsDNA 167 74.89% 
Yellow fever virus YF Flaviviridae ssRNA+ 11 71.42% 
Measles virus, vaccine strain MeV,vaccine Paramyxoviridae ssRNA- 5 62.50% 
Measles virus, WT strain MeV,WT Paramyxoviridae ssRNA- 5 62.50% 
Adenovirus n/a Adenoviridae dsDNA 16 42.10% 
Tioman virus n/a Paramyxoviridae ssRNA- 3 37.50% 
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5.3.3 Viral Genes Cloning 
All viral genes were first cloned into the pDONR221 Gateway compatible donor 
vector (Life technologies, CA). Different approaches were used based on the available 
resources (viral genome type, gene characteristics, et al). Viral genes were directly 
amplified by PCR if the viral DNA or cDNA templates were available. Viruses of 
ssRNA+ genome type, such as coxsackievirus, were first reverse-transcribed into cDNA 
before PCR amplification. Some viral genes are not continuous across the viral genome, 
for example, UL89 from human cytomegalovirus (HCMV). Each gene fragment was 
amplified separately and then fused together by PCR elongation to obtain full-length viral 
genes. Genes without available templates, such as the superantigen gene from the 
IDDMK1,2-22 strain, were produced using de novo gene synthesis.  Many Gateway 
compatible viral entry clones were obtained from the scientific community (Figure 5-1). 
Viral genes in the pDONR221 vector were transferred to a T7 promoter based in vitro 
expression vector pANT7_cGST by LR reaction (Festa et al., 2013). All viral genes 
cloned in this vector have a C-terminal glutathione S-transferase (GST) fusion tag in 
frame with the protein. The sequence verified clones were stored in the plasmid 
repository (http://dnasu.org/DNASU/) (Seiler et al., 2014). 
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5 - 1 Study Design 
1. Gene cloning: various approaches were used to capture viral genes into protein 
array compatible expression vector.  
2. Array construction: protein arrays were constructed as previous described and 
quality assured. 
3. Antibody profiling: antibodies to viral proteins were profiled between T1D case and 
healthy control group. 
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5.3.4 Nucleic Acid Programmable Protein Array (NAPPA) Production 
Using the standard protocol (Miersch et al., 2013; Miersch and LaBaer, 2011), 
1200 ng/µL plasmid DNA was co-printed with rabbit anti-GST polycolonal antibody (GE 
Healthcare, PA), BSA (bovine serum albumin) and bissulfosuccinimidyl suberate (BS
3
) 
protein cross-linker (Thermo Fisher Scientific, MA) as printing mix using Genetix 
QArrayer (Genetix, UK). Each viral gene was printed in duplicate on each slide. Human 
immunoglobulin (Ig)G, IgA and IgM were printed to show successful detection by 
secondary antibodies. Plasmid encoding a known T1D AAb (IA-2 protein) was printed as 
a positive control for T1D samples. Empty spots, spots printed with printing buffer 
without plasmid DNA, spots printed with printing buffer with plasmid encoding a 
hemagglutinin (HA)-fusion protein and anti-GST capture antibody were negative controls. 
HA-fusion protein can be expressed but not captured by anti-GST capture antibody to 
serve as negative control for non-specific capturing. NAPPA has been successfully 
applied in AAb biomarker discovery and protein post-translational modifications studies 
(Takulapalli et al., 2012; Yu et al., 2014c). 
5.3.5 Array Quality Assessment 
As previously described (Qiu and LaBaer, 2011; Ramachandran et al., 2008), 
plasmid DNA on the array was stained by Quant-iT™ PicoGreen® dsDNA Assay Kit 
(Life technologies, CA). For protein display, every four slides were blocked in 30 mL 
SuperBlock Blocking Buffer (Thermo Fisher Scientific, MA) at room temperature (RT) 
for 1 hour (hr) on the shaker. Then slides were rinsed five times with deionized (DI) 
water and placed in a metal slide rack (Amazon, WA) for drying by centrifugation at 
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1000 rpm for 3 min at RT. 160 μL human HeLa cell lysate-based protein expression 
system (Thermo Fisher scientific, MA) was injected into HybriWell (Grace BIO-LABS, 
OR) sealed slides and incubated in the oven (EchoTherm, CA) at 30°C for 1.5 hrs for 
protein expression and 15°C for 30 min for protein capture. Viral proteins were produced 
with a C-terminal GST fusion tag and captured in situ by co-printed anti-GST capture 
antibody on the array. The use of a tag at the C-terminus ensures that captured proteins 
have been fully translated. Each slide was incubated with 5% milk-PBST (0.2% Tween-
20), 3 mL 1:200 diluted anti-GST monoclonal antibody (Cell Signaling Technology, MA) 
and 3 mL1:500 diluted horseradish peroxidase (HRP) labeled goat anti-mouse IgG 
antibody (Jackson ImmunoResearch Laboratories, PA) for 1 hr at RT on the shaker, 
respectively. Slides were washed three times with 5% milk-PBST, 5 min each time in 
between. Finally, slides were washed with PBST and rinsed with DI water. Each slide 
was incubated with 500 µL 1:50 diluted tyramide signal amplification (TSA) buffer 
(PerkinElmer, MA) to generate fluorescent signals. Then slides were washed, dried and 
scanned by Tecan scanner (Männedorf, Switzerland). 
5.3.6 Anti-viral Antibody Profiling 
Anti-viral antibodies were profiled on the HS 4800™ Pro hybridization station 
(Tecan, Männedorf, Switzerland). Proteins were expressed as described. Expressed slides 
were placed in the hybridization chambers and programmed with 1 hr of blocking with 
5% milk-PBST, 16 hrs of incubation with 160 µL 1:50 diluted serum at 4°C followed by 
1 hr of detection with 160 µL 1:500 diluted Alexa Fluor 647® Goat Anti-Human IgG or 
160 µL 1:300 diluted Alexa Fluor 647® Goat Anti-Human IgA and DyLight
TM
 549-
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conjugated Goat Anti-Human IgM (Jackson ImmunoResearch Laboratories, PA) at RT. 
Slides were washed, dried and scanned by Tecan scanner (Männedorf, Switzerland). A 
pooled sample was prepared by mixing equal volumes of individual samples. The pooled 
sample was run on every serum screening day to show day-to-day technical 
reproducibility. 
Strong antibody response resulted in saturated signals of the local spot with 
diffusion to the neighboring spots. Serum dilution was determined by the optimal 
sensitivity with minimum diffusion. The presence of diffusion was defined as ring. To 
determine the signal intensities for the rings, the median intensity in between the ring 
spot and the neighboring spot was quantified as the raw ring intensity. The median 
intensity in between the ring spot and the second closest spot (excluding the spot area) 
was quantified as the background ring intensity. The net ring intensity was calculated by 
subtracting the background ring intensity from the raw ring intensity. The data was only 
extracted for the spots with rings as ring positive net intensity data. The maximum of the 
ring positive net intensity for duplicates of each viral antigen was used in quantitative 
analysis. 
5.3.7 RAPID (Rapid Antigenic Protein In situ Display) ELISA 
96-well ELISA plates (Corning Life Sciences, CA) were coated with 50 µL 10 
ng/mL anti-GST antibody (GE Healthcare, PA) in coating buffer (0.5 M carbonate 
bicarbonate buffer, pH 9.6) overnight at 4°C. On the next day, coated plates were washed 
five times with 100 µL PBST and blocked with 100 µL 5% milk-PBST for 1.5 hrs. 
Meanwhile, 40 ng/μL viral protein encoding plasmid was expressed in the human HeLa 
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cell lysate-based protein expression system at 30°C for 1.5 hrs in the oven. Viral antigen 
was diluted in milk-PBST at 1:200. 50 µL diluted antigen was captured in each well at 
RT for 1 hr on a shaker at 500 rpm. Plates were washed with five times of PBST. Each 
well was incubated with 50 µL 1:1000 diluted serum at RT for 1 hr, washed again and 
incubated with 50 µL 1:10,000 diluted HRP labeled anti-human secondary antibody 
(Jackson ImmunoResearch Laboratories, PA) at RT for 1 hr. Plates were incubated on a 
shaker at 500 rpm. Finally, the plates were washed and incubated with 50 µL 1-Step Ultra 
TMB - ELISA Substrate for 10 min (Thermo Fisher scientific, MA) for detection and 50 
µL 2M sulfuric acid to stop the reaction. OD450 was measured by Envision® Multilabel 
Reader (PerkinElmer, MA).  
5.3.8 Statistical Analysis 
Sample information is presented as proportions, medians and ranges. Positive 
antibody response to viral antigen was defined by the presence of a ring in at least one of 
the replicates of that protein. Positive antibody response to viruses in each individual was 
defined by the positivity of antibody response to at least one viral antigen from the entire 
viral proteome. Odds ratios (ORs) and exact 95% confidence intervals (CIs) were 
calculated for viruses and T1D association using conditional likelihood estimation and 
Fisher’s exact test (Breslow and Day, 1980). Exact Wilcoxon rank sum tests were applied 
to the maximum of the ring positive net intensity data to determine the significance of 
antibodies to individual viral proteins between cases and controls. The Benjamini-
Hochberg procedure was used to adjust p-values to account for multiple testing. These 
tests were performed using the coin package in R 3.0.3. Exploratory subgroup analyses of 
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the association between sero-positivity to viral proteins and three known T1D AAbs 
(GADA, IA-2A or ZnT8A), gender and age subgroups (<=12 and >12) were performed. 
P-value<0.05 were considered significant. Heatmaps were generated in MultiExperiment 
Viewer version 4.9 (http://www.tm4.org/mev.html). Graphs and plots were generated in 
GraphPad Prism 6.
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5.4 Results 
5.4.1 Viral Protein Array Production and Quality Assessment 
A high-throughput pipeline (Figure 5-1) was established and cloned 292 ORFs 
from seven viruses reported to be associated with T1D and 354 ORFs from other 
common viruses into the protein array compatible expression vector (Table 5-2). Among 
these, 15 out of 23 viral strains had 100% ORFs from the viral genome. The high 
coverage of viral ORFs and the diversity of viral strains would help us to fulfill the goal 
of a systematic survey of anti-viral antibodies in new-onset T1D patients. After printing, 
plasmids on the array were stained by PicoGreen that showed uniform DNA quality 
across the slide (Figure 5-2). The fluorescent signals of protein display were pseudo-
 
 
5 - 2 Quality of DNA and Protein Display 
(A) Visual representative images of DNA and protein display, green indicates pico-
green staining of DNA printed on the array, red indicates the antibody detection of 
protein display on the array; (B) Scatter plot of the reproducibility of protein display 
between two slides. 
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colored with a rainbow color scheme. The correlation coefficient of signal intensities of 
protein display as detected by the anti-GST tag antibody between two slides was above 
0.92 (Figure 5-2).  
5.4.2 Profiling of Anti-viral Antibodies  
Quality assured slides were challenged with serum samples from 42 new-onset 
T1D patients and 42 age-gender matched healthy controls, with median ages of 11.5 and 
12, respectively. IgG was profiled on a set of 84 slides, IgA and IgM were profiled 
simultaneously on another slide set. Arrays were probed with the pooled sample to assess 
intra and inter-array reproducibility. The inter-spot correlation coefficients for IgG and 
 
5 - 3 Inter-spot Correlation of IgG and IgA Profiling 
(A) Representative images of IgG or IgA class antibody response on NAPPA probed 
by the pool sample; 
(B) Scatter plots of inter-spot correlation of IgG or IgA class antibody response. 
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IgA profiling of duplicate spots on the same array were 0.94 and 0.91, respectively 
(Figure 5-3).  
The inter-array correlation coefficients of IgG, IgA and IgM profiling of duplicate 
arrays on different days ranged from 0.92 to 0.94 (Figure 5-4). The high inter-spot 
precision on one slide and day-to-day reproducibility on different slides demonstrated the 
robustness of the serum screening practice and good control of assay quality. 
 
 
5 - 4 Reproducibility of Anti-viral Antibody Profiling 
(A) Representative images of IgG, IgA and IgM sero-reactivity of a pooled sample on 
two slides from two serum screening days. 
(B) Scatter plot and correlation coefficients of IgG, IgA and IgM sero-reactivity of a 
pooled sample on two slides from two serum screening days. 
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RAPID-ELISA was used to confirm the sero-reactivity obtained on the viral 
protein arrays. RAPID ELISA is an established in-house developed immunoassay. Like 
NAPPA and several well-established clinical assays for T1D autoantibodies, it relies on a 
cell free system to produce antigens. The same viral antigen-encoding plasmids used on 
the array can be directly applied in RAPID ELISA. The intra-assay and inter-assay 
reproducibility is typically 0.99 (Figure 5-5).  
 
5 - 5 Reproducibility of RAPID ELISA 
(A) Intra-assay reproducibility presented by antibody profiling against two antigens on 
duplicated wells on the same day.  
(B) Inter-assay reproducibility presented by scatter plots of day-to-day reproducibility 
of anti-BFRF3 (EBV) profiling on three different days, their correlation coefficients 
were listed in table. 
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Because of the ease in developing a RAPID ELISA to any antigen in the 
collection, this allowed us to confirm the performance of a smaller number of candidate 
antigens with many samples reproducibly, quickly and affordably. RAPID ELISA data 
was consistent with clinical radioimmunoprecipitation assay (RIA) and the luciferase 
immunoprecipitation systems (LIPS) assay data (data not shown). Given its easy 
adaptability, high reproducibility and comparability to established clinical assays, it was 
chosen as a confirmatory platform to validate the signals on the array. The ring positive 
net intensities of two EBV antigens, BFRF3 and BLRF2, obtained on the viral protein 
arrays agreed well with ELISA, further proving the validity of this innovative array 
platform in profiling anti-viral antibodies (Figure 5-6). 
 
 
5 - 6 Concordance of Antibody Response to Viral Proteins 
(A) BFRF3 and (B) BLRF2 from Epstein-Barr virus (EBV). 
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5.4.3 Differential Anti-viral Antibody Response on Arrays 
A protein array approach enables the assessment of different sero-reactivity 
patterns for all the proteins from the same virus. Heatmaps of IgG and IgA sero-reactivity 
to viral proteins from the seven viruses previous associated T1D were generated using the 
ring positive net intensities (Figure 5-7). IgG antibody response to VP1 from 
coxsackievirus B (CVB), nucleoprotein from mumps virus (MuV) and influenza A virus 
were detected in almost every individual in both case and control group, which suggests 
they are the immunodominant antigens upon viral infection. IgA sero-reactivity was 
generally a subset of antigens that also showed IgG sero-reactivity and weaker than IgG 
sero-rectivity for the same viral protein, however, VP3 and VP4 from CVB were both 
more reactive for IgA response than IgG. Although the secondary antibody can clearly 
detected control IgA and IgM spots simultaneously on our arrays, no positive serological 
IgM reactivity was observed. This may be due to the lack of acute infection when the 
samples were drawn and low titer of IgM concentration in the serum.  
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5 - 7 Heatmaps of IgG and IgA Sero-reactivity 
Sero-reactivity to viral proteins from the seven viruses previous associated T1D. 
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5.4.4 Higher Frequency of Antibody Response to EBV in T1D Patients 
The apparent antibody positive rate of each virus between the case and the control 
groups was compared. As a sensitive criterion, a positive antibody response to a virus in 
each subject was defined by a positive antibody response to at least one viral antigen 
from the viral proteome. By this criterion, the prevalence of antibody positive rate 
obtained on the array is shown in Table 5-3.   
5 - 3 Frequencies of Antibody Responses to Studied Viruses 
Virus 
T1D 
(n) 
T1D 
(%) HC(n) HC(%) Odds Ratio 95% CI 
p-
Value 
*HCMV 24 57.1% 23 54.8% 1.1 0.4 to 2.8 1.000 
*EBV 37 88.1% 22 52.4% 6.6 2.0 to 25.7 *0.018 
*CVB 42 100.0% 42 100.0% 0.0 0.0 to Inf 1.000 
*RUBA 22 52.4% 25 59.5% 0.8 0.3 to 2.0 1.000 
*MuV 41 97.6% 40 95.2% 2.0 0.1 to 123.8 1.000 
*HERK 3 7.1% 2 4.8% 1.5 0.2 to 19.3 1.000 
*RV 27 64.3% 32 76.2% 0.6 0.2 to 1.6 1.000 
HBV 1 2.4% 0 0.0% Inf 0.0  to Inf 1.000 
HPV16 2 4.8% 1 2.4% 2.0 0.1 to 123.8 1.000 
HPV18 4 9.5% 0 0.0% Inf 0.7 to Inf 1.000 
CHIKV 1 2.4% 0 0.0% Inf 0.0 to Inf 1.000 
SFV 1 2.4% 0 0.0% Inf 0.0 to Inf 1.000 
SINV 0 0.0% 0 0.0% 0.0 0.0 to Inf 1.000 
Influenza A 
virus(H1N1) 41 97.6% 42 100.0% 0.0 0.0 to 39.0 1.000 
Influenza A 
virus(H3N2) 37 88.1% 40 95.2% 0.4 0.0 to 2.6 1.000 
VZV 37 73.8% 27 64.3% 1.6 0.6 to 4.5 1.000 
SV40 1 2.4% 0 0.0% Inf 0.0 to Inf 1.000 
VACV 1 2.4% 2 4.8% 0.5 0.0 to 9.8 1.000 
YF 0 0.0% 0 0.0% 0.0 0.0 to Inf 1.000 
MeV,vaccine strain 14 33.3% 14 33.3% 1.0 0.4 to 2.7 1.000 
MeV,WT strain 31 73.8% 35 83.3% 0.6 0.2 to 1.8 1.000 
Adenovirus 34 81.0% 36 85.7% 0.7 0.2 to 2.6 1.000 
Tioman virus 0 0.0% 0 0.0% 0.0 0.0 to Inf 1.000 
 
It agreed well with the background rates of infection determined by epidemiology 
studies where the sera were sampled. For example, the prevalence of HPV infection was 
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low while the frequencies of influenza A viruses were high in the study subjects. Notably, 
the antibody positive rate of EBV was more frequent in new-onset T1D cases than in 
healthy controls (88% VS 52%; OR 6.6, 95% CI 2.0-25.7; p-value=0.018) while none of 
the other viruses showed difference between the two groups (Table 5-3). Sero-positivity 
against EBV was higher in cases than controls among both genders and age subgroups 
(>=12 and <12) (Table 5-4). 
5 - 4 Sero-positivity of EBV in Gender and Age Subgroups 
Subgroup T1D HC 
Odds 
Ratio 95% CI p-Value 
Female (n=21) 85.71% 57.14% 4.500 1.01 to 20.11 0.049 
Male (n=21) 90.48% 47.62% 10.450 1.93 to 56.64 0.007 
Age(<=12) (n=24) 83.33% 50.00% 5.000 1.61 to 19.07 0.019 
Age(>12) (n=18) 94.44% 55.56% 13.600 1.48 to 125.32 0.021 
 
Many immunodominant EBV proteins were detected based on antibody-mediated 
immunity such as BFRF3 and BLRF2 (viral capsid antigen/VCA), BZLF1 (early 
antigen/EA) and EBNA1 (nuclear antigen). On average, each case has antibody response 
to 8 EBV proteins while each control has antibody response to 6 EBV proteins.  
The association of antibody response to individual viral protein and subgroups of 
T1D patients was assessed. IgG antibody response to IA-2 was statistically significantly 
higher in T1D patients (p=0.007) confirming the detection of known T1D autoantigens 
on the protein array platform. However, of all the 646 viral proteins on the array, none of 
them exhibited statistically significant differences between cases and controls. Next, the 
association of antibodies against all viral proteins with the sero-positivity to three known 
T1D autoantigens (IA-2, GAD65 and ZnT8) was analyzed. No proteins exhibited 
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statistically significant associations with any of the three known T1D autoantigens or 
gender. Only one protein, IgG antibody response to the NP protein from influenza A 
virus (H1N1) was significantly (p=0.007) higher in age (>12) than age (<=12) subgroup 
of T1D patients (data not shown).
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5.5 Discussion 
This is the first study that examined anti-viral antibodies to individual viral 
proteins at the proteomic level in new-onset T1D patients. It was accomplished by using 
an innovative and flexible protein array platform, resulting in a study with several unique 
strengths suggesting higher a frequency of EBV-specific immune response in T1D. 
By examining antibody responses to hundreds of individual viral antigens, the 
role of viral infections in T1D development was analyzed at a dimension never achieved 
before. Previously, publications focused on the detection of antibodies to whole viruses 
or a limited number of viral proteins (Banatvala et al., 1985; Gamble et al., 1969). Such 
studies might underrepresent the prevalence of viral infections because some patients 
may not produce antibodies that respond to those antigens. Even some commercial 
ELISA kits cannot achieve 100% sensitivity in detecting viral infections (Tramper-
Stranders et al., 2006). The examination of all proteins for each virus affords the 
opportunity to look for associations not only with viral infection but with immune 
responses to specific viral antigens. By focusing on the host immune response, the 
missing events due to the transient nature of detecting viral DNA/RNA was avoided, 
which may only be present briefly during infection (Lee et al., 2013).  
High-throughput and low sample consumption are great advantages of the array 
platform over conventional one antigen-at-a-time immunoassays. Using this platform, 
only 3.2 µL sera were needed to probe thousands of antigens on the slide. On average, 
each antigen consumes as little as 0.002 µl of serum sample, which is significantly less 
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than individual assay such as enzyme immuno assay (EIA) or RIA that consumes a few 
microliters per antigen per assay.  
This protein array platform also offers great opportunity for multiplexed detection 
of different immunoglobulin classes and flexibility to include any genes of interest into 
the study design. Typically, IgG is considered the most common and durable response, 
providing information of historical infections, IgA indicates the mucosal immunity and 
IgM correlates with acute infection. On the other hand, the emerging NGS techniques 
provide powerful opportunities to uncover new viral/microbiome strains that associated 
with T1D (Lee et al., 2013; Mejia-Leon et al., 2014). Any proteins with known gene 
sequences can be included in the innovative array platform to assess their sero-reactivity. 
Therefore, it is straightforward to incorporate metagenomics findings of T1D-relevant 
viruses/pathogens into the design of the viral/pathogen protein arrays to study their sero-
reactivity. This combination of antibody immunoprofiles and viral metagenomics in T1D 
will lead to a better understanding of viral infections in T1D. 
The prevalence of subjects with positive antibody response to the studied viruses 
(Table 5-3) agreed well with the infection rate of the corresponding virus from 
epidemiological studies in the United States (Table 5-5) (Balfour et al., 2013; Butel, 2012; 
Dunne et al., 2007; Eisenhut et al., 1999; Nwanegbo et al., 2004; Staras et al., 2006; 
Vogetseder et al., 1993; Weinbaum et al., 2008), proving the validity of the array 
platform in detecting historical viral infections. In addition to infection, antibody 
responses to viruses may also depend on the vaccine history, vaccine efficacy, antibody 
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specificity and detection methods (JD Cherry, 2013; Latner et al., 2014). Unfortunately, 
the vaccination history for these de-identified samples was not available. 
5 - 5 Infection Rate and Vaccination Information of Studied Viruses 
Virus Infection Rate Vaccine 
HCMV 36.3% - 58.9% (US) NA 
EBV 50 - 89% (US) NA 
CVB 52,812 detections between 1970-2005 NA 
RUBA no longer endemic (US) Yes 
MuV no big outbreaks (US) Yes 
HERK 0% (US) NA 
RV 3 million cases per year (US) NA 
HBV 804,000 - 1.4 million (US) Yes 
HPV16 1% (US) Yes 
HPV18 0.125% (US) Yes 
CHIKV 0% (US) NA 
SFV 0% (US) NA 
SINV 0.1% (German) NA 
Influenza virus 4 - 5600 cases per week (US) Yes 
VZV 1 million per year (US) Yes 
SV40 0% - 4.2% (US) NA 
VACV 0% (US) NA 
YF 0% (US) NA 
MeV 50 - 350 cases per year (US) Yes 
Adenovirus 37% (US) NA 
Tioman virus 0% (US) NA 
 
These results clearly demonstrate the importance of taking a systems approach to 
assess the relationship between infection and chronic disease. A significant association 
between antibody response to EBV and new-onset T1D patients (88% VS 52%; OR 6.6, 
95% CI 2.0-25.7; p-value=0.018) was found. Unfortunately, none of the EBV proteins 
showed a statistical difference between cases and controls which further emphasized the 
importance to take a systematic view to examine every individual protein from EBV. 
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Similarly, immunoassays based on the whole viral particles only detect responses against 
viral capsid antigens. Of note, the EBV and T1D association is not depended on gender 
or age subgroups (Table 5-4).  
Connections between EBV and T1D date back to 1974 (Burgess et al., 1974a). 
Earlier studies focused on detecting low-grade temporary viral infections using PCR or 
serological antibody in a small sample size (Elliott RB, 1995b; Foy et al., 1994). It was 
reported EBV infection was not associated with islet cell and insulin AAb seroconversion 
(Elliott RB, 1995b). Antibody levels to VCA and EA was profiled by a commercial 
ELISA kit and found lower VCA IgG class antibody levels in T1D patients (Hyoty et al., 
1991). This apparent difference in response to EBV may arise from several potential 
reasons. One possibility may be differences in the methods for determining viral 
infections. This study profiled antibodies to every individual EBV protein, whereas this 
earlier study focused on antibody responses to several EBV proteins. If only one protein 
or several proteins from VCA or EA from the data was considered, none of them showed 
significant higher prevalence in cases than controls (Table 5-6). There were also 
differences in sample source: the sample used in this study was obtained in US compared 
to Finland for the previous study. Viral infections are both seasonal and regional. 
Differences of viral infections in the general population may be different based on sample 
locations. 
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5 - 6 Antibody Responses to VCA and EA Antigens of EBV 
Gene 
Symbol 
Antigen 
Class Case Control 
Odds 
ratio 95% CI 
p 
value 
BFRF3 VCA 0.62 0.40 2.3897 1.0 o 2.7 0.0513 
BLRF2 VCA 0.57 0.38 2.1667 0.9 to 51.2 0.0824 
BXLF1 EA 0.05 0.05 1 0.1 to 7.5 1 
BGLF5 EA 0.02 0.00 3.0723 0.1 to 77.6 0.4957 
BMRF1 EA 0.00 0.00 1 0.0 to 51.6 1 
BZLF1 EA 0.45 0.29 2.0652 0.8 to 5.1 0.1159 
 
The mechanism through which EBV might contribute to the pathogenesis of T1D 
remains uncertain. However, several possible scenarios can be envisioned. First, EBV 
may be spread from circulating infected B cells to pancreatic tissue, resulting in local 
antiviral immune responses. Second, EBV infection induces the release of cytokines, 
which promotes the maturation of immune cells to enhance their cytotoxicity (Hornef et 
al., 1995; Williams et al., 2005). Third, EBV infection may trigger a cross reactive 
autoimmune response through molecular mimicry of viral antigens and host proteins 
(Parkkonen et al., 1994b). These hypotheses need further evaluation. Recent evidence 
showed viral infection may play a role in accelerating the progression from β cell 
autoimmunity to clinical T1D (Stene et al., 2010). The antibody responses detected in this 
work indicated past infections. As the samples used in this study were from post-onset 
T1D patients, further investigation of longitudinal samples is needed to determine 
whether infection is important during seroconversion or progression to clinical diagnosis 
of T1D. The successful application of the array platform in detecting antibodies to 
thousands of viral antigens provided a better tool to investigate this problem. 
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Historically, coxsackievirus is the most frequently cited T1D-related virus. The 
E2 strain of CVB was selected in this study because it was first isolated from the 
pancreas of a child with diabetic ketoacidosis (Yoon et al., 1979). However, no difference 
in the apparent history of infection (OR 1, p-value=1.000) was found, which is consistent 
with the recent work by Hyöty H et al. using a neutralizing antibody assay to investigate 
41 different enterovirus serotypes (Oikarinen et al., 2014). The other five viruses 
previously reported to be related with T1D did not show prevalence difference between 
cases and controls.   
Despite its virtues, the present study has some limitations. This study samples 
were new-onset T1D patients with relative small sample size and not matched for HLA 
genotypes. Viral antibodies from new-onset patients may provide limited information for 
the involvement of these viral infections/antibodies during the progression from initiation 
of autoimmunity to the onset of T1D symptoms. The relatively small sample size also 
prevented us from drawing strong statistical conclusions. Furthermore, the HLA genotype 
is important in modulating the immune responses during viral infection. In addition, only 
one of the most relevant viral strains based on previous publications was investigated in 
this study. The infection rate between viral serotypes varies and specific serotypes may 
have different roles in association with T1D (Laitinen OH, 2014; Oikarinen et al., 2014). 
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5.6 Conclusions 
In summary, the use of viral protein array platform in profiling anti-viral 
antibodies was successfully demonstrated.  A preliminary study was completed and found 
a potential link between EBV infection and T1D development. The success of this work 
established the utility of a flexible high-throughput multiplexed platform to profile a large 
number of longitudinal samples including time points surrounding “seroconversion” and 
clinical diagnosis. A comprehensive understanding of antibody responses to thousands of 
viral antigens in these longitudinal samples and samples from HLA-matched healthy 
controls will greatly improve our knowledge of the role of viral infection in T1D 
development. 
5.7 Acknowledgements 
I wish to thank Dr. Roivainen Merja (National Institute of Health and Welfare, 
Finland), Dr. Tom Hobman (University of Alberta, Canada), Dr. Biao He (University of 
Georgia, USA), Dr. Marc Vidal (Harvard Medical School, USA), Dr. David E Hill 
(Dana-Farber Cancer Institute, USA), Dr. James M. Pipas (University of Pittsburgh, 
USA), Dr Jürgen Haas (University of Edinburgh, UK) and Dr. Vincent Lotteau 
(Universite´ de Lyon, France) for kindly providing viral templates/clones. I thank Kristi 
Barker (Arizona State University, USA) for critically reading this chapter. This study was 
supported by the innovative grant from Juvenile Diabetes Research Foundation (JDRF) 
5-2012-537.
 135 
CHAPTER 6 
6 ANTI-VIRAL ANTIBODY PROFILING BY HIGH DENSITY PROTEIN 
ARRAYS 
6.1 Abstract 
Viral infections elicit anti-viral antibodies and have been associated with various 
chronic diseases. Detection of these antibodies can facilitate diagnosis, treatment of 
infection and understanding of the mechanisms of virus associated diseases. In this work, 
anti-viral antibodies were assayed using a novel high density-nucleic acid programmable 
protein array (HD-NAPPA) platform. Individual viral proteins were expressed in situ 
directly from plasmids encoding proteins in an array of microscopic reaction chambers. 
Quality of protein display and serum response was assured by comparing intra- and inter- 
array correlation within or between printing batches with average correlation coefficients 
of 0.91 and 0.96, respectively. HD-NAPPA showed higher signal to background (S/B) 
ratio compared with standard NAPPA on planar glass slides and ELISA. Antibody 
responses to 761 antigens from 25 different viruses were profiled among patients with 
juvenile idiopathic arthritis (JIA) and type 1 diabetes (T1D). Common as well as unique 
antibody reactivity patterns were detected between patients and healthy controls. HD-
viral-NAPPA will enable the study of host-pathogen interactions at unprecedented 
dimensions and elucidate the role of pathogen infections in disease development
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6.2 Introduction 
Viral infections not only elicit acute symptoms but have been implicated in a 
variety of chronic illnesses including autoimmune diseases and cancers (Fujinami et al., 
2006; Moore and Chang, 2010). One direct consequence of viral infections is the 
elicitation of antibodies against viral proteins (Odumade et al., 2011). Detection of these 
antibodies can facilitate diagnosis and treatment of viral infections (Odumade et al., 
2011). It can further help elucidate the roles of viral infections and the role of specific 
viral antigens in disease development (Cepok et al., 2005). 
ELISA is a traditional method to study anti-viral antibodies; however, it is 
typically limited to only one or a few protein antigens and often requires significant 
investment in optimizing antigen production (Athmaram et al., 2013). Even within the 
same virus, different antigens display markedly different immunogenicity. Sero-reactivity 
to these antigens may correlate with different clinical parameters and have different 
clinical utility (Schaade et al., 2001). The opportunity to gather the information of 
antibody responses to an entire viral proteome will enable the understanding of the 
relationship between individual anti-viral antibody responses and clinical parameters and 
measurements. It is very common that more than one virus has been epidemiologically 
associated with certain diseases (Jun and Yoon, 2004). Comprehensive studies of 
complete viral proteomes for multiple viruses are impractical with the traditional one-
antigen-at-a-time approach. An assay platform which can examine responses to whole 
proteomes of many viruses could generate a comprehensive overview of responses to 
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viral infections, providing biological log files of past infections, and possibly unveil viral 
associations with autoimmune diseases or cancers. 
Protein arrays provide an ideal tool to profile antibodies in blood against 
thousands of proteins on a microscopic format (Sutandy et al., 2013). Traditional protein 
array technology is based on expressing, purifying and printing thousands of different 
proteins. This is scientifically challenging and labor intensive. NAPPA circumvented 
these inherent problems by printing plasmids with cDNA encoding each protein instead 
of the proteins themselves (Ramachandran et al., 2008). NAPPA has been successfully 
used in novel autoantibody biomarker discovery and protein functional studies (Anderson 
et al., 2011; Ceroni et al., 2010; Gibson et al., 2012; Miersch et al., 2013; Wright et al., 
2012; Yu et al., 2014b). 
Standard NAPPA involves just-in-time in situ protein expression from printed 
cDNAs using in vitro transcription and translation (IVTT)-coupled cell lysates (Miersch 
and LaBaer, 2011; Qiu and LaBaer, 2011; Ramachandran et al., 2008). Expressed tagged 
proteins are captured on a planar glass surface by co-printed anti-tag antibodies. When 
feature densities are increased, mRNAs and proteins from one feature start to diffuse to 
the neighboring features during protein expression resulting in mixed protein display 
(Takulapalli et al., 2012). Diffusion prohibits standard NAPPA from achieving densities 
higher than 2,500 features per array. HD-NAPPA overcame these challenges by 
expressing and capturing proteins in arrays of isolated sealed ‘nanowells’ to prevent 
diffusion and cross-talk between spots (Takulapalli et al., 2012). The utility of HD-
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NAPPA has been demonstrated in commercial antibody target detection and protein-
protein interactions (Takulapalli et al., 2012).  
Connections between viral infections and JIA and T1D were supported at the 
epidemiological, serological and molecular levels (Franssila and Hedman, 2006; Jun and 
Yoon, 2004). Parvovirus B19 (PB19) and coxsackievirus B4 (CVB) were isolated 
directly from the synovial tissue of a patient with severe arthritis and the pancreas of a 
child with diabetic ketoacidosis, respectively (Dijkmans et al., 1988; Yoon et al., 1979). 
PCR, in situ hybridization (ISH) and immunohistochemistry (IHC) staining were 
employed to detect viral genomes or proteins among JIA and T1D patients (Foy et al., 
1994; Pak et al., 1988). Other immunological methodologies, including plaque, ELISA 
and complement fixation assays, were applied to measure antibodies specific to viral 
antigens from various biological samples such as serum, plasma and synovial fluid 
(Banatvala et al., 1985; Gamble et al., 1969; Oikarinen et al., 2014). All these 
immunoassays depended on the detection of anti-viral antibodies to the intact whole virus 
or a limited number of viral proteins. This precluded us from acquiring a complete 
picture of viral infections in JIA and T1D (Clarris, 1978; Craig et al., 2013b).  
To characterize the advantages and demonstrate the utility of HD-viral-NAPPA to 
document past viral infections, anti-viral antibodies to 761 viral antigens from 25 
different viruses were profiled in the two most common juvenile autoimmune diseases: 
JIA and T1D. HD-viral-NAPPA enabled studying anti-viral antibodies in JIA and T1D 
patients at unprecedented breadth and depth. HD-NAPPA showed high reproducibility of 
protein display and serum profiling on HD-viral-NAPPA. HD-viral-NAPPA greatly 
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improved sensitivity in detecting anti-viral antibodies compared to standard NAPPA and 
ELISA. Unique and common signatures of anti-viral antigen antibodies were found. It 
was clearly demonstrated that HD-viral-NAPPA is a flexible, sensitive and high-
throughput platform enabling quantitative measurements of anti-viral antibody levels in 
infectious and autoimmune diseases.
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6.3 Experiments 
6.3.1 Serum Samples 
T1D samples were collected at the University of Florida with written informed 
consent and approval of institutional review board (IRB) at the University of Florida. 
Peripheral blood samples were obtained from T1D patients diagnosed within three 
months according to the American Diabetes Association (ADA) criteria. Serum was 
prepared and stored as aliquots at -80°C. T1D controls were age/gender matched family 
members of patients and tested to be negative for the known T1D autoantibodies (GADA, 
IA-2A and ZnT8A). JIA samples were collected at Queen's University of Belfast with the 
Office for Research Ethics Committees Northern Ireland (ORECNI) approval (ORECNI 
408/03). JIA patients and JIA patients with uveitis were matched with disease subtypes 
and antinuclear antibodies (ANA) status in addition to age/gender. Healthy controls were 
only age/gender matched to JIA patients or JIA patients with uveitis. Uveitis is the 
inflammation of the uvea which is regarded as a severe symptom in JIA patients (Thurn, 
1988). The sample information of T1D and JIA is characterized in Table 6-1 and 6-2. 
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6 - 1 Sample Characteristics of T1D Sample Set 
Characteristics New Onset Patients (n=20) Healthy Controls (n=20) 
Age     
Mean+ SD 13.2+4.96 13.3+4.94 
Median 13.5 13.5 
Gender      
Male(%) (14)70% (14)70% 
GADA positive (14)70% 0 
IA-2A positive (14)70% 0 
ZnT8A positive (11)55% 0 
 
6 - 2 Sample Characteristics of JIA Sample Set 
Characteristics 
JIA 
(n=10) 
JIA with Uveitis (n=10) 
Healthy control (n=10) 
Age       
Mean+ SD 5.83+3.86 4.78+3.43 6.17+6.46 
Median 3.86 3.51 2.71 
Gender        
Male(%) (1)10% (1)10% (1)10% 
Disease Subtype       
Oligo 7 7 NA 
Ext.Oligo 1 1 NA 
Poly 2 2 NA 
ANA status       
negative (5)50% (5)50% NA 
 
6.3.2 HD-viral-NAPPA Fabrication 
6.3.2.1 DNA Preparation 
Viral genes were cloned into the T7-based mammalian expression vector 
pANT7_cGST (Cormier et al., 2011; Festa et al., 2013; Yu et al., 2014a). All genes were 
sequence verified and are publicly available at https://dnasu.org/DNASU/ (Seiler et al., 
2014). Plasmid DNA was extracted and quality assured as described (Miersch and 
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LaBaer, 2011; Qiu and LaBaer, 2011). DNA concentration was normalized to 100 ng/µL 
before printing. 
6.3.2.2 Silicon Nanowell (SiNW) Substrate Preparation 
All SiNW substrates were fabricated at Arizona State University Center for Solid 
State Electronics Research (CSSER). The detailed procedure for nanowell production 
was described in (Takulapalli et al., 2012). Briefly, isotropic wet etching was used to 
produce circular nanowells with flat surface at the bottom. Nanowells were 250 μm in 
diameter and 70 μm in depth. The etched silicon wafers were diced to yield the SiNW 
substrates the same size as a standard microscope slide. A silicon dioxide layer was 
thermally grown on the surface and later coated with a 3-Aminopropyltriethoxysilane 
monolayer for NAPPA chemistry. 
6.3.2.3 Piezoelectric Printing in Nanowells 
HD-viral-NAPPA was printed by au302 piezoelectric dispensing system 
(Engineering Arts LLC, Tempe, AZ) with integrated alignment system. “On the fly” non-
contact dispensing with 16-pin dispensing head was used to dispense DNA/printing mix 
at 175 mm/sec speed. Each nanowell was filled with 1,200 picoliters of printing mix 
followed by 300 picoliters of DNA. Each SiNW substrate was equally divided into four 
sub-arrays. Each viral gene was printed in duplicate within the sub-arrays. Printed arrays 
were stored desiccated in a nitrogen atmosphere at room temperature until use. 
6.3.3 Protein Expression 
After printing, SiNW substrates were blocked using SuperBlock TB (Thermo 
Scientific, Waltham, MA) for 30 min. The substrates were rinsed, dried and placed in an 
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airtight chamber (Takulapalli et al., 2012) with a flexible film above the substrates. Air in 
the chamber was removed by vacuum from a fluid gap between the substrate and the 
flexible film. Human HeLa cell lysate-based IVTT system was injected into the fluid gap 
by syringe thus filling nanowells with lysate. Excess reagent was swept away from the 
substrate by flowing pressurized viscous liquid over the flexible film. Individual 
nanowells were thus sealed into isolated reaction chambers by the flexible film and 
pressurized viscous liquid.  The chamber was placed in an incubator (EchoTherm chilling 
incubator, Torrey Pines Scientific, Carlsbad, CA) for protein expression at 30
o
C for 2 hrs 
and capture at 15
o
C for 1 hr. Displayed proteins were detected with a monoclonal anti-
GST antibody (Cell signaling Inc., Danvers, MA) and Alexa Fluor® 647 goat anti-mouse 
IgG (H+L) (Life technologies, Carlsbad, CA). Substrates were washed, dried and scanned 
by Tecan PowerScanner™ (Tecan Group Ltd, Männedorf, Switzerland).  
6.3.4 Serum Profiling on HD-viral-NAPPA 
The scheme of antibody profiling on HD-viral-NAPPA was shown in Figure 6-1. 
Following protein expression, substrates were blocked in 5% milk-PBST (0.2% Tween) 
for 1 hr and later incubated with serum samples in proplate 4-well tray set (Grace Bio-
Labs, Bend, OR) at 4
o
C overnight. Next day, the substrates were washed and detected by 
Alexa Fluro® 647-conjugated goat anti-human IgG (Jackson ImmunoResearch, West 
Grove, PA). Finally, substrates were washed, dried and scanned as described. 
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6.3.5 RAPID ELISA 
RAPID ELISA was performed to verify the sero-reactivity to viral proteins 
(Anderson et al., 2008). Briefly, each well of 96-well ELISA plates (Corning life science, 
Union City, CA) was coated with 50 µL 10 μg/mL anti-GST antibody (GE Healthcare 
Life Sciences, Pittsburgh, PA) in coating buffer (0.5 M sodium bicarbonate buffer, pH 
9.6) at 4°C overnight. Next day, coated plates were washed with PBST and blocked with 
 
 
6 - 1 Antibody Profiling on HD-viral-NAPPA 
A. Step 1: Production of HD-viral-NAPPA by printing plasmid DNA and capture 
antibody into Silicon NanoWells (SiNWs); Step 2: Protein display on HD-viral-
NAPPA after isolated expression and in situ capture in individual wells; Step 3: 
Antibody profiling to detect distinct sero-reactivity against individual antigens. 
B. Images of a SiNW substrate by scanning electron microscopy (top), proteins 
displayed on HD-viral-NAPPA as detected by anti-GST antibody (middle), and sero-
profiling on HD-viral-NAPPA (bottom).  
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5% milk-PBST (0.2% Tween) for 1.5 hrs. Meanwhile, 40 ng/μL plasmids encoding viral 
antigens were expressed in the human HeLa cell lysate-based IVTT system at 30°C for 
1.5 hrs. Viral proteins were diluted 1:200 in milk-PBST and captured in the wells. Then 
plates were washed with PBST, incubated with serum samples diluted at 1:1,000, washed 
with PBST again and incubated with peroxidase AffiniPure goat anti-human IgG 
(Jackson ImmunoResearch Laboratories, West Grove, PA). Finally, the plates were 
detected by 1-Step Ultra TMB - ELISA Substrate (Thermo scientific, Waltham, MA) for 
10 min and then 2 M sulfuric acid was used to stop the reaction. OD450 was measured by 
Envision Multilabel Reader (Perkin Elmer, Waltham, MA).  
6.3.6 Statistical Analysis 
Sample characteristics including age, gender and known autoantibody status were 
presented as proportion, median and mean with standard deviations. Signal intensities of 
protein display and serum profiling were extracted by Array-Pro Analyzer 
(MediaCybernetics, Rockville, MD). Raw signal intensities of protein display were log 
transformed before comparing their intra-array, intra-batch and inter-batch correlations. 
To calculate the S/B ratios on the array platform, the background signal was represented 
by the median of the raw signal intensities of all the antigens on an array probed with a 
serum sample. For ELISA, the background signal was represented by the median signal 
of all the antigens for a serum sample probed on the same day. Wilcoxon rank-sum test 
was used to test the difference of sero-reactivity among subgroups in the JIA sample set. 
Heatmaps were generated in MultiExperiment Viewer version 4.9 obtained from 
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http://www.tm4.org/. Bar graphs and plots were generated in GraphPad Prism 6 
(GraphPad software, La Jolla, CA).
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6.4 Results 
6.4.1 Quality of Protein Display on HD-viral-NAPPA 
761 viral genes from 25 viral strains were collected to build the HD-viral-NAPPA 
platform (Table 6-3). Among these, 16 viral strains had 100% of viral genes available in 
this collection. During printing, each array was divided into four sub-arrays and each 
viral gene was printed in duplicate on each sub-array. 
To confirm the quality of protein display on HD-viral-NAPPA, protein display 
levels for all ~1,500 features on two sub-arrays from the same printing batch and one 
sub-array from a separate printing batch was compared. Representative array images and 
scatter plots of signal intensities of protein display are shown in Figure 6-2. The average 
intra-array, intra-batch and inter-batch correlation coefficients of protein display 
calculated by the log transformed raw signal intensity were 0.92, 0.91 and 0.91, 
respectively.  
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6 - 3 List of Viruses in This Study 
Virus Species Abbre. Family Genome 
ORF 
clones 
% of complete 
ORFeome 
Human 
Cytomegalovirus 
HCMV/HHV-
5 Herpesvirinae dsDNA 164 100% 
Esptein-Barr virus EBV/HHV-4 Herpesvirinae dsDNA 85 100% 
Coxsackievirus B CVB Picornaviridae ssRNA+ 12 100% 
Rubella virus RUBA Togaviridae ssRNA+ 6 100% 
Mumps virus MuV Paramyxoviridae ssRNA- 9 100% 
Human 
endogenous 
retrovirus K HERK Retroviridea ssRNA- 4 100% 
Rotaviruses RV Reoviridae dsRNA 12 100% 
Parvovirus B19 B19 Parvoviridae ssDNA 6 100% 
Hepatitis B virus HBV Herpesviridae dsDNA 10 100% 
Human 
Papillomavirus16 HPV16 Papillomaviridae dsDNA 10 100% 
Human 
Papillomavirus18 HPV18 Papillomaviridae dsDNA 9 100% 
Chikungunya 
virus CHIKV Togaviridae ssRNA+ 9 100% 
Semliki Forest 
virus SFV Togaviridae ssRNA+ 9 100% 
Sindbis virus SINV Togaviridae ssRNA+ 9 100% 
Influenza A virus 
(H1N1) n/a Orthomyxoviridae ssRNA- 10 100% 
Influenza A virus 
(H3N2) n/a Orthomyxoviridae ssRNA- 10 100% 
Varicella-zoster 
virus VZV Herpeviridae dsDNA 91 93.10% 
Simian virus 40 SV40 Polyomaviridae dsDNA 6 85.71% 
Vaccinia virus VACV Poxviridae dsDNA 167 74.90% 
Yellow fever virus YF Flaviviridae ssRNA+ 11 71.42% 
Measles virus, 
vaccine strain MeV,vaccine Paramyxoviridae ssRNA- 5 62.50% 
Measles virus, 
WT strain MeV,WT Paramyxoviridae ssRNA- 5 62.50% 
Herpes simplex 
virus 1 HSV-1 Herpesviridae dsDNA 83 61.90% 
Adenovirus n/a Adenoviridae dsDNA 16 42.10% 
Tioman virus n/a Paramyxoviridae ssRNA- 3 37.50% 
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6.4.2 Quality of Serum Profiling on HD-viral-NAPPA 
The work flow of serum profiling on HD-viral-NAPPA includes the production of 
HD-viral-NAPPA, protein display and antibody profiling to detect sero-reactivity against 
individual antigens. To demonstrate the quality of serum profiling, the same pair of T1D 
patient and control samples were applied on two arrays from the same printing batch and 
one array from a separate printing batch. Four sub-arrays of each array (1,522 features, 
761 unique viral genes) were probed twice with the patient sample and twice with the 
 
 
6 - 2 Quality of Protein Display on HD-viral NAPPA 
(A) Visual representative images of HD-viral NAPPA protein display on slides within 
the same printing batch and across different printing batches. 
(B) Scatter plot of log transformed signal intensities for protein display on slides 
within the same printing batch and across different printing batch. 
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control sample. The average correlation coefficients of intra-array, intra-batch and inter-
batch for both samples were all above 0.95. The results were highly reproducible as 
shown by the representative array images and the correlation coefficients between sub-
arrays in Figure 6-3. 
6.4.3 Higher Sensitivity in Detecting Antibodies on HD-NAPPA 
Assay sensitivity of sero-reactivity on HD-NAPPA and standard NAPPA was 
compared. The same set of 190 unique genes was printed on both glass, using the 
standard NAPPA method (Miersch and LaBaer, 2011; Ramachandran et al., 2008), and 
the SiNW surface, using the HD-NAPPA method (Takulapalli et al., 2012). A serum 
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(B)
Batch 1 1 1 1 2 2
Slide 34 34 35 35 56 56
Batch Slide Subarray 1 3 1 3 1 3
1 34 1 1.00 0.98 0.99 0.98 0.94 0.99
1 34 3 0.98 1.00 0.98 0.96 0.94 0.97
1 35 1 0.99 0.98 1.00 0.98 0.96 0.98
1 35 3 0.98 0.96 0.98 1.00 0.93 0.98
2 56 1 0.94 0.94 0.96 0.93 1.00 0.93
2 56 3 0.99 0.97 0.98 0.98 0.93 1.00
Sample#1
Batch 1 1 1 1 2 2
Slide 34 34 35 35 56 56
Batch Slide Subarray 1 3 1 3 1 3
1 34 1 1.00 0.93 0.99 1.00 0.97 0.97
1 34 3 0.93 1.00 0.93 0.93 0.91 0.93
1 35 1 0.99 0.93 1.00 0.99 0.97 0.97
1 35 3 1.00 0.93 0.99 1.00 0.97 0.97
2 56 1 0.97 0.91 0.97 0.97 1.00 0.97
2 56 3 0.97 0.93 0.97 0.97 0.97 1.00
Sample#2
Lowest Highest
0.8 1.0  
 
6 - 3 Quality of Serum Profiling on HD-NAPPA 
(A) Visual representative images for serum profiling on two arrays from the same 
printing batch and one array from a different printing batch. 
(B) Correlation coefficients for intra-array and inter-array correlation within the same 
printing batch, inter-array correlation across different printing batch. Sample#1 is a 
T1D patient sample, sample#2 is a healthy control sample. 
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sample was applied at three-fold serial dilutions from 1:300 to 1:24,300 on both 
platforms. The S/B ratio was used to assess sero-positivity, which was the signal of any 
feature divided by the median signal on the same array, because the majority of features 
on the array were considered non-responses (see Materials and methods). An increase in 
the S/B ratio was found as high as 9 times for anti-EBNA1 response from Epstein-Barr 
virus (EBV) at 1:900 dilution and more than 2 times for anti-VP1 (CVB) response at 
1:300 dilution when comparing HD-NAPPA with standard NAPPA (Figure 6-4). Sero-
reactivity to the BFRF3 antigen of EBV among the JIA sample set was profiled on HD-
viral-NAPPA and by ELISA to compare their ability to measure positive sero-reactivity. 
Overall, sero-positivity for all 30 samples agreed well on both platforms except for 
sample U13, which showed S/B >2 on HD-viral-NAPPA but was not distinguishable 
from background by ELISA (red arrows on Figure 6-4). Additional tests are needed to 
further confirm the sero-positivity. Sample J10 had more than 12 times higher S/B ratios 
on HD-viral-NAPPA than that of ELISA. The wide S/B ratio range made HD-viral-
NAPPA a more sensitive immunoassay platform in distinguishing sero-positive from 
sero-negative samples than standard NAPPA or ELISA (Figure 6-4). 
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6 - 4 Higher Sensitivity in Detecting Anti-viral Antibodies on HD-NAPPA 
(A) S/B ratio of sero-reactivity to EBNA1 (EBV) and VP1 (CVB) at serial dilutions 
on HD-NAPPA and NAPPA. 
(B) S/B ratio of sero-reactivity to BFRF3 (EBV) among JIA sample set on HD-
NAPPA and ELISA. 
 
 153 
6.4.4 Anti-viral Antibodies of Three Common Viruses in JIA 
Sero-reactivity to 761 viral antigens from 25 viruses by HD-viral-NAPPA using 
JIA and T1D samples (Table 6-3). The T1D samples included 20 new onset patients and 
20 healthy controls. The percentage of males with T1D was 70%, which is slightly higher 
than the expected distribution, probably due to sampling error, but was appropriately 
matched with controls. The JIA samples included 10 patients, 10 patients with the 
symptom of uveitis and 10 healthy controls. In the case of JIA, the percentage of males in 
the cases was 10%, reflecting the well-documented gender disparity of JIA, which 
primarily affects females (Thierry et al., 2014). The controls for JIA were appropriately 
gender matched. Among 25 viral strains, PB19, rubella virus (RUBA) and EBV are the 
most reported viruses associated with JIA. The heatmaps of sero-reactivity to the three 
viruses for both diseases were generated (Figure 6-5). The power of a proteomic 
approach in discovering autoimmune disease-associated viral infections is the 
opportunity to test all possible viral antigens to see which one gives the best response. 
This could not be achieved by a more conventional one-antigen-at-a-time approach.  In 
the JIA sample set, sero-reactivity to the capsid protein (RUBA) was significantly higher 
in JIA patients than healthy controls by Wilcoxon rank-sum test (p<0.05; Figure 6-3B); 
whereas, no difference of sero-reactivity to other proteins (E1, E2 and P150) from RUBA 
was observed.  JIA patients with uveitis had less sero-reactivity to most EBV proteins 
compared to the other subgroups. In the T1D sample set, the prevalence of antibodies to 
EBV proteins was higher in patients than controls (Figure 6-5). 
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6.4.5 Profiles of Anti-viral Antibodies in JIA and T1D Samples 
Profiles of anti-viral antibodies were generated on HD-viral-NAPPA and 
illustrated in the heatmaps (Figure 6-6). Overall, most samples (both cases and controls) 
were positive for CVB, RUBA, mumps virus (MuV), rotavirus (RV), adenovirus, 
influenza A virus and measles virus (MeV), while negative for Human endogenous 
retrovirus K (HERK) and varicella zoster virus (VZV). The JIA samples have less sero-
(A) (B) JIA
*
*
T1D                      JIA
 
 
6 - 5 Anti-viral Antibodies to PB19, RUBA and EBV 
(A) Heatmaps of S/B ratio of sero-reactivity to viral proteins from the three viruses on 
HD-NAPPA in T1D and JIA sample sets. 
(B) Jitter plots of sero-reactivity to representative viral antigens (RUBA-capsid, EBV-
BFRF3 and PB19-protein X) on HD-NAPPA in JIA sample set. 
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reactivity to human cytomegalovirus (HCMV) proteins compared with T1D samples 
which may result from the age and geographic difference between these two sample 
collections. Interestingly, antibody response to herpes simplex virus (HSV) was found to 
be more prevalent in both JIA and T1D patients than healthy controls. 
 
 
6 - 6 Profiles of Anti-viral Antibodies in JIA and T1D Patients 
(A) JIA sample set, J stands for JIA patients, U stands for JIA patients with uveitis, C 
stands for healthy controls. 
(B) T1D sample set, P stands for T1D patients, C stands for healthy controls. 
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6.5 Discussion 
Host innate and adaptive immunity works cooperatively to fight against viral 
infections (Anderson et al., 2011). Antibodies recognizing antigen proteins are produced 
during this process. Detection and quantification of these antibodies will aid sero-
diagnosis of infections, design of preventive vaccines, discover innovative therapeutics 
and monitor of anti-viral treatments (Odumade et al., 2011). Traditional methods 
focusing on one-protein/one-virus at a time suffer greatly from the limitation of 
throughput. Protein arrays, as one of the key innovations in the era of functional 
proteomics, provide an ideal tool to profile antibody response to thousands of proteins on 
a microscopic slide in a multiplexed manner (Sutandy et al., 2013). NAPPA, as a robust 
in situ cell free protein array platform, prints full length cDNAs on the arrays instead of 
purified proteins (Ramachandran et al., 2008).  
HD-NAPPA achieved higher density and less diffusion by expressing and 
capturing proteins in isolated sealed ‘nanowells’ (Takulapalli et al., 2012). It shares some 
common advantages with standard NAPPA. First, antigens are expressed by a HeLa cell 
lysate-based IVTT system, yielding high expression levels and functional conformations 
of displayed proteins. Second, the ability to reconfigure new arrays allows exploration of 
sero-reactivity to any antigens from new pathogens, new strains or new mutants in 
diseases as they emerge. This is especially important for microbial studies because 
conventional protein arrays for human and yeast, although expensive, are at least 
commercially available; but, similar arrays are not available for microorganisms. Third, 
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both assays are highly reproducible and the turnaround time for one assay for thousands 
of proteins is as short as one day.  
In addition, HD-NAPPA introduces some unique advantages. First, based on its 
high density feature, as many as 24,000 proteins can be tested simultaneously compared 
to only 2,500 proteins by standard NAPPA on each array. Second, the high density nature 
reduces the sample amount needed for assaying each protein, thus preserving precious 
resources. Third, here HD-NAPPA was demonstrated to have higher sensitivity and 
better S/B in detecting antibody responses compared with standard NAPPA and ELISA. 
Fourth, HD-NAPPA protocols use much less DNA per printing batch when compared to 
standard NAPPA, which means that many more samples can be tested based on a single 
round of DNA preparation and reducing cost of array production. Fifth, HD-NAPPA has 
negligible diffusion between neighboring spots reducing false positives during serum 
screening. 
Aside from the above advantages, there are some limitations of NAPPA 
technology. Although it is easier and more robust to prepare and print DNA than to 
express, purify and print proteins, it is nevertheless beyond the means for most general 
research labs to work with thousands of genes/proteins at the genome/proteome level. 
Collaboration or fee-for-service (such as http://nappaproteinarray.org/) might make more 
sense in this setting. Fast and accurate noncontact piezoelectric dispensing systems 
capable of targeting nanowells are required for printing HD-NAPPA but are inaccessible 
to most researchers. An affordable user-friendly non-contact printing instrument is 
currently in development to allow widespread adoption of HD-NAPPA. Finally, it should 
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be noted that this platform is well-suited for screening for possible interactions or 
responses at the proteome level. But, all candidates that emerge from such screens must 
be confirmed by orthogonal methods and, where relevant, with in vivo assays. 
In this study, HD-NAPPA showed superior S/B ratio to standard NAPPA from a 
direct comparison of sero-reactivity to the same set of genes on these two platforms. On 
average, more than a seven fold increase in the S/B ratio of anti-EBNA1 sero-reactivity 
was obtained at various sample dilutions (Figure 6-4). The S/B ratio of HD-NAPPA also 
compares favorably to reported serum antibody studies using purified protein arrays 
(Robinson et al., 2002) or Luminex bead arrays (Wong et al., 2009). Thus, this tool 
detects serum antibodies at high sensitivity and can potentially improve the accuracy of 
clinical studies.   
To demonstrate the great utility of HD-NAPPA, HD-viral-NAPPA was 
constructed containing 761 protein antigens from 25 viral strains. There are over 10,000 
nanowells per SiNW array in the current configuration (Takulapalli et al., 2012). ORFs 
for all 761 viral antigens were printed in the nanowells, in duplicate, four times to 
produce four sub-arrays on one array. This allowed for the profiling of the sero-reactivity 
against all viral antigens of four serum samples on one array in parallel. The quality of 
protein display was evaluated by array-to-array reproducibility. 0.64%, 4.16 % and 
3.81% of features with CVs higher than 20% was observed using the log transformed raw 
signal intensities when comparing intra-slide, inter-slide and inter-batch correlations, 
respectively. Preliminary studies suggest that this may be due to imperfect dispensing of 
the same amount of DNA into the nanowells, resulting in inconsistent protein display on 
 159 
arrays from two different arrays. The piezoelectric printing protocol is currently under 
development to achieve higher dispensing reproducibility. Nonetheless, this affected a 
very small fraction of the features on the array and was mitigated somewhat by having 
duplicate spots for each gene on the array. 
Anti-viral antibodies in the two most common juvenile autoimmune diseases, JIA 
and T1D were profiled, as a demonstration of HD-NAPPA in serological studies. It has 
long been suspected that certain types of viral infections are involved in the development 
of these two autoimmune diseases (Jun and Yoon, 2004; Ravelli and Martini, 2007). T1D 
controls were collected in the United States (US) as T1D patient samples, and JIA 
controls were collected in the United Kingdom (UK) as JIA patient samples. In the anti-
viral antibody profile, the prevalence of sero-reactivity to HSV was higher in both JIA 
and T1D patients than healthy controls while the sero-reactivity to EBV was more 
prevalent only in T1D patients. The percentage of males is lower than females in JIA, it is 
the opposite in T1D. No obvious differences of anti-viral antibody profiles were seen 
between the genders. Although the sample size in this study is too small to draw any 
statistical conclusions, this may suggest a potential role of these viral infections in JIA or 
T1D development. Interestingly, the antibody responses to EBV proteins were higher in 
JIA patients and healthy controls than JIA patients with uveitis. It has been reported that 
JIA patients went into remission after EBV infection (Kawada et al., 2013). Therefore, 
the potential protection of EBV infection against uveitis in JIA patients warrants future 
investigation.  
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The protein array platform detects multiplexed antibody responses to viral 
antigens from the whole viral proteome. Many viruses undergo latency after active/lytic 
infection and may subsequently become reactivated after a latent stage (Odumade et al., 
2011).  Different viral antigens are preferentially expressed depending on these different 
states. Thus, both the antibody response and its magnitude to specific viral antigens may 
provide clues to the different stages of viral infection (Klutts et al., 2009). In cases where 
the lifecycle of a virus is well understood, a viral proteome array can be revealing. For 
example, EBV commonly enters latency in adults and in that state continues to produce 
the EBNA protein, which may explain the strong IgG response observed to that protein in 
adults (Klutts et al., 2009). The prevalence of strong anti-EBNA responses is much less 
common in children (unpublished observation). For less understood viruses, the inclusion 
of the whole viral proteome allows the investigation of every viral antigen that is linked 
to either active/lytic or latent stages of viral infection. Furthermore, IgM is often used to 
detect acute infection while IgG detects past infection. The array platform allows 
multiplexed detection of IgG and IgM using secondary antibodies labeled with two 
different fluorescent dyes. In summary, the inclusion of all viral antigens from the 
complete viral proteome and the ability of multiplexed detection of IgM and IgG may 
enable the discrimination between active/lytic or latent viral infection.
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6.6 Conclusions 
The utility of HD-viral-NAPPA in profiling anti-viral antibodies in diseases was 
successfully demonstrated. The small sample size used in this study may preclude 
reaching strong statistical conclusions. However, high quality serological profiles were 
generated in 70 subjects; observed reactivity differences among them and confirmed 
results with orthogonal ELISA data. HD-NAPPA may be applied to large scale anti-
microbial antibody studies and help us better understand the role of microbial infections 
in various autoimmune diseases. 
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CHAPTER 7 
7 CONCLUSIONS AND FUTURE WORK 
7.1 Conclusion 
The major findings and contributions of my dissertation include: 
(i) A proteome-scale, two-stage serological AAb screening against 6,000 
human proteins was performed and identified 26 novel AAbs including a known T1D-
associated AAb (ZnT8). An orthogonal immunoassay named Luciferase LIPS assay was 
developed and used to validate these candidate AAbs. AAb to a dual specificity 
typrosine-phosphorylation-regulated kinase 2 (DYRK2) was validated with 36% 
sensitivity at 98% specificity. The AUC for a combination of DYRK2A and the classical 
IA-2A was 0.90 compared to 0.72 for DYRK2A and 0.64 for IA-2A alone. This is the 
first systematic screening for novel AAbs against large number of human proteins by 
protein arrays in T1D.   
(ii) A most comprehensive search for novel AAbs in T1D using a knowledge-
based approach by ELISA and a screening-based approach by NAPPA was performed. 
Six AAbs were identified and validated with sensitivities ranged from 16% to 27% at 
95% specificity. Their prevalence in T1D cases complement to the major known T1D-
assocaited AAbs and varied in different age subgroups. 
(iii) Seroreactivity to 646 viral antigens was assessed in 42 new-onset T1D 
patients and 42 age-gender matched healthy controls. Prevalence of anti-viral antibodies 
agreed well with the infection rates of the corresponding virus based on epidemiological 
studies. Antibody positive rate of EBV was significantly higher in cases than controls 
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(OR 6.6; 95% CI 2.0-25.7) while the other viruses did not differ between the two groups. 
The EBV and T1D association was significant in both genders and age subgroups (<=12 
and >12). These results suggest a potential role of EBV in T1D development. 
(iv) HD-NAPPA showed higher S/B ratio compared with standard NAPPA on 
planar glass slides. HD-NAPPA also showed high quality of protein display and serum 
profiling with average correlation coefficients within or between printing batches at 0.91 
and 0.96, respectively. Common as well as unique antibody reactivity patterns were 
detected between patients and healthy controls in T1D on HD-NAPPA. 
With these results, two papers were published, one manuscript is in revision and 
one manuscript is in preparation for publication. All of them are listed as below: 
1. Miersch, S.*, Bian, X.*, Wallstrom, G., Sibani, S., Logvinenko, T., 
Wasserfall, C. H., Schatz, D., Atkinson, M. A., Qiu, J., Labaer, J. (2013). Serological 
autoantibody profiling of type 1 diabetes by protein arrays. J Proteomics. 94, 486-96. 
PMID: 24148850. (*Co-first authorship) 
2. Bian, X., Wallstrom, G., Wasserfall, C. H., Wang, J., Barker, K., Wang, 
H., Atkinson, M. A., Schatz, D., Qiu, J., Labaer, J. Identification of novel autoantibodies 
in type 1 diabetes by protein arrays. In preparation. 
3. Bian, X., Wallstrom, G., Davis, A., Wang, J., Park, J., Throop, A., Steel, 
J., Yu, X., Wasserfall, C. H., Atkinson, M. A., Schatz, D., Qiu, J., Labaer, J. 
Immunoproteomic profiling of Virus Antibodies in New-Onset Type 1 Diabetes on 
Protein Arrays. In revision. 
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4. Bian, X., Wiktor, P., Kahn, P., Brunner, A., Khela, A., Karthikeyan, K., 
Barker, K., Wasserfall, C. H., Gibson, D., Rooney, M. D., Qiu, J., LaBaer, J. Anti-Viral 
Antibody Profiling by High Density Protein Arrays. Proteomics. 2015 Mar 11. doi: 
10.1002/pmic.201400612. [Epub ahead of print]. PMID: 25758251. 
7.2 Future Work 
The focus of this dissertation is tracking the humoral immune response in T1D 
including the AAbs and anti-viral antibodies by an innovative protein array platform. 
Novel AAbs provide value in identifying individuals at risk, stratifying patients with 
different clinical courses, improving our understanding of autoimmune destructions, 
identifying cellular immune response antigens and providing candidates for prevention 
trials. A complete picture of viral infections was drawn by profiling anti-viral antibody 
responses to individual viral proteins from the whole viral proteome which will give us a 
better understanding of the role of viral infections in T1D development. The work done 
in this dissertation successfully demonstrated the great use of innovative protein arrays in 
studying these two important questions in T1D, however, some future work can be 
continued from this study. 
7.2.1 Enriching the Gene Collection to Cover the Full Human Proteome 
The human genome project (HGP) has been successfully completed and revealed 
20,500 human genes in human genome (Watson, 1990). More recently, the human 
proteome project (HPP) aims to identify all the proteins translated from human genome 
(Legrain et al., 2011). There is continuous effort to clone more human genes into a 
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protein array compatible expression vector that was used in this study. The additional 
genes need to be included in future studies. 
7.2.2 Longitudinal Samples for AAb and Virus Study 
In the AAb study, age-gender matched cases and controls were used to screen for 
novel AAbs. In the second study, cases were new-onset T1D patients and had a longer 
duration of disease than the first study. It is known AAbs may appear at different stages 
of disease progression including the prediabetic period. Because their levels might not 
persist, they may not have been detected in the blood samples taken at the time of 
diagnosis or in clinically active patients. AAbs might also be specific to certain 
individuals emphasizing the heterogeneous nature of the disease (e.g., different rates of 
progression, etiological factors, genetic backgrounds). In the future, a systematic study to 
profile AAbs using longitudinal samples collected before “seroconversion” to clinical 
T1D will enhance our understanding of the natural history and mechanisms leading to 
diabetes specific autoimmunity.  
Viral infection or presence may act as a longitudinal factor during the process of 
the induction of single islet antibody, the simulation from single islet antibody to multiple 
islet antibodies, or the progression from β cell autoimmunity to clinical onset of T1D 
(Schneider and von Herrath, 2014b). Several studies reported that the initial development 
of autoantibodies and progression to multiple autoantibodies occurred at an early age. 
Subsequently, individuals progress to clinical T1D at different paces during which viral 
infections may act as an accelerator (Chmiel et al., 2015; Parikka et al., 2012). For 
example, enterovirus infection was shown to increase progression to clinical onset in the 
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Diabetes and Autoimmunity Study in the Young (DAISY) study (Stene et al., 2010). 
Profiling of anti-viral antibodies using longitudinal samples may discover viruses that 
induce “seroconversion” or trigger T1D. 
7.2.3 Post-translational Modifications (PTMs) of Autoantigens 
During T1D progression, β-cells suffer from ER and oxidative stress due to the 
inflammatory response from chemokines and cytokines. Proteins undergo missfolding or 
post-translational modifications (PTMs) in cells under these stresses. One hypothesis is 
that modified proteins generate new epitopes and are recognized as non-self by the 
immune system (Dunne et al., 2012). The types of antigen modifications include 
alternative splicing, overexpression, deamination, transglutamination, glycosylation and 
citrullination. Several studies reported autoimmunity against proteins with PTMs in T1D. 
The insulin A-chain epitope recognized by human T cells was modified by forming a 
vicinal disulfide bond in adjacent cysteine residues at position A6 and A7 (Mannering et 
al., 2005). WE14 peptide from chromogranin A can be modified by translgutaminase and 
release a highly reactive T-cell epitope in NOD mice (Delong et al., 2012). PTMs of 
peptide from insulin had higher T-cell autoreactivity than native peptides (van Lummel et 
al., 2014). Epitopes of citrullinated GAD65 were recognized in T1D patients (McGinty et 
al., 2014). Citrullinated glucose -regulated protein 78 is an autoantigen for both B-cell 
and T-cell response in NOD mice (Rondas D, 2015). Most of the above studies were 
focused on the detection of autoreactive T-cells against modified peptides in mice. There 
is no study that investigated the AAb response to antigens with PTMs in human. These 
modified autoantigens may be more relevant to T1D pathogenesis than their native form. 
 167 
The protein array platform in this study will be much more powerful if it can display 
proteins with PTMs and assess their AAb responses in high-throughput manner. 
7.2.4 Integration with T1D Microbiome and Virome  
The human microbiome includes all the commensal, symbiotic and pathogenic 
microorganisms in the human body. The human virome is the collection of viruses in 
human body. They were suspected to be involved in T1D pathogenesis (Kondrashova and 
Hyoty, 2014). The role of bacteria in T1D onset was described in mouse models. Feeding 
probiotic bacteria can delay or prevent diabetes in NOD mice (Matsuzaki et al., 1997). 
Bacteria strains in diabetic mice and non-diabetic mice were different (Roesch et al., 
2009). The T1D autoimmune microbiome was defined in human in multiple studies 
(Brown et al., 2011; Giongo et al., 2011; Mejia-Leon et al., 2014; Schneider and von 
Herrath, 2014b). The disease specific virome was investigated in inflammatory bowel 
disease (Norman et al., 2015). NGS was used to sequence the gut virome in children with 
rapid onset of T1D or islet autoimmunity (Lee et al., 2013). These DNA based 
approaches such as sequencing are clearly powerful to investigate the T1D 
mircobiome/virome asscoation. However, they may not tell the full story since viruses 
may be cleared by immune system. Anti-viral antibodies may persist longer after 
infection. So the profile of anti-mircobiome/viral antibodies can complement the genomic 
study. With the flexibility of the NAPPA platform, genes of newly discovered T1D-
associated micobiome/virome can be easily cloned and their encoding proteins can be 
displayed on arrays to test the prevalence of anti-microbiome/viral antibodies. 
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In summary, T1D is a complicated chronic autoimmune disease that involves the 
interplay between genetic, immunological and environmental factors. There is an 
emerging need to understand T1D etiology from different perspectives of the humoral 
immune response. The use of protein arrays in this study provides a better understanding 
of T1
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